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ABSTRACT 
In Chapter 2, bis- and tris- arylsulfonamides, were investigated as possible 
inhibitors of the p53-MDM2 protein-protein interaction (PPI). The lead compound, 19, 
inhibited the PPI, in a fluorescence polarisation (FP) based competitive binding assay 
with ICso 26.4 pM and the most potent analogue, 66, with ICso 3 µM. The active 
compounds in this series, possess a 5-chloro-4-nitro-2-sulfonamoyl substituted thiophene 
ring that is very susceptible to SNAr reactions at the 5-position. Analogues of 19 and 66 
were prepared to investigate the SAR of these inhibitors. No improvements in activity 
or structural activity relationship (SAR) consistent with MDM2 binding were observed 
and no active analogues without the reactive functionality were found. These compound 
are no longer being investigated. 
Chapter 3 describes a 3-D shape-based virtual screening campaign to find new 
lead compounds. Using queries based on the established Nutlin, benzodiazepine and 
spiro-oxindole inhibitors, the ZINC database was screened using the program ROCS to 
find compounds that have good shape similarity (measured by 3D Tanimoto) and similar 
functional group overlap to the query molecules. 155 compounds were purchased and 
tested 16 of which inhibited the MDM2-p53 PPI in the FP assay at IC50 ranging between 
48.22 and 140.42 1tM. Three analogues, 156,168 and 180, induce low levels of p53 
induction in cells using a Luciferese based reporter gene assay with most the potent 
compound, 180, showed 5.75 fold induction at 8.89 µM. A number of the hit compounds 
warrant further investigation. 
Chapter 4 describes the investigation 1.5-benzodiazepiene-2-ones and 
1,3-dihydrobenzimidazolin-2-ones as novel scaffolds on which to base potential p53 
inhibitors. A small series of analogues of each class were prepared and their ability to 
disrupt the MDM2-p53 PPI determined using an FP assay. None of the 
1.5-benzodiazepiene-2-ones showed any inhibition of the PPI at concentrations up to 
500 µM. Some of the 1,3-dihydrobenzimidazolin-2-one based compounds showed low 
levels of inhibition with the most potent analogue, 214 having IC5o 196.18 PM. These 
inhibitors showed some SAR based on the size of substituents and the presence of a 
6-chloro substituent that has been shown to considerably enhance the activity in other 
classes of inhibitor. Compounds of this type warrant further investigation using a more 
diverse compound library. 
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1. Introduction 
1.1 Cancer 
According to the World Health Organisation (WHO), 7.6 million deaths worldwide 
were due to cancer in 2005. This number is predicted to rise to 11.5 million by 2030, 
with lung, stomach, colorectal, liver and breast cancers being respectively responsible 
for the most deaths. The prevalence of different cancers varies on the basis of geographic 
location, age and gender. Many risk factors associated with various cancers have been 
identified including genetic predisposition, certain viral and bacterial infections as well 
as environmental and lifestyle factors with tobacco use being the single most important 
risk factor. It has been suggested that 40% of cancers are preventable. ` 
Cancer occurs when cells proliferate abnormally and independently from the 
signals that normally control them. Whilst it is common to classify cancers based on the 
organ or tissue they affect, on a genetic and biochemical level cancers are very 
heterogeneous. The aberrations responsible for abnormal growth can vary considerably 
between two cancers in the same tissue and conversely, be similar in those occurring in 
different parts of the body. The term cancer really refers to over 200 different diseases in 
which the genetic and biochemical backgrounds may be considerably different. Because 
of this what cures one cancer may have little or no effect on another. The need for new 
therapeutic strategies is nowhere more important than in oncology. Despite the 
identification of potential drug targets drug approval rates have dipped alarmingly over 
the last few years. 3 It has however been suggested that while the quantity of drugs being 
approved may be decreasing that their quality may in fact be improving as ongoing 
research aims to better understand what occurs within specific diseases and develop 
appropriate ways to treat them. 
1.2 Tumorigenisis 
How and when cells divide, stop dividing, differentiate and die are very tightly 
controlled processes that allow each and every multi celled organism to become what 
and indeed who, their genetic blueprint says they should be. Each cycle of mitosis is 
very tightly regulated by various checkpoints that ensure it occurs correctly and that 
when defects occur they are not passed on to the daughter cells. However, it is possible 
that the genes which code for the various components that regulate these processes 
become mutated such that tumour suppressors, which normally restrict growth, 
experience loss of function and oncogenes, which promote growth, experience increased 
function. Sufficient deactivation of tumour suppressors and activation of oncogenes 
causes cells to proliferate uncontrollably resulting in cancer. 
Tumorigenisis, whereby normal cells become malignant cancers, is not a single 
event but rather a process where by cells acquire a number physiological capabilities that 
allow them to grow and function independent of the controls and signals of the organism 
to which they belong. Hanahan and Weinberg have described six of these acquired 
capabilities, most of which are usually required for Tumorigenisis, as "the hallmarks of 
cancer". 5 These capabilities are; self-sufficiency in growth signals, insensitivity to 
growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis and tissue invasion and metastasis. 
Owing to how successful cell-cycle check points are, mutations are a very rare event. 
The number of genetic lesions required to achieve the six hallmarks of cancer varies 
depending on the tumour suppressors and/or oncogenes involved. However, as these 
checkpoints are lost, the genome becomes increasingly unstable and prone to more 
mutations which in turn allow more of the hallmarks to be acquired. 
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1.3 Cancer treatment 
Traditionally cancer treatment is based on surgery, radiotherapy or chemotherapy 
with cytotoxic agents. Often combinations of these approaches are used. The side effects 
synonymous with radiation and chemotherapy arise as a result of their genotoxic mode 
of action and poor selectivity for cancer cells over normal cells. The side effects may be 
acute such as hair loss, nausea or fatigue or chronic leading to infertility, disrupted 
endocrine function and the occurrence of secondary unrelated tumours later in life. 6,7 As 
cancer cells are very similar to the cells that they originate from the targets of cancer 
drugs are also found in normal cells making selective treatment of cancer difficult to 
achieve. Most chemotherapeutic agents are genotoxic and target DNA or cellular 
components associated with replication. Their selectivity is due to their increased 
accumulation in rapidly dividing cells. As a result slow growing cancer cells can be 
resistant to treatment and rapidly dividing normal cells such as bone marrow and hair 
follicles accumulate high levels of anti cancer drugs and are adversely affected. Only the 
seriousness of cancer allows drugs with such a poor therapeutic index to be used. 
Advances in the understanding of genetics at a molecular level have made it 
possible to identify the specific defects responsible for individual cancers. Coupled with 
better understanding of the biochemical roles and structures of the proteins and enzymes 
coded for by these genes, these defects present potential targets for drug intervention to 
restore correct function. If suitable drugs can be developed it should make it possible to 
reinstate the body's natural defences against cancer. So far, only a small number of these 
target specific drugs have been developed. Examples include Imatinib (Gleevec®) which 
inhibits the BCR-ABL tyrosine kinase expressed in Chronic myelogenous leukemia, 8 
Gefitnib (Iressa®) and Erlotinib (Tarceva®) which inhibit the EGFR tyrosine kinase that 
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is overexpressed or mutated in some cancers8.9 and Lapatinib (Tykerb®) which is 
effective in breast cancers in which ERBB2 receptors are overexpressed. 10 While they 
show excellent clinical activity, without the toxicity of cytotoxic agents, their use is 
limited to a small number of cancers in which their specific target is significant. 
Developing drugs that target the most common aberrations in all cancers is highly 
desirable. One such target is the tumor suppressor p53.11-1-3 
1.4 The p53 tumor suppressor 
The p53 tumour suppressor protein is at the centre of the cells defence 
mechanisms against cancer. In response to genotoxic stress or DNA damage p53 
coordinates various cellular responses, including cell cycle arrest and apoptosis, to 
ensure that the integrity of the genome is maintained. So important is the role of p53, it 
has been bestowed the title "Guardian of the Genome". 14 Loss of p53 function directly 
results in the acquisition of a number of the hallmarks of cancer such as apoptosis, 
insensitivity to growth signals, limitless replicative potential and sustained angiogenesis. 
Furthermore without a functional p53 pathway the genome becomes less stable making 
it more susceptible to further mutation and the acquisition of more cancer hallmarks. The 
p53 pathway is believed to be compromised in most, if not all, cancers. 15 Its reactivation 
is therefore a very attractive strategy for non-genotoxic cancer therapy. The following 
sections present an overview of p53, its function, the various ways it can be lost and 
approaches under investigation by which it maybe restored. This is followed by more 
detailed discussion of the subject of this work, inhibition of the protein-protein 
interaction between p53 and its main regulator and oncogene, MDM2. 
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1.4.1 Discovery of p53 
p53 was first described in 1979 as a 53 kDa protein that co-immunoprecipitated 
with the SV40 large T-antigen by a number of groups investigating cancer causing 
viruses. 16,17 Subsequently, high levels of p53 were observed in other types of cancer 
cells but not in non-transformed cells. These observations lead to the belief that p53 was 
involved in transformation and was in fact an oncogene and it was not until 1989 that its 
role as a tumour suppressor was established. "'18 
Initial studies into p53 function supported the idea that it is an oncogene. Primary 
cells transfected with p53 underwent transformation and when introduced to p53 null 
cells they showed increased in vivo tumorigenic properties. However, conflicting 
observations established an association between the incidences of p53 mutation in 
human cancers indicating that functional p53 was required for tumour suppression' 9.20 
and that p53 actually prevented transformation. 21 22 The conflict was resolved when it 
was discovered that the p53 cDNA clone used in the initial experiments was derived 
from transformed cells that contained dominant negative mutations. Experiments 
performed with wild type p53 clones did not exhibit the transforming effects observed in 
Za the original experiments establishing p53 as a tumour suppressor protein. _25 
1.4.2 Structure of p53 
The structural features and functional activities of p53 have been conserved across 
several species of vertebrates and invertebrates for over one billion years. 26-28 Human 
p53 consists of 393 amino acids and although it obtained its name from its apparent 
molecular weight of 53 kDa when it was discovered, its actual molecular weight is 43.7 
kDa. The difference arises as p53's migration on gels is retarded by the presence of a 
proline rich domain. 29 The protein can be divided into three structural regions; the amino 
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terminal region, the central region and the carboxy terminal region. Within these are a 
number of functional domains; the N-terminal region contains the transactivation domain 
(residues 1-42) and a proline rich domain (residues 63-97), the central domain (residues 
102-292) contains the sequence specific DNA-binding regions and the carboxy terminal 
contains the tetramerisation domain (residues 323-356) and negative regulatory domain 
(residues 360-393) (Figure 1). p53 exists and functions as a tetramer. This explains why 
mutations are dominant negative and introduction of mutant p53 caused transformation 
of cells in early experiments as, depending on the location of the mutation, one mutant 
sequence may be sufficient to abolish the function of the entire tetrameric unit. 30 
1-42 63-97 102-292 323.356 360.393 
Transacdvatlon Pro ine rkh Sequence-Specific DNA-Biedin` Tetn nerfsatlon Negative 
regulation 
Figure 1 Domain structure of p53 
1.4.3 Function of p53 
The tumour suppressor activities of p53 are manifold. It is most well known as the 
central node and regulator of the p53 pathway controlling cell cycle arrest and apoptosis 
in response to genotoxic damage or cellular stress (Figure 2) These functions allow it to 
halt the cell cycle so DNA repair can take place or kill the cell if the damage is 
irreparable. As a sequence specific. DNA-binding transcription factor p53 control's over 
100 transcription targets and much of its tumor suppressor activity results from their 
expression.; ' 
6 
p53 is both unstable and tightly regulated (discussed in Section 1.5.5.1). Under 
normal unstressed conditions p53 exists at barely detectable concentrations. In response 
to genotoxic stress, DNA damage, UV radiation or hypoxia a number of enzymes such 
as ATM, ATR Chkl and Chk2 signal to p53 by effecting various post translational 
modifications that increase its stability and disrupt interactions with its negative 
regulator MDM2 and result in its subsequent accumulation. 12-34 This in turn leads to the 
transcription of downstream targets that, depending on the severity of the threat to the 
genome, will either halt cell replication, temporarily through cell cycle arrest, or 
permanently by induction of senescence or programmed cell death (apoptosis). 
p53 initiates cell cycle arrest at the GUS and G2/M cell cycle checkpoints. 35,36 
The main mechanism by which p53 induces cell cycle arrest is by transactivation of the 
p21 protein, a cyclin dependent kinase inhibitor, resulting GUS arrest. 37 Ptprv/ESP also 
associated with GUS arrest is also a p53 transcription target. 38 A number of genes 
associated with G2IM arrest, GADD45,14-3-3-a and Gtsel(B99) have been identified 
as p53 transcription targets. 39-41 
p53 induces apoptosis through both the transcription dependent and independent 
pathways. 42.43 The transcription dependent pathways involve the transcription of 
pro-apoptotic genes such as Bax, 44 Bid, 45 PUMA, 46 NOXA, 47 Apaf-1,48 FAS, 49 and 
KILLER (DR), 50, among many others. 31 Following DNA damage, p53 has been found to 
re-locate to the mitochondria where it can directly associate with anti-apoptotic proteins 
effecting apoptosis by the transcription-independent mechanism. 45' 51.5a 
What governs whether the p53 response leads to cell cycle arrest or apoptosis is 
still unclear. It may be cell-specific and dependant on the nature and strength of the 
genotoxic stimulus-55'56 However, it does appear that low levels of p53 induce cell cycle 
7 
arrest and higher levels induce apoptosis such that arrest and repair occur first and if the 
damage is too severe to be repaired, further p53 accumulation results in apoptosis. 
Genoto. ic Stress 
UV Light 
DNA Damage 
Q® 
mir ýº Caspase Apoptosk 
Cax ade 
Tjö 1 
'' 
t 
Apoptosis 
p53 Degradation 
Ooc) ®® 
-ý Cell Cycle Progression 
Figure 2 The p53 pathway protects the cell and initiates cell-cycle arrest and apoptosis in response 
to genotoxic stress. p53 is auto regulated via a negative feedback loop with MDM2. MDM2 acts as 
an E3 ubiquitin ligase leading to protosomal degradation of p53. 
Another means by which p53 can prevent the proliferation of defective cells is by 
induction of senescence. Senescence (telomere shortening) is an irreversible cellular 
state of proliferation and differentiation arrest that is associated with aging and tumour 
prevention. Initial work indicating the involvement of p53 in regulating senescence 
showed that cells deficient in p53 had a longer lifespan than their wild type counterparts. 
However, the cells did eventually enter a senescent state indicating that p53 has a role in 
the timing and initiating of senescence. `7.58 
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p53 has also been associated with regulation of DNA repair. It has been shown, 
that when exposed to radiation mouse lymphoid or myeloid cell lines, in which p53 is 
mutant or absent, have severely impaired ability to rejoin double strand breaks. 59 It was 
also found that in human primary fibroblasts with mutant p53 there was a reduced ability 
to induce apoptosis and repair DNA. 60 Co-localisation of p53 to damaged DNA in 
response to exposure to a variety of stresses has been shown using in situ end labelling 
of eells. 61 Two DNA repair proteins, XPC and DDB2 were identified as being p53 
transcription targets. 62 
1.4.3.1 Regulator of Angiogenesis 
The exact role of p53 in angiogenesis has not been completely defined. However, 
it is known that p53 down-regulates the angiogenic process by regulating various factors. 
The anti-angiogenic factor, thrombospondin- I is induced by p5363.64 and the vasculature 
growth promoters VEGF and NOS are down regulated 65 
1.5 p53 activation in cancer therapy 
The functions of p53 are ablated in most, if not all, cancers as a means of evading 
apoptosis either by disabling p53, directly through mutation or deletion, or indirectly by 
alterations of various components of the pathways that regulate p53.67 The following 
sections are a brief summary of the role of p53 in current cancer therapy and novel 
approaches currently under investigation to activate it. 
1.5.1 p53 is activated by traditional chemotherapy and radiation therapy 
Radiation treatment and the majority of drugs currently used to treat cancer are 
genotoxic. They kill cells by damaging their DNA which, as mentioned earlier, activates 
p53. So even though the mechanisms by which they exert their effects on DNA are well 
9 
understood, much of their anti cancer activity is due to induction of p53. This is borne 
out by the fact that cancers not expressing wt p53 are often aggressive, difficult to treat 
and associated with poor prognosis. ' 69-71 
As discussed in Section 1.3, the development of non-genotoxic targeted 
therapies, especially those that reactivate p53, is highly desirable. A number of diverse 
strategies are been investigated for the non-genotoxic activation of p53 depending on 
how its function is lost. ' 72.73 Some of these are considered briefly in the following 
sections before a more detailed discussion of the p53-HDM2 protein-protein interaction. 
1.5.2 Reactivation of mutant p53 
In approximately 50 % of cancers p53 function is lost directly through mutation of 
p53. making it the most mutated gene in cancer. 74 Over 2,000 p53 mutations have been 
characterised in human cancers. 95 % of p53 mutations occur in the core DNA-binding 
domain and 75 % are missense mutations that tend to be at specific hot spots with 
mutation patterns correlating well with tumour type and specific mutagen exposure. 75.76 
Mutations can be at the residues involved in DNA contact or be structural, disrupting 
local or global protein conformation. As p53 is a relatively unstable protein, with a 
melting point of 44°C and a half life of just 9 minutes at body temperature, it is easily 
destabilised by mutation. 75' " It has been shown that activity of p53 can be restored in 
cells harbouring a temperature sensitive mutant protein by slightly lowering the 
incubation temperature. '8 As mutant p53 occurs in approximately half of all cancers and 
is associated with poor prognosis, restoration of its function is highly desirable. A 
number of diverse approaches to treating cancers with mutant p53 are been 
investigated. ' 1'72 
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1.5.2.1 Gene therapy 
Where p53 function is lost though mutation, reinsertion of wt protein through 
gene therapy would appear to be the most obvious and general solution to the problem. 
Whilst this approach has been investigated extensively it is not straight forward. Gene 
therapy itself is still very much an idea in development and has many issues that need to 
be overcome. A specific issue that arises for p53 is that both the newly introduced and 
existing mutant sequences will make up the tetrameric protein structure required for 
DNA binding and the mutant will still dominate activity so reactivation will not occur. i0 
One approach is to modify the introduced p53 so it can only form tetramers with itself 
and in doing so create an active protein. ' 1'" 
The first ever gene therapy, known as Gendicine, has been approved in China for 
the reinsertion of functioning p53 via an adenovirus vector for the treatment of head and 
neck cancer. 79,79,79 This approval was granted on the back of one small clinical trial (120 
patients). Used in conjunction with radium treatment, it was shown to bring about 
significantly increased tumour regression over radium alone. The only side effect was a 
fever in 30% of patients from which all recovered. However, given the size of the 
clinical trial and that it is unclear how it works, further investigation will be required 
before it receives widespread acceptance. The approach is currently undergoing clinical 
trials in The United States under the name Advexin. The validity of this approach will be 
determined in time but this does indicate that gene therapy is a step closer and provides 
further evidence that p53 reactivation is viable for the treatment of cancer. 12,13 
1.5.2.2 ONYX-015 
The absence of wt p53 has been investigated as a means of setting tumour cells 
apart from healthy ones. In one such approach an engineered oncolytic virus 
(ONYX-015) is used to kill cancer cells. As the virus cannot survive in the presence of 
wt p53 it inhibits it by coding for the p53 inactivating protein, EIB. In the engineered 
virus EIB is deleted so it cannot replicate in normal cells hence allowing it to selectively 
replicate inside, then lyse and kill cancer cells deficient in wt p53.80 While Onyx-015 has 
shown promise both for safety and efficacy in clinical trials in conjunction with 
genotoxic chemotherapy for the treatment of head and neck cancers81 efficacy as a single 
agent was limited. 82 A similar virus, known as H101, was recently approved in China to 
be used in conjunction with radiation for the treatment of head and neck cancers. 82,83 
1.5.2.3 Pharmacological rescue of mutant p53 
Some mutations destabilise the conformation of p53 required for DNA binding. 
Pharmacological stabilisation of the mutant protein using peptides and small molecules 
has been investigated and has shown promise for reactivation of p53 with a number of 
the most common mutations. '2' 13 These molecules bind to either the core DNA binding 
or tetramerisation domains of p53. They stabilise its active conformation and have been 
shown to restore p53 activity in cells. 68-71 
1.5.3 Non genotoxic activation of wt p53 
There are many potential therapeutic targets within the p53 pathway for the 
treatment of tumours that retain wild type (wt) p53. These can be upstream of p53 in the 
enzymes responsible for activating it in response to genotoxic damage, downstream of 
p53 at the effectors of apoptosis or at the proteins that regulate its levels. 
1.5.4 Upstream targets in the p53 pathway 
By interacting with the upstream components of p53 that control its various post 
translational modifications it may be possible to induce a non-genotoxic response. The 
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Tenovin series of compounds are inhibitors of the NAD' dependent histonedeacetylases 
SirTl and SirT2 that deacetylate p53 at L382 resulting in its destabilisation and 
deactivation. Inhibiting deacetylation by SirTi and 72, the Tenovin compounds induced 
p53 in a non-genotoxic manner and suppressed xenograft tumor growth in vivo. 84 
1.5.5 Downstream targets in the p53 pathway 
p53 is at the centre of a complex cell cycle regulation system. 85 In order to bring 
about its anti tumour properties it requires a functional downstream pathway. 86 This 
downstream pathway presents a host of targets whereby it may be possible to directly 
bring about the effects of p53 such as cell cycle arrest or apoptosis. This approach may 
be useful where wt p53 is not present and cannot therefore initiate this response or where 
the actual defect occurs downstream of p53 at or above the particular drug target. 
Important approaches being extensively investigated are the use of cyclin-dependent 
kinase inhibitors that mimic p21 to induce cell cycle arrest, 87 inhibitors of the PPI's 
between the Bcl-2 anti-apoptotic proteins, and their pro-apoptotic counterparts to 
promote apoptosis in cells where these proteins are overexpressed, B8.90 or direct 
activation of caspases by the use of Smac mimetics to disrupt the interaction of the anti 
apoptotic protein XIAP with the caspases. 91,92 
1.5.5.1 Targeting the regulation of p53: MDM2 
Targeting the regulatory pathways of p53, namely by inhibiting its main 
inhibitor, MDM2, is a very active area of research and the subject of this thesis. It is 
discussed in detail in the following sections. 
13 
1.6 MDM2 
Because p53 has strong growth-suppressive activity, it must be tightly regulated 
to allow normal cellular to function. It is regulated by one of its own transcription 
products, known as murine double minute-2 (MDM2). The corresponding human protein 
is sometimes referred to as HDM2 but here the abbreviation MDM2 is used regardless of 
species. Targeting the regulatory pathways of p53, namely by inhibiting the activities of 
MDM2, is a very active area of research. 
1.6.1 MDM2: Structure 
MDM2 is a 491 residue protein. The N-terminus contains the p53-binding domain 
from amino acids 19-108. The NES and NLS (nuclear export signal and nuclear 
localisation signal) domains are found between residues 178 and 192. The central acidic 
domain spanning residues 237-300 immediately followed by the zinc finger domain 
from residues 301-332. At the at the C-terminus, there is a ring finger domain residues 
433-488 that also includes the nucleolar localisation signal (NoLS) between residues 
464-471). 93 
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Figure 3 The domain structure of MDM2. 
1.6.2 MDM2: p53 regulator and oncogene 
MDM2 was first identified as an oncogene in the mouse cell-line (3T3DM) that 
co-precipitated with p53.94,95 Further evidence of its relationship with p53 came from 
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experiments which showed that MDM2-'- knockout mice are not viable but MDM2-'- 
/p53-'- mice are. 96' 97 It is now known that, as MDM2 is a transcription product of p53, 
they control each others levels by means of a negative feedback loop. (Figure 2) 15,98-99 
MDM2 interacts with p53 and maintains it at low basal levels via three distinct 
mechanisms: (a) a protein-protein interaction (PPI) between MDM2's N-terminus and 
the transactivation domain of p53 that physically blocks its transcription factor activity; " 
10° (b) acting as an E3 ubiquitin ligase labelling it for protozoa degradation; 1°' and (c) 
facilitating its nuclear export removing it from its site of action. I 'r 
Depending on the nature of genotoxic or non-genotoxic stress a cell may 
experience, the negative regulation of p53 by MDM2 is interrupted in several different 
ways resulting in p53 accumulation and subsequent cell cycle arrest and/or induction of 
apoptosis. The functions of MDM2 in p53 suppression are inhibited upon association 
with the ARF protein, which is induced upon oncogenic stress (Figure 2). 103 Similarly, 
MDM2 is inhibited upon ribosomal stress by the ribosomal proteins L5, L11, and 
L23.104''05 Both p53 and MDM2 are regulated through posttranslational modifications, 
including ubiquitinylation, 106 sumoylation, and multi-site phosphorylations by a range of 
kinases, especially the DNA damage-induced kinases. 107 In response to genotoxic stress 
these posttranslational modifications inhibit p53-MDM2 binding allowing p53 to 
accumulate and exert its tumour suppressor activities. 33,33,34 
p53 function can be ablated through direct overexpression of MDM2 (in ca. 7% of 
cancers). 1°8 MDM2 overexpression due to gene amplification is especially frequent (ca. 
30 %) in human osteogenic sarcomas and soft tissue sarcomas. 109 For the approximately 
50% of all cancers that retain wild-type p5310, and especially those in which it is 
overexpressed, MDM2 is a potential target for therapeutic intervention to restore normal 
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p53 function by non-genotoxic means. The three mechanisms by which MDM2 exerts its 
effects on p53 each offer distinct possibilities and the search for inhibitors of them is a 
very active area of research. The ultimate goal would be to discover small molecules as 
an orally available, non-genotoxic, mono-therapeutic means of inducing p53 
accumulation or at least increasing the p53 response to current chemotherapy such that 
lower doses of harmful agents are required. 
1.6.3 Targeting MDM2 to reactivate p53 
Most research effort has been focused on directly inhibiting the MDM2-p53 PPI. As 
this target is the focus of this thesis, both the PPI and progress made at discovering 
inhibitors of it are discussed in detail in Section 1.7. 
The E3 ubiquitin ligase activity of MDM2, that leads to protosomal degradation of 
p53, is a distinct target that can be used to rescue wt p53.1 11 JNJ-26854165 was the first 
MDM2 inhibitor to enter clinical trials (Figure 4). 1 12 This compound first appeared in the 
public domain as it entered clinical trials and very little about its discovery or 
development has been disclosed. It has since emerged that, its mode of action is 
inhibition of MDM2's ubiquitin ligase activity. It elevates p53 levels and induces 
apoptosis. 113,114 A number of other ubiquitin ligase inhibitors have been identified that 
stabilise p53 and induce the p53 mediated apoptosis. While some of these show 
off-target toxicity and others require further evaluation, they do provide support for the 
concept of inhibiting the E3 ubiquitin ligase activity of MDM2 to activate p53.11 5 
As of yet no specific inhibitors of the third mechanism by which MDM2 regulates 
p53, facilitating its nuclear export, have been described. ' 16 Leptomycin B does inhibit 
nuclear export of p53 resulting in its accumulation and associated tumour suppressor 
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activity. ' 7 However the molecular target of Leptomycin B is CRMI which is an export 
factor for numerous proteins. 116 Leptomycin was withdrawn from phase I clinical trials 
due to undesirable side effects. "7 However, specific inhibition of p53 export may still be 
a useful way to restore its tumour suppressor function. 
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Figure 4 JNJ-26854165 is the first reported MDM2 inhibitor to enter clinical trials. It is believed to 
have unique mode of action to the well described inhibitors. 
1.7 The MDM2-p53 PPI 
Given that p53 and MDM2 exist and operate within the cell nucleus, suitable 
inhibitors would need to be small molecules to have the membrane permeability required 
to access the target. This would also facilitate oral administration. Prior to elucidation of 
the structure of the MDM2-p53 PPI it was thought that PPI's would have large poorly 
defined interfaces and it would not therefore be possible to inhibit them using such 
drug-like molecules. However, the X-ray co-crystal structure, between the MDM2 
N-terminus and an l 1-mer peptide of residues 16-27 from p53's transactivation domain, 
showed that the bulk of the interaction involves just three hydrophobic residues of p53 
buried in a well defined hydrophobic cleft in MDM2, of a size that could be filled with a 
druglike molecule (Figure 5). 1 This observation lead to the notion that PPI's could be 
reduced to hot-spots 103.108' 109.118.119 and a wider acceptance of PPI's as tractable targets 
for druglike molecules. 
17 
The fact that all proteins and their binding sites are flexible is also evident from 
structural studies with MDM2. The elucidation of the apo-structure of MDM2 showed 
that the well defined binding pocket is in a closed conformation and opens upon binding 
to p53.120 The driving force for the interaction would appear to be the stabilization of 
both MDM2 and of the amphipathic helix of p53 that supports and projects the three 
main binding residues into the cleft. This study also shows the presence of a flexible lid 
which covers the cleft in the apo structure but is displaced upon binding a p53 peptide. 
The solved crystal structures of MDM2 bound to peptides are truncated at the 
N-terminus so do not include the lid. Comparison of the MDM2 conformations in the 
various bound structures (Figure 5, Figure 10 and Figure 11) clearly demonstrates that 
the small-molecule inhibitors bind to MDM2 so that it adopts a similar conformation as 
it does upon binding p53. However, more recent NMR studies that focus on the lid 
dynamics of the apo, peptide bound and small molecule bound structures, 
' 21 show that 
the lid of the binding site is displaced upon binding a long peptide but not upon binding 
the small molecule inhibitor Nutlin or a shorter peptide sequence. This is also evident in 
the X-ray structure of the benzodiazepine series of small molecule inhibitor in which 
some of the lid structure is maintained and very clearly adopts a helical structure that lies 
over the leu26 pocket (Figure 11). '22 Complete displacement of the lid by peptides that 
extend beyond the deep cleft of the binding site is to be expected as they will occupy this 
area. These observations indicate that maintaining intramolecular contact between the lid 
and the binding site is energetically favourable when occupied by small molecules. The 
presence of the lid may need to be considered during inhibitor design especially when 
considering the placement of solvent exposed groups as the binding site will be more 
closed than it appears in crystal structures such as I YCR. ' In the apo-state the lid is in 
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equilibrium between major closed and minor open conformations. This dynamic may be 
important in molecular recognition allowing potential ligands access to the binding site. 
Molecular dynamics experiments also indicate that aromatic-aromatic interactions 
between the incoming peptide and residues at the perimeter of the binding site may be 
important initial interactions for molecular recognition. 123 The importance of this 
observation may be relevant in inhibitor design as all of the best inhibitors posses at least 
two aromatic rings. 
Figure 5 The p53-MDM2 interaction (PDB code: 11'CR)1 MDM2 is shown as a grey CPK surface, 
p53 backbone as a green ribbon and p53 residues F", W. L24 and Lu as green CPK sticks. 
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1.7.1 Peptide antagonists of the MDM2-p53 PPI 
Considerable work has been done with peptides that has increased understanding of 
structural aspects of the MDM2-p53 PPI. 124"126 These studies defined the basic 
pharmacophore and SAR required by PPI inhibitors. The observations made during this 
work have been influential in the development of the small molecule MDM2 inhibitors 
since discovered. 
The wt-p53 sequence of the p53 peptide that binds to MDM2 is 
16QETFSDLWKLLF27. Screening of phage displayed peptides led to the discovery of a 
12 amino acid peptide MPRFMDYWEGLN (known as the 12-1 peptide) that exhibited a 
28-fold potency increase over the corresponding wt sequence. ' 
27 Interestingly only the 
three deeply buried residues are conserved. The basic pharmacophore feature of all 
potent ligands is indeed three suitably oriented hydrophobic groups. This is generally 
regarded as the minimum requirement of an inhibitor of this PPI. A very simple 
pharmacophore model defining the spatial arrangement of three hydrophobic groups 
(Figure 6) was proposed by Wang et a] who used it as the first part of a virtual screening 
campaign that lead to the discovery of an inhibitor with nM activity (compound 1). 128 
Hydrophobic 
Group 1 
6.0±1.0A 5.1±1.0A 
Hydrophobic Hydrophobic 
Group 2 Group 3 
9.0 ± 1.5 
Figure 6 The basic pharmacophore of the PPI as used to screen for the Quilinoi inhibitors 1 120 
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Truncation and the use of artificial amino acids to explore various structural features 
of peptide based inhibitors lead to an 8 amino acid peptide (Figure 7) that showed an 
IC50 of 5nM inhibition of the PPI representing a greater than 1700-fold increase in 
affinity for MDM2 over the 12 amino acid wt-sequence. 129 The three deeply buried 
residues are again conserved and chloro-substitution at the 6-position of the tryptophan 
residue showed that better occupancy of the binding site resulted in increased 
hydrophobic contacts between ligand and target with very substantial potency gains. 
Aryl-halides are a common structural feature of the optimized small molecule inhibitors. 
The helix stabilizing amino acids, Aib and Ac3C show the importance of a rigid scaffold 
in presenting the binding residues such that they have good shape complimentarity with 
the binding site. The increases in affinity brought about by Pmp and Glu residues 
indicate that further polar contacts can be made outside of the cleft. 
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Figure 7 Optimised potent peptide inhibitor. 
The co-crystal structure of this peptide bound to MDM2 was solved showing that it 
binds in the expected manner (Figure 8). 130 This peptide also induces apoptosis in 
MDM2-over-expressing cancer cells via non-genotoxic p53 activation. 13' Being a 
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peptide this highly potent inhibitor lacked sufficient membrane permeability to be of use 
therapeutically. It did however show that inhibition of the MDM2-p53 PPI had the 
desired effect in cells and provided precedent for further investigation of the concept. 
Furthermore its structural features have been inherited by subsequent small molecule 
inhibitors. The most potent inhibitors are those that mimic the optimised peptide most 
closely. ' 32.133 
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Figure 8. MDM2-binding mode of an optimised p53-derived peptide. Residues of the p53 peptide 
(grey CPK sticks) are labelled (Ac3C, cyclopropylglycine; 6-CI-Trp, 6-chloro-tryptophan; Pmp, 
phosphonomethylphenylalanine; Aib, aminoisobutyric acid). MDM2 is shown as a green CPK 
surface. Constructed from PDB entry 2GV2.1-" 
1.8 Small molecule antagonists of the MDM2-p53 PPI 
Over twenty distinct classes of small molecule inhibitors of this interaction have 
now been described. '-'4 Of all the small molecule inhibitors described, three are of 
particular importance (Figure 9). The Nutlins, 135 1,5-benzodiazepiene-2,4-diones 
(BDPD's)"6- 140 and the spiro-oxindoles13 , 141 all bind MDM2 with nM affinity and 
induce cell cycle arrest and or apoptosis consistent with the target rationale. Typically, 
these compounds are only active in cells that express wt-p53, and upon treatment the 
expression of p53 transcription products such as p21, MDM2, PIG-3 and PUMA can be 
observed. Importantly, the presence of posttranslationally unmodified p53 shows that 
they act in a non-genotoxic manner. Furthermore, optimised analogues from these 
compound series have all been shown to cause tumour regression in xenograft mouse 
models. 
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Figure 9. Chemical structures of potent small-molecule p53-MDM2 interaction inhibitor 
compounds. The groups that interact with the F19, WZ', and LM subsites of the p53-binding cleft of 
MDM2 are shown in green, red, and purple, respectively, compare to Figure 8. Solubilising groups 
are indicated in blue. 
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Although chemically distinct, these three potent inhibitors all adhere to the basic 
hydrophobic three-pronged pharmacophore model. Each uses a unique, rigid, 
heterocyclic scaffold to project three lipophilic groups into the three sub pockets of the 
binding site that are occupied by the F'9, W23 and L26 side chains of p53. As these 
interactions are predominantly hydrophobic, altering the size of the lipophilic binding 
groups in order to optimally fill the binding site in a shape-complimentary manner 
greatly increases affinity. Potent members of all three inhibitor chemotypes bear halide- 
substituted aromatic groups positioned to maximise these contacts. Indeed the Nutlins, 
and most of the BDPD analogues rely entirely on hydrophobic contacts for their 
affinity. 135-140 Several compounds contain chloro phenyl substituents that closely mimic 
the 6-Cl-Trp modification discussed above in the context of peptide inhibitors. 
Efforts to increase polar interactions have also been shown to increase potency. 
When the o-amino group was added to the benzodiazepines to make a new polar contact, 
not made by the peptides, lead to increased affinity. 137 The spiro-oxindoles are built 
around an oxindole ring that has a H-bond donor and closely mimics the W23 residue of 
p53. ' 4' 
Because the p53-binding cleft of MDM2 is highly hydrophobic, minimal 
non-peptide inhibitors are by necessity very lipophilic and thus lack aqueous solubility. 
Throughout their development all of these inhibitors have evolved to bear a solvent 
exposed polar-group to improve aqueous solubility. The compounds have tolerated the 
addition of these differently. In the case of the benzodiazepines addition of these groups 
improves cellular potency but at the expense of some binding affinity. To date, no 
medicinal chemistry development of the Nutlins has been disclosed. However, the 
solvent exposed group is the main variation between the 3-compounds presented in the 
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original report 135 and a review of the patent literature suggests considerable dependence 
of biological activity on the nature of this group. 142 In the case of the spiro-oxindoles 
however, addition of a solubilising group to the core structure immediately resulted in 
increased binding and cellular activity and further optimization lead to development of 
the most potent inhibitors described to date. 132 
Whether solubilising groups just act as property improving appendages or become an 
additional pharmacophoric feature depends largely on their attachment point. Comparing 
the docked pose of MI-219 (Figure 12) and the crystal structures of the p53 peptide 
(Figure 5) shows that the chain mimics hydrophobic contacts made by L22 of p53. The 
polar groups are thought to mimic polar contacts made by the Pmp or Glu residues of the 
optimized peptides. The crystal structures of Nutlin-2 (Figure 10) and BDPD (Figure 11) 
show that their solubilising groups face to the opposite side of the binding site and could 
not make the same interactions. Given that the lid structure is now known to be closed 
upon small molecule binding it begs the question does this interact with solvent exposed 
groups on these inhibitors? 
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Figure 10 X-ray co-crystal structure of Nutln-2 (shown as cyan CPK sticks) bound to MDM2 (PDB 
code: 1RV1)IM MDM2 is shown as a grey CPK surface 
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Figure II X-ray co-crystal structure of a 1,5-benzodiazepienedione inhibitor (shown as magenta 
CPK sticks) bound to MDM2 (shown as a grey CPK surface) bound to MDM2 (PDB code: 1T4E). 
This is the only co-crystal structure in which some of the MDM2 lid region is maintained. This 
region remains closed over the L26 sub-pocket denoted by the blue arrow. The green arrow denotes 
the attachment position of solvent exposed groups during subsequent development of this series. 
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Figure 12 Spiro-oxindole inhibitor MI-219 (shown as purple CPK sticks) docked into MDM2 (PDB 
code: IYCR, ' shown as a grey CPK surface). These compounds mimic all off the features of the 
peptide and as a result are the most potent known inhibitors. Strategic positioning of the solvent 
exposed group allows these compounds to simultaneously mimic the hydrophobic interactions of 
L22 in the wt-p53 the additional polar contacts made by the phosphomethyl phenylalanine and the 
glutamic acid of the optimized peptide. 
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Compounds 1-6 (Figure 13) and MI-219 (Figure 12) were all reported by 
Shaomeng Wang's group at the University of Michigan. '28' 132' 133' 141,143 Compound 1 
was discovered through virtual screening for compounds that matched the basic 
pharmacophore shown in Figure 6 followed by docking into MDM2 from the X-ray 
structure 1 YCR. ' It inhibits the MDM2-p53 PPI at nM concentrations and induces a 
non-genotoxic p53 response in cell lines that possess wt-p53.128 No further analogues of 
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Figure 13 A diverse range of inhibitors of the MDM2-p53 PPI have been discovered by the Wang 
group using virtual screening. '2*'43 
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1 have been reported. Compounds 2-6 were discovered by virtual screening using an 
ensemble based receptor model that combined multiple protein structures to better 
represent flexibility within the binding site. Compound 2 was particularly potent with Ki 
of 110 nM. The remaining compounds all exhibit low pM activity. Interestingly, only 
compound 6 from this report possesses three potential binding groups and docking 
suggests that 2 binds without occupying the L26 subpocket. 143 No further analogues of 
these compounds have been reported. 
A series of isoindolinone based inhibitors, exemplified by compound 7 (Figure 14) 
were discovered and developed using in silico screening and structure based design in 
the context of MDM2 from the X-ray structure IYCR. ' The most potent of these 
inhibitors exhibit low pM binding activity but importantly show growth inhibition in the 
NCI 60 cell-line panel. COMPARE analysis indicted that these represent a novel class of 
anti-cancer agent. i°d They also induce transcription of p2l and MDM2 consistent with 
p53 activation. 145''°6 These inhibitors were suspected to display multiple binding modes 
as supported by docking. NMR analysis of 12 analogues bound to MDM2 narrowed the 
possible binding modes down to four possible poses in which either the isoindolinone or 
chloro phenyl groups occupy the W23 sub pocket. 147 This information will be useful to 
guide further development of these inhibitors. 
A pharmacophore derived from the p53 peptide lead to the discovery of a large 
acylsulfonamide inhibitor (12) with low gM binding and cellular activity. '48 However 
subsequent studies show that this molecule causes precipitation of MDM2. 
'34 
Compound 10 was discovered using structure-based computational design to design 
a library of compounds based on a scaffold that projects its side chain functionalities 
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Figure 14 A structurally diverse range of reported inhibitors of the MDM2-p53 PPI 
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with distance and angular relationships equivalent to those seen in the MDM2 
interacting motif of p53. It inhibits the MDM2-p53 PPI at 12µM concentrations. 
Chemical shift perturbation studies confirmed that 10 binds to the p53 binding pocket of 
MDM2.149 
A series of compounds based on a bicyclic[2.2.1]heptane scaffold (11) were 
discovered using unity and docking into IYCR. They were reported to inhibit the 
MDM2-p53 PPI and induce apoptosis in cancer cells. No binding affinity has been 
reported. 150 
The terpheny] scaffold has been used to mimic a number of a-helices and disrupt 
other important PPI's such as those between the pro-apoptotic protein Bak and the anti- 
apoptotic proteins Bcl-XL and Bcl-2.15' The phenyl rings adopt a staggered conformation 
and the orientation of their substituents mimic the p53 residues involved in binding to 
MDM2.152 Compound 13 exhibited high affinity for MDM2 but showed no cellular 
activity. However a weaker binding analogue showed p53 induced transcription activity 
at 30 pM concentration. 153 
A series of diazepine inhibitors similar to compound 14 were designed based on the 
benzodiazapien-l, 4-dione X-ray co-crystal structure IT4E, 122 on the basis that this 
scaffold would mimic the p53 a-helix. Inhibitors with low pM affinity were prepared but 
no cellular activity Was reported. 154 
The chalcones, exemplified by 15, were the first class of inhibitors to be described. 
They have been shown, by NMR to bind to MDM2 with the chloro phenyl group 
occupying the W23 pocket. 155 The remainder of the molecule makes contacts outside of 
the binding site and a salt bridge between the acid of the ligand and K51 of MDM2. 
However they have been shown to be unable to dissociate the preformed complex. 
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Replacing the carboxylic acid with boronic acid resulted in molecules that induce 
apoptosis in p53"ý+ HCT-I 16 with 10 fold selectivity over the corresponding isogenic 
p53-'- cell line. 156 
Compound 16, dubbed RITA (reactivation of p53 and induction of tumour cell 
apoptosis), was discovered using a cell proliferation assay with HCT p53+'1+ and p53 -1- 
isogenic cell lines to screen for compounds that could stimulate growth arrest in a p53 
dependent manor. This compound is particularly interesting as it binds to p53 rather than 
MDM2. Although it has been shown not to dissociate the preformed complex, it inhibits 
the PPI between the two proteins induce p53 accumulation, transcription of its target 
genes and apoptosis in a non-genotoxic manner. ' 57 
The natural product hexylitaconic acid (9) is reported to inhibit the MDM2-p53 PPI 
at 230 µM concentrations no cellular data has been published. '58 
The oxindole 17159 and spiro-oxindole 18160 from the patent literature again show 
the potential of the oxindole to mimic W23 of p53.17 is reported to inhibit the MDM2- 
p53 PPI and induce p53 accumulation and transcription of p21 in cells expressing wt 
p53. No indication of the potency was given. 18 Is reported to inhibit the MDM2-p53 
PPI at 372 nM concentrations. 
Most recently a novel class of inhibitor (compound 8) was discovered161 using a 2D 
similarity search based on Nutlin-3 followed by shape matching with a negative image 
of the MDM2 binding site. 8 Is of particular interest in the context of this thesis as it was 
also a hit in the virtual screening described in Chapter 3. A number of analogues of this 
compound were prepared that exhibit low pM binding, and selectively inhibit 
proliferation of cells expressing wt p53 over those expressing the mutant protein. 161 
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The sulfonamides described in Chapter 2 (compound 19) were also discovered 
through structure based screening using LIDEAUS. 162,163 
1.9 Therapeutic Window 
The key question for any therapeutic strategy that aims to activate the p53 response 
is whether or not this will result in a selective effect on tumour cells as opposed to the 
cells of healthy tissues. p53 has been linked to ageing and it has been suggested that p53 
activation in normal cells is responsible for some of the side effects of traditional 
chemotherapy. 31,164,165 
There is evidence that elevating levels of p53 by MDM2 suppression is tolerated. 
For example, it has been shown that mice with a hypomorphic MDM2 allele produce 
only about 30% of the normal level of MDM2 and exhibit increased transcriptional and 
functional activation of p53. '66 Although the animals are small and show p53-dependent 
apoptosis of lymphoid cells, they are viable, do not age prematurely, and are resistant to 
tumour formation. 167 Similarly, in vivo suppression of MDM2 using antisense 
oligonucleotides has been demonstrated to result in therapeutic antitumor effects without 
overt toxicity. 122 From these and other results'68 it is clear that the p53 pathway differs 
significantly in normal and p53 wild-type cancer cells and that the latter are selectively 
sensitive to increases in p53 effector functions. 
Extensive pharmacological studies on the effects of inhibiting the MDM2-p53 PPI 
using both the Nutlin and spiro-oxindole based inhibitors also suggest that cancer cells 
are more susceptible to the proapoptotic effects of p53 than non-cancerous cells. ' 69-173 
The p53 response induced by MDM2 inhibitors leads to both cell-cycle arrest and 
apoptosis in tumor cell lines but only causes cell-cycle arrest in normal cells. 86,170, »i, 174 
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This selectivity is not only an important indicator of a potential safety margin it also 
suggests that by inducing cell-cycle arrest in normal cells MDM2 inhibitors can have a 
chemoprotective effect when used with genotoxic agents. By inducing GUS and G2/M 
arrest, Nutlin-3 has been shown to protect non-cancerous cells against the cytotoxic 
agents gemcitabine and paclitaxel, that kill proliferating cells in S- and M-phase 
respectively, without reducing their efficacy in cancer cells harbouring mutant p53. '75 176 
Nutlin-3 was also shown to be lack toxicity towards bone marrow cells both when used 
alone or in conjunction with the genotoxic agents doxorubicin, chlorambucil and 
fludarabine against leukaemia cell lines that express wt-p53.173' 177' 178 This is significant 
as bone marrow is very susceptible to the effects of genotoxic agents. 
The mode of action of MDM2 inhibitors is consistent with the target rationale. All 
compounds require cells to possess wt-p53 and a functioning downstream p53 pathway 
for activity. They cause expression of p53 transcription products such as p21, MDM2, 
PIG-3 and PUMA among many others (Section 1.4.3). Cells that overexpress the target, 
MDM2, are considerably more susceptible to apoptosis upon treatment with Nutlin-3 
than those that express only low levels. 86 p53 induction is non-genotoxic as shown by 
the lack of post translationally modified p53 found in cells treated with MDM2 
inhibitors. Furthermore, cells deficient in the enzyme ATM, which acts upstream of p53 
and effects its post translational modification in response to genotoxic stress, 33 are also 
susceptible to apoptosis induced by MDM2 inhibition. 179 These results indicate that the 
post translational modifications of p53 that occur in response to genotoxic stress are 
more necessary to prevent it binding to MDM2 than for activating its transcription factor 
activity. 32 That MDM2 inhibitors can induce a complete p53 response without a 
genotoxic stimulus bodes well for their potential as mono-therapeutic agents. 
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Both Nutlin-3 and MI-219 are orally bioavailable and show tumor regression in 
xenograft mouse models of human cancers that express wt, but not mutant, p53.86' 135,171 
Both compounds are well tolerated by the animals which show no overt signs of toxicity. 
Furthermore, neither inhibitor caused apoptosis in small-intestine crypts or thymus 
tissues that are known to be susceptible to p53 induced apoptosis. 180' 80,181 
1.9.1 MDMX: a possible barrier to p53 reactivation? 
MDMX is a homologue of MDM2 that also regulates p53 182 and is overexpressed 
in many cancers, 183 However its expression is not regulated by p53 so, like MDM2, it is 
not part of a negative feedback loop. It does not have ubiquitin ligase activity but it is 
itself a target for MDM2 ubiquitination. It binds p53 at the same site with similar affinity 
as MDM2 and in doing so blocks its transcriptional activity. A p53 based peptide 
inhibitor, which binds to both MDM2 and MDMX, has been shown to activate p53 in 
cells that overexpress both proteins and induce tumor regression in xenograft models. 184 
Despite the apparent similarities to MDM2, Nutlin-3 and MI-219 exhibit 260 and 
>10,000 fold less affinity respectively for MDMX than they do for MDM2. '7' MDMX 
overexpression can prevent p53 reactivation by Nutlin-3.185' 186 These results indicate 
that in cancers where MDMX is overexpressed, it is a potential barrier to successful 
targeting of MDM2. A recently solved co-crystal structure of MDMX bound to a p53 
peptide showed that the L26 pocket is smaller than in MDM2 explaining why MDM2 
inhibitors have such low affinity for MDMX (Figure 15). 187 The SAR of MDM2 
inhibitors is consistent with this observation. While the affinity of only very few MDM2 
inhibitors for MDMX has been reported, it does appear that the more potent and 
optimized they are for MDM2 the more selective they are for it over MDMX. Increasing 
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the size of the hydrophobic binding groups results in better occupation of MDM2 and 
increases potency such that optimized MDM2 inhibitors are probably to big to occupy 
the binding site of MDMX. 
The role of the lid in molecular recognition has previously been implicated for 
MDM2.12' A recent computational comparison of MDM2 and MDMX binding suggests 
that significant differences in the flexible N-terminus lid of the two proteins may affect 
how each initially recognizes p53 or indeed a small molecule and influences 
selectivity. 188 
The encouraging results observed with MDM2 inhibitors provide precedent that 
MDMX inhibition may also be achievable While the development of dual inhibitors of 
MDM2 and MDMX is desirable it appears that that MDM2 potency would be sacrificed 
in doing so. Ultimately specific inhibitors of each protein that could be used together or 
separately depending on which protein dominated in a particular cancer may ultimately 
be required. 
Figure 15 The overlaid co-crystal structure of MDMX (PDB code: 2Z5S) and MDM2 (PDB code: 
IYCR) bound to a p53 peptide (not shown). A: The L26 pocket of MDMX (gold mesh) is clearly 
smaller than that of MDM2 (Grey Surface). B: While most of the back bone of MDMX (Gold 
Ribbon) aligns well with MDM2 (Silver Ribbon) the helix that makes up the end of the L26 pocket is 
less well aligned. Differences in flexibility between the two proteins maybe responsible for the 
observed selectivity in binding small molecule inhibitors. 
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1.9.2 Conclusion 
The results from the in vitro and in vivo studies outlined above give a good 
indication of the safety of MDM2 Inhibitors as mono-therapeutic, orally bio available 
and non-genotoxic means of p53 reactivation. The selectivity they show for cancer cells 
underlies the lack of observed on-target toxicity. Furthermore results of these studies 
indicate the potential scope of this approach as a novel cancer therapy and create a 
profile of the type of tumors that are likely to respond to it. Profiling of tumors in 
patients to determine the status of the p53 pathway and its regulatory proteins will 
facilitate determining the best course of treatment for a given patient. 
What has been achieved thus far strongly supports the non-genotoxic activation of 
p53 in the battle against cancer. With an undisclosed analogue of the Nutlins (R7112) 
and the E3 ubiquitin ligase inhibitor, JNJ-26854165, now in clinical trials and MI-219 in 
late stage, pre-clinical development this goal is closer than ever. The ultimate proof of 
concept will be if the promise shown by MDM2 inhibitors in the laboratory can be 
translated to the clinic. 
1.10 Aims of this project 
This project aims to find novel MDM2-p53 PPI inhibitors. In Chapter 2 attempts to 
develop a known but unoptimised MDM2 inhibitor are described. Chapter 3 uses 3-D 
shape based virtual screening to look for new inhibitors. Chapter 4 investigates an 
alternative benzodiazepine based scaffold and the possibility of using the 
1,3-dihydrobenzimidazolin-2-one ring system as a tryptophan mimic as the basis for 
developing new inhibitors. The work is guided by what is known about the structural 
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aspects of the three main classes of inhibitor. Detailed background discussion for each 
approach is provided at the start of each chapter. 
1.11 Fluorescence polarization binding assay. 
All assays of the compounds described herein, both in this project and the work 
that preceded it, were performed at Cyclacel. The binding activity was evaluated using a 
fluorescence polarization based competitive binding assay. Detecting protein-ligand 
binding by fluorescence polarisation is based on the principles that when a fluorophore is 
excited by plane polarized light the emission created is also polarised; that smaller 
molecules rotate faster than larger molecules in solution and that rotation depolarizes the 
emission light. Fluorescence polarisation measures the vertical and horizontal 
components of fluorescence. As the process of fluorescence requires a measurable 
amount of time, during which rotation occurs, polarisation values are inversely related to 
the speed of molecular rotation which is related to molecular weight or volume. 
Therefore a fluorescently labelled ligand will have a higher polarisation value when 
complexed with any molecule large enough to slow its rate of molecular rotation in 
comparison to a low polarisation value of the uncomplexed rotating ligand. In an assay 
an active inhibitor will increase the concentration of uncomplexed fluorophore 
proportional to its concentration and affinity for the protein, resulting in reduced 
polarisation which allows the binding activity of the inhibitor to be determined. 
For the purposes of screening potential inhibitors of the p53-MDM2 interaction a 
fluorescently tagged p53 based tracer peptide (fluoroscein-MPRFMDYWEGLN) and 
full length MDM2 were used. The peptide sequence, MPRFMDYWEGLN, is an 
optimized p53 based peptide (known as the 12/1 peptide) and has been described 
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previously127,189. The activity of each compound was determined and reported as the 
concentration required to displace 50 % of the tracer peptide from the protein (IC50, µ1\'I). 
Throughout the study compound 19, Nutlin-3 and the optimised 12-1 peptide (non- 
labelled) are used as positive control compounds. The binding assay is the first step of 
the screening cascade and the most important for the discussion of this project. Only 
compounds that were active in it would be considered for functional cell assays. 
1.11.1 Loss of assay sensitivity 
During the course of this investigation the FP assay became considerably less 
sensitive. This was thought to be due to degradation of the MDM2 protein. Although 
attempts to improve the assay were unsuccessful, it was possible to correct the results 
relative to the positive control inhibitors that were used through out the study and 
preceding work. Compound 19, Nutlin-3 and the 12-1 peptide showed ICso values that 
were on average 3.18 fold higher than previously observed (Table 1). The IC50 values of 
compounds determined under the less sensitive assay conditions were normalised with 
respect to the previous work by dividing the observed value by 3.18. Compounds that 
showed measureable inhibition at 500µM are also noted and where possible the same 
correction factor is applied to these too. While the assay is insufficiently sensitive to give 
accurate quantitative data, it is sufficiently sensitive to determine a compounds relative 
activity and distinguish active compounds from inactive ones. 
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FP FP Relative 
Entry Compound (IC5o, pM) (ICso, PM) decrease 
Original low sensitivity (times) 
1 19 26.4 80 3.03 
2 Nutlin 0.45 1.42 3.14 
3 12-1 peptide 0.77 2.6 3.38 
4 Mean 
---- ---- 
3.18 
Table 1 The loss in sensitivity was consistent for all of the control compounds used throughout the 
study. An average of this was used to normalise results with respect to previous assays. 
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2. Bisarylsulfonamides 
2.1 Introduction 
Bisarylsulfonamides, as exemplified by compound 19, were investigated as 
possible inhibitors of the MDM2-p53 PPI. This work was a continuation of a hit-to-lead 
study initiated at Cyclacel. The aim of this study was to investigate the structural activity 
relationships (SAR) of these compounds and to determine if they could be developed 
further as potential non-genotoxic cancer therapies. A series of analogues of 19 were 
prepared to investigate the importance of various structural features with respect to 
target affinity. Their ability to bind to MDM2 and inhibit the PPI between it and a 
fluorescein labelled peptide, based on the MDM2 binding region of p53, was determined 
using a fluorescence polarisation based competitive binding assay (Section 1.11). In 
order for this series of compounds to be considered suitable for further development, 
active analogues would need to exhibit binding activity at low micro or nanomolar 
concentrations, show clear SAR, not contain the reactive 5-chloro-4-nitrothiophene 
moiety and induce a non-genotoxic p53 response in cell lines containing wt-p53. 
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The following sections describe the discovery and the results of an initial hit to 
lead investigation initiated at Cyclacel. The results of this project are then discussed in 
the context of what was known from the previous work at Cyclacel and about the most 
important inhibitors described in the literature. 
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2.2 Discovery 
The bis-arylsulfonamide MDM2 inhibitors, exemplified by 19, were identified by 
virtual library screening of the Maybridge compound library using LIDAEUST"' (Llgand 
Discovery At Edinburgh UniverSity). t62 LIDAEUS"" is a structure-based, database 
mining program used to find potential lead compounds for specific targets. 19° The 
program automatically docks small-molecule libraries into the target binding site. Hits 
are generated based on how well the molecule is deemed to dock within the binding site 
of the target. In this screening campaign the p53/MDM2 crystal structure (1 YCR) 
determined by Kussie et al' was used as the target. 
This approach yielded 191 hits 7 of which showed binding activity with 
IC5o< 100 pM in a fluorescence polarisation competitive binding assay. These were 
typically aryl and thienyl-sulfonamides and sulfonate esters. From these, the 
sulfonamides were selected for further investigation as they show better stability than the 
sulfonate esters, are easier to prepare and allow more diversity to be achieved in an 
analogue study as their nitrogen can carry an additional substituent which the oxygen of 
the sulfonate ester cannot. The latter consideration is of particular importance with 
respect to this target, as molecules with three groups, that could potentially fill all three 
sub-pockets of the MDM2 binding site, could be investigated. Through this series of 
screening and selection the lead compound 19, which exhibits low pM activity in the FP 
binding assay, was selected as a starting point for the investigation of bis-aryl 
sulfonamides as potential MDM2-p53 PPI inhibitors. 
Functional assays showed that these compounds did induce a p53 response in 
cells as would be expected for MDM2-p53 PPI antagonists. Compound 1 and its 
analogues significantly induced p53 transcriptional activity, measured in a 
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luciferase-based p53 reporter gene assay (Figure 16). As expected, downstream p53 
regulated transcription products, p2l and MDM2, were induced in cancer cells treated 
with bis-arylsulfonamides (Figure 17). These p53-MDM2 antagonists potently and 
selectively killed cancer cells by apoptosis. The effects of the compounds was not 
limited to cells containing wild-type p53, suggesting that either another target of MDM2 
is affected or that these compounds also exhibit non-MDM2 specific activity. It is 
possible that regulation of the E2F-1 transcription factor is also involved in the mode of 
action of p53-MDM2 antagonists. Compound 19 down regulates E2F-l levels and 
transcriptional activity (Figure 17). The N-terminus of MDM2 is known to physically 
and functionally interact with E2F-119-193 
Figure 16 Luciferase-based p53 reporter gene assay shows that compound 11) induces a 
concentration dependent increase in p53 transcriptional activity. 162 
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Figure 17 Western blot analysis shows a dose dependant increase in p53 and its transcription 
products and down-regulation of E2F1 at low pM inhibitor concentrations of 19.162 Concentrations 
of 19 are 0 pM, 16 pM, 8 pM and 4 µM from left to right for each time interval. 
2.3 Early development SAR and binding hypothesis 
2.3.1 Replacing the 4-nitro and 5-chloro substituents 
Prior to the start of this project a number of analogues of 9 were prepared and tested 
at Cyclacel to investigate the importance of various parts of the molecule with respect to 
binding activity. Replacing the 5-chloro and 4-nitro substituents of 19 was important for 
the development of these inhibitors. Such electron deficient thiophene systems are 
highly activated towards nucleophilic aromatic substitution at the 5-position. In vivo 
such reactive compounds would be susceptible to attack by nucleophiles such as 
glutathione, whose function it is to neutralise reactive and potentially toxic 
compounds. 194 Analogues of 19 bearing the 5-chloro and 4-nitro substituents were 
indeed found to react with reduced glutathione via nucleophilic aromatic substitution at 
the 5-position and the resulting compound did not inhibit the PPI. 
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Entry Compound. R' R2 R3 FP IC5o/ pM 
1 19 Cl NO2 p-Cl 26.41 
2 20 Cl H p-Cl 319.53 
3 21 H NO2 p-Cl 123.21 
4 22 NO2 H p-Cl 462.38 
5 23 Br H p-Cl 290.22 
6 24 Cl Br p-Cl >500 
7 25 Br Br p-Cl 197.73 
8 26 Me NO2 p-Cl >166.67 
9 27 Et NO2 p-Cl 237.38 
0 
10 28 hs NO2 p-Cl 16.16 
11 29 NO2 p-CI >500 
0 
12 30 NO2 p-Cl 418.66 
OH 
13 31 NO2 p-CI 64.38 N 
H 
14 32 NO2 p-Cl 154.48 
N 
I5 33 S} H p-Cl >500 
9, 
O 
16 34 H p-CF3 146.49 
17 35 H p-CF3 >500 
N 
CF3 
18 36 N/ H p-CF3 349.86 
O 0 
19 37 Me CI N p-Cl 122.87 
10 
- 
20 38 Cl Ci 
aNH 
p-Cl 134.58 
Table 2 Initial investigation into replacing the 4- and 5-substituents at Cyclacel. 
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A series of analogues of 19, investigating alternative 4- and 5-substituents, were 
prepared (Table 2). Analogue selection was not systematic but looked at a variety of 
analogues for which there were readily available starting materials. Most of these 
compounds were considerably less active than 19. However 28 (Table 2, Entry 10) 
showed slightly increased activity over 19. Also of interest was 31 (Table 2, Entry 13) 
which was only about 2 fold less active than 19. These compounds are starting points for 
further investigation and are discussed in detail in Sections 2.6.3 and 2.6.4. 
23.2 Alternatives to the Thiophene Ring System 
A limited number of compounds containing heterocyclic, bicyclic or phenyl ring 
systems, for which the required starting materials were readily available were prepared 
and investigated as possible alternatives to thiophene (Table 3). All analogues showed 
considerably less binding activity than 19. 
2.3.3 Modifying the N-Substituents 
Analogues in which the N-substituents were varied were prepared (Table 4). 
Different types and numbers of substituents were well tolerated as were the use of 
benzyl instead of phenyl N-substituents. However all analogues displayed similar 
activity with only 55 and 59 being slightly less active than 19 (Table 4, entries 2 and 6). 
These analogues have smaller and larger p-substituents respectively than 19. Further 
investigation into the nature and pattern of these substituents was required to determine 
if any SAR existed. This was the initial starting point for the work in this project. 
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Entry Compound Cy R R FP ICS (AM) 
ý` 
1 39 IN H CF3 278.10 
2 40 ýö 
- 
H CF3 448.41 
G 3 41 I_ H CF3 106.46 
4 42 H CF3 193.10 
5 43 sN I H CFA 165.39 
6 44 NH I 
ý 
CF3 308.00 
S- -- N 
N 8 45 Iý H 
0 
CF; 374.60 
9 46 H CF- 274.99 
10 kH 47 ýH" Ns H >500.00 
11 
s 
48 HN Cl H >500.00 
12 
EtOZC S 
49N Cl H >500.00 
13 50 Eý2ý Cl H 331.38 N 
H 
14 51 7N Cl H 418.42 
N H 
15 52 °2" Cl H >500.00 
16 53 H CFj 150.83 
02N 
17 54 
CI 
IoH CF3 128.73 
Table 3 Initial investigation into alternatives to the thiophene ring system at Cyclacel. 
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Entry Compound n R' R FP IC50 (µM) 
1 19 0 Cl H 26.41 
2 55 0 F H 41.90 
3 56 0 CF; H 20.39 
4 57 1 H F 26.98 
5 58 1 H Cl 24.77 
6 59 0 OMe H 44.78 
Table 4 Initial investigation at Cyclacel show that benzyl and phenyl N-substituents are tolerated as 
are various groups on their aryl ring. 
Limited investigations were also undertaken to investigate N, N-disubstituted 
analogues (Table 5). The additional N-substituent was not just tolerated but in most 
cases actually improved activity. This lead to compound 66, the most potent inhibitor in 
the series (Table 5, entry 8). This is consistent with the hypothesis that compounds 
bearing an additional substituent would potentially have better shape complimentarity 
with the binding site and occupy all three sub-pockets where the bis-aryl analogues, such 
as 19, could only occupy two sub-pockets. However the results were not consistent and 
posed more questions than answers. For example, why would compound 60, (Table 5, 
entry 2) show such high activity when the additional group it possesses is too small to 
occupy an additional sub-pocket yet the intermediate sized i-Pr group of compound 61, 
(Table 5, entry 3) essentially abolishes activity and some larger benzyl substituents 
enhance activity (Table 5, entries 4 and 5)? While it could be argued that the total loss of 
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activity by the larger o-substituents of 64 and 65, (Table 5, entries 6 and 7), was because 
these groups made the molecule too big to fit in the binding site or, in the case of the 
nitro group in particular, that they were just chemically unsuitable for the binding site, 
the total loss of activity was still somewhat surprising. 
CI S 
S\O 
02N Zýll 
11ý4 
Entry Compound. N R R FP ICso/ µM 
1 19 0 Cl H 26.41 
2 60 0 Cl Nie 5.87 
3 61 0 Cl 249.35 
4 62 0 Cl 7.08 
5 63 0 Cl -CF' 
i 
8.45 
6 64 0 Cl >500 
7 65 0 C1 I 
OCF3 
>500 
8 66 1 CF, OF 3.00 
Table 5 Initial investigations at Cyclacel showed that additional N-substituents may increase binding 
but there is no clear pattern in how they do so. 
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2.3.4 SAR Summary 
Only Sulfonamides and Sulfonate esters are tolerated 
Sulfonamide cannot be reversed or replaced with carboxamide 
Sulfonyl group must be attached directly to thiophene 
Thiophene > Heteroaromatic or Phenyl 
But is very dependant on substituents 
00 
n=0.1 
S S, Various substituents and 
CIýY Nn Ph '0- substitution patterns are tolerated 
R' larger p-substituents abolsh activity 
O-, N 
ý R': Substitited Bn > Me >H 
5-Chloro-4-nitro consistiently the most active substituents 
It may be possible to use alternative 5-substituents 
4 poiibo1! Ieq:: rc- 1ýý'rýeý ". 
. 
ýýctgdýt. on. 
Figure 18 SAR Summary after initial investigation at Cyclacel prior to the start of this project. 
Very little SAR emerged from the preliminary investigations. What was known at 
this stage is summarized in Figure 18. These investigations posed some interesting 
questions and showed potential starting points for the development of these inhibitors. It 
was clear that alternative scaffolds to the sulfonamide, with the exception of sulfonate 
esters were inactive. Increasing the length between the sulfonyl group and thiophene 
abolished activity as did reversing the sulfonamide such that the thiophene is bound to 
the sulfonamide nitrogen rather than the sulfur. Yet increasing the length of the N-aryl 
link, in going from phenyl to benzyl was well tolerated and even slightly increased 
activity. Thiophene based systems still appear to be the best in binding assays and no 
alternative ring systems were found. But even for the thiophene based systems the 
5-chloro-4-nitro substituents appeared to be required for activity. However, some 
analogues showed that either could be replaced without total loss of activity. On the 
other hand, a wide range of N-substituents were tolerated on the opposite side of the 
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molecule. However, with the exception of a small number of analogues, which totally 
abolished activity, and some moderate increases in activity when N, N-disubstituted 
analogues were employed very little SAR was observed. 
2.3.5 Binding hypothesis 
At this stage the evidence from the analogue study pointed to dominance of SAR by 
the highly activated thiophene system. The relatively flat SAR could also be as a result 
of multiple binding modes. Macromolecular NMR studies of the N-terminus domain of 
MDM2 showed that the largest chemical shift perturbations upon binding these 
inhibitors were in the vicinity of the p53 binding site. The possible occurrence of 
multiple binding modes for the bis-arylsulfonamides could be due to their inability to 
completely fill the binding site as they only possess two potential binding groups. This 
notion was supported by molecular modelling. Docking studies, where 19 was docked 
into the binding site of MDM2 from the X-ray structure of the peptide complex (PDB 
code 1 YCR), ' showed the possibility of multiple binding modes (Figure 19). In the first 
pose the inhibitor fills two sub-pockets of MDM2 and only one in the second pose. Both 
of the poses shown suggest that the role of the nitro group may be as an H-bond acceptor 
with glutamine 72 or glutamine 59 respectively. That the N, N-disubstituted analogues 
could better fill the binding site is also supported by docking (Figure 20). Docking 
compound 66 into MDM2 (I YCR)', suggests it is capable of occupying all three sub- 
pockets of the binding site and making the H-bond interaction, via its nitro-group, with 
glutamine 72. The increase in activity observed for the NN-disubstituted analogues is 
consistent with better filling of the binding site. However, the increase 
52 
Figure 19 Two proposed poses for target binding. Compound 19 (green CPK sticks) docked in 
MDM2 (1 YCR)'(MDM2 residues, yellow CPK sticks). 
53 
54 
7"T 
Figure 20 66 (green CPK sticks) docked in 11D112 ll 1'CR)' Top 1MDM2 residues, yellow 
CPK sticks), bottom (grey surface). 
observed in binding activity is more modest than would be expected for filling an 
additional sub-pocket. The extra hydrophobic contacts could be somewhat offset by an 
increased entropy penalty that these more flexible molecules might pay upon binding. 
2.4 Results and Discussion 
The following sections describe the work performed in this project. The aim was 
to investigate various structural aspects of the molecules and answer some of the 
questions raised during the initial work at Cyclacel. Some starting points have been 
identified from the preceding work, here that work is completed by preparing more 
complete series' of compounds focused on specific parts of the molecule. The aim is to 
determine if the reactive groups can be replaced and a meaningful SAR established. 
2.5 Developing the N-substituents 
The PPI itself and the three best inhibitor classes rely mostly, or even 
exclusively, on making hydrophobic contacts with the binding site for their affinity. 
They maximize this by having excellent shape complimentarity with the binding site. In 
order for the arylsulfonamides to be developed they would have to have their size and 
shape optimized so they also exhibit excellent shape complimentarity with the binding 
site. To achieve this, a more rigid molecule of the correct size and shape would be 
required. A more rigid inhibitor of the correct shape, rather than a flexible one which 
could adopt the correct shape, would reduce the possibility of multiple binding modes 
and make a much better starting point from which to address the stability issues on the 
other side of the molecule. Rigid molecules would also pay less of an entropy penalty 
upon binding than flexible ones. Taking the thienyl moiety as one sub-site binding group 
and the sulfonamoyl as the scaffold most of this shape would be defined by the nature of 
55 
the N-substituent(s). The following sections take the previous work as a starting point. 
The initial investigation focuses on the N-substituents to try and determine if any SAR 
exists and the optimum shape for this part of the molecule can be established. A more 
complete set of analogues were prepared examining the effects of substitution pattern on 
binding. 
As the only the 5-chloro-4-nitrothiophene based analogues have shown consistent 
activity this group was maintained throughout the investigation of the N-substituents. 
Although replacing the 5-chloro group is dealt with later (Section 2.6), the methyl group 
was investigated as the first 5-chloro alternative at the same time as the work on the 
N-substituents was performed. A number of corresponding analogues based on it were 
prepared too. Although evidence suggested it was not active it is a similar size to 
chlorine (2, A vs. 1.8 A)195 so sterically should behave similarly if making hydrophobic 
contacts with MDM2 are the basis for the activity of these inhibitors. 
2.5.1 N-Aryl Substitution Pattern 
The optimised peptide, Nutlins, spiro-oxindoles and benzodiazepienediones all use aryl 
halide substituents, a structural feature shared with the sulphonamide inhibitors. The 
nature and substitution pattern of the N-aryl substituents was the first structural feature to 
be investigated. Whilst a number of analogues with various substituents in different 
positions had been investigated previously (Table 4) no systematic study of substituent 
position had been performed. The first set of analogues investigate the N-benzyl 
analogues mono-substituted with trifluoromethyl at each position of the benzene ring. 
The unsubstituted, p-chloro and 3,5-bis-trifluoromethyl analogues were also examined 
(Table 6). 
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The analogues were prepared in three steps from 2-chlorothiophene or 
2-methylthiophene (Scheme I). There is considerable difference in the reactivity of the 
various positions of thiophene towards electrophiles. Performing chlorosulfonation prior 
to nitration ensured the correct substitution pattern was achieved. Due to the deactivating 
nature of the substituents being added no di-substitution products were observed for the 
chloro-analogues. When the same chlorosulfonation conditions were used on 
2-methylthiophene however, the methyl group was sufficiently activating to allow 
significant dichlorosulfonated product to be formed in the first step. This problem was 
solved by diluting the reactants in chloroform and omitting PCl5 albeit with a lower yield 
than obtained for the chloro-analogue. Nitration with fuming nitric acid worked well for 
both systems. 
The final step allowed diversification of the N-substituent by the use of different 
benzyl amines. SNAr was found to be a competing reaction because of the highly 
activated nature of the thiophene ring system and the major contributor to the modest 
yields in the final step. Slow addition of no more than I eq of amine and TEA in a DCM 
solution to the sulfonyl chloride in DCM at 0°C, with the sulfonyl chloride always in 
excess helped to suppress this. 
CI S (a) CI S IS O (b) 
72, E 
CL/ CI 73% 
00 00 
C1 N HR 
02N H2N = R' 02N 
Scheme I (a) CISO3H, PC].,;, 0°C then ambient overnight. (b) 100% fuming HNO3 ambient 4 hours. 
(c) TEA (Ieq); benzvlamine (Ieq) DCM 0°C 5 min warmed to ambient. (R' see Table 6) 
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RSo 
H nl JR 
02N 
Entry Compound nR R' Yield FP IC50 (pM) SD 
1 19 0 Cl p-Cl n/a. 22.22 4.86 
2 67 1 Cl H 48% 28.88 3.58 
3 68 1 Cl p-Cl 40% 8.43 4.05 
4 69 1 Cl o-CFz 40% 11.35 3.73 
5 70 I Cl m-CF; 48% 13.6 2.61 
6 71 I Cl p-CF3 48% 10.18 3.31 
7 72 1 Cl m, m-CF: 35% 10.3 4.84 
8 73 0 Me p-Cl n/a* >250 
--- 
9 74 1 Me H 54% >250 
--- 
10 75 1 Me p-CI 29% >250 
--- 
11 76 1 Me o-CF; 61% >250 
--- 
12 77 1 Me m-CF: 58% >250 
--- 
13 78 1 Me p-CF; 69% >250 
--- 
13 79 1 Me m. m-CF: 68% >250 
Table 6 Increasing the size of the N-group from phenyl to benzyl and attaching substituents to the 
aryl ring appears to slightly increase activity but little or no SAR is seen upon changing the type or 
position of the aryl substituent. Replacing 5-Cl with 5-Me abolishes activity. *19 Previously 
prepared at Cyclacel. 
The FP assay shows that there is very little difference in binding activity when 
either the type or position of the aryl substituent is changed (Table 6). Going from 
phenyl to benzyl and adding a substituent both slightly increase activity. However the 
changes in activity are small and not what would be expected for ligands intended to 
bind to a well defined site relying mainly on hydrophobic interactions. None of the 
5-methyl analogues show any activity. Given the similar size of the two substituents this 
shows that the role of this chlorine is not solely to maximize hydrophobic interactions 
with the protein. These observations continue to support the two possibilities that (a) the 
observed activity is dominated by the 5-chloro-4-nitrothienylsulfonyl moiety as a whole 
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and the N-substituents are unimportant or (b) that multiple binding modes occur. More 
extensive variations to both parts of the molecule were performed to examine this. 
2.5.2 N-Picolyl groups 
All three of the most active literature inhibitors use pendant solubilising groups 
attached to the scaffold such that they project away from the binding site to improve the 
pharmaco properties of the compound. The small sulfonamide scaffold offers less 
possible points of attachment for solubilising groups than any of the most active 
inhibitors. So the physicochemical properties would need to be an intrinsic property of 
the core ligand. One possible way to alter the properties would be to use various 
heterocycles. Another reason to consider heterocyclic groups is that they could 
potentially make polar contacts with the binding site leading to increased affinity. This 
has been shown for the benzodiazepienediones. While most benzodiazepine analogues 
rely solely on hydrophobic interactions, some were able to make polar contacts and 
exhibited enhanced affinity for MDM2,138 
As a simple preliminary investigation to see if heterocyclic rings would be tolerated 
the benzyl of 67 was replaced with 2-, 3- and 4-picolyl groups in compounds 80,81 and 
82 respectively (Table 7, entries 1,2 and 3). All three compounds show the same activity 
and although they show almost two fold decrease in activity over the corresponding 
benzyl compound, 67, these groups are somewhat tolerated and indicate that other 
heterocycles could be used in the future. The corresponding 5-methyl analogues 83,84 
and 85 were also prepared but found to be inactive (Table 7, entries 4,5 and 6). 
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Sc ýO 
, 
C/'N 
ON1 
H2 
Entry Compound R Isomer FP IC50 (pM) SD 
1 80 Cl 2 27.52 16.49 
2 81 Cl 3 41.3 2 
3 82 Cl 4 38.05 7.75 
4 83 Me 2 >250 
--- 5 84 Me 3 >250 
--- 6 85 Me 4 >250 
--- 
Table 7 Replacement of benzene with pyridine rings. 
2.5.3 NN-disubsdtuted sulfonamides 
The most active compound at the start of this investigation was 66 (ICSO, 3 µM) 
(Table 5, entry 8). As it incorporated three potential hydrophobic binding groups, it was 
consistent with the hypothesis that mimicking all three p53 residues would result in 
better occupancy of the binding site and the resulting increased hydrophobic interactions 
would lead to increased activity. 
Initially the plan was to complete this study by determining the optimum 
substitution pattern on the NN-bis benzyl rings and to determine if the observation with 
N-alkyl substituents is significant. Synthetically the main challenge here would be to 
prepare the required secondary amines so the compounds could be prepared by 
condensation of the desired amine and sulfonyl chloride, as in Scheme 1, or to introduce 
the second N-substituent to the N-benzyl analogues, described in section 2.5.1, using the 
modified Mitsunobu chemistry developed by Tsunoda. ' 96 ' 197 
Some preliminary investigations using commercially available amines were 
performed and the previously inactive compounds 64 and 65 (Table 5, entries 6 and 7) 
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were retested and found to have low 
. tM affinity similar to the other bis-benzyl 
analogues (Table 8, entries 3 and 4). This observation indicates that some of the 
anomalies shown in Table 5 arose from the original assay. Compared to the 
corresponding mono benzyl, compound 67 (Table 6, entry 2) the NN-bisbenzyl 
compound, 86, showed a 2-fold increase in potency consistent with previous 
observations (Table 8, entry 1). However addition of the N-methyl substituent in 
compound 87 (Table 8, entry 2) showed the same activity as the corresponding analogue, 
67 (Table 6, entry 2). This observation is consistent with the methyl group being too 
small to make a meaningful contribution to the affinity. Again all of the 5-methyl 
analogues were inactive (Table 8, entries 5-7). 
0 
Rs ýsýýo \N-R' 
O2N R' 
Entry Compound R R' R" FP IC5o SD 
1 86 CI Benzyl Bcn/\ 12.65 2.75 
2 87 Cl Benzyl Mcth\ l 24.55 0 
3 64 Cl p-Cl Phenyl p-NO, Bcnil 7.54 --- 
4 65 Cl p-CI Phenyl in-OCF, Benn I 7.51 --- 
5 88 Me Benzyl Bcniý 1 >250 
--- 
6 89 Me Benzyl Meth\ I >250 
--- 
7 90 Me Beni \1 I'hi'ný I >250 --- 
Table 8 Tertiary sulfonamides show increased activity over corresponding secondary ones but show 
little variation between analogues. 5-methyl analogues show no activity. 
The flat SAR observed for a variety of N-substituents supported the hypothesis that 
the 5-chloro-4-nitro-2-sulfonamoyl substituted thiophene ring was dominating the SAR. 
Because of this synthesis of a series of analogues to investigate the aryl substitution 
patterns of the NN-bisbenzyl sulfonamides was discontinued until after alternatives to 
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the chloro and nitro groups were investigated but ultimately abandoned when it became 
apparent that these groups could not be replaced. 
2.5.4 Increasing rigidity; a-branched benzyl substituents 
The NN-bis benzyl analogues, like 67, have two additional single bonds and are less 
rigid as a result. Although docking suggests they are the correct size and can adopt the 
correct shape to occupy the binding site, their increased flexibility means they may have 
to pay too large an entropic penalty to do so and hence only show a modest increase in 
binding activity over the N-benzyl analogues. The Nutlin, benzodiazepienedione and 
Spiro-oxindole series of inhibitors are all based on rigid, cyclic scaffolds that direct their 
binding groups into the three sub-pockets occupied by the three p53 residues. It has been 
demonstrated that stabilizing the a-helix of the p53 peptide 131 and using geometric 
constraints in the benzodiazepienes138 considerably improves binding. Various ways to 
prepare more rigid sulfonamide based inhibitors were considered. N-acylsulfonamides, 
such as 91, where the carbonyl group would help to lock the configuration, were 
considered. However, a very similar class of compounds were being investigated as an 
anti cancer agents at that time albeit on a different target by another group. 198 
Furthermore it was felt that these compounds would not lend themselves well to adding 
a third binding group at the nitrogen, so no further investigation was performed. 
cl s s° 
o 
1IHýý 
02N Cl 
91 
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It was instead decided to investigate attaching the third binding group to the 
a-carbon of the N-benzyl group. Given that additional N-substituents appeared to 
enhance binding, it seemed reasonable to investigate whether substituents at the adjacent 
carbon could do the same. This would lead to a much more rigid and potentially more 
ligand efficient molecule in which two of the binding groups would be attached to the 
same sp 3 centre. Firstly both enantiomers of a-methylbenzyl analogues were prepared by 
the same route shown in Scheme I using the optically pure a-methylbenzylamines. This 
investigated the possibility of using substituents at the methylene carbon of the benzyl 
group. 
RSS; 
'N 
_ý -lü 
02N 
Entry Compound R Enantiomer FP ICso (µM) SD 
1 92 Cl S 18.75 5.65 
2 93 Cl R 21.4 1.1 
3 94 Me s >250 
--- 
4 95 Me R >250 
--- 
Table 9 C-methyl substituents are tolerated but do not enhance activity over the corresponding 
des-methyl analogue 67. 
The activity of the 5-chloro compounds 92 and 93 (Table 9, entries I and 2) was the 
same as the corresponding unsubstituted N-benzyl and N-methyl-N-benzyl compounds, 
67 (Table 6, entry 2) and 87 (Table 8, entry 2) with no significant difference observed 
between the enantiomers. This result is expected as the methyl group is too small to act 
as a binding group in its own right. It did at least show that such modifications were 
tolerated. In keeping with the previous work the 5-methyl derivatives, 94 and 95 showed 
no activity (Table 9, entries 3 and 4). 
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Larger substituents would need to be examined to prove this theory. The obvious 
choice was to replace the a-methyl with phenyl as in compound 96. Docking studies 
showed top ranked poses that occupied the site filling all three subpockets (Figure 21). 
Further evidence that supported this idea was the discovery of 1.128 This novel class of 
inhibitor exhibited nM affinity and demonstrated all the correct attributes in functional 
cell assays. Two of the binding groups on 1 are attached to the same spa carbon 
supporting the idea that the phenyl groups could be presented in this manner. 
To investigate this, compound % was prepared in the same way as the sulfonamides 
already described, by reaction of the required sulfonylchloride with 
diphenylmethanamine. As the amine was not readily available and was prepared in 2 
steps from benzophenone via reduction of the corresponding oxime (Scheme 2). 199 
The oxime synthesis was facile and proceeded in high yield. Reduction of the oxime 
to diphenylmethanamine was performed in the presence of magnesium and ammonium 
formate. 20° In the final coupling step excess base was used to mop up any free acid 
which could protonate the amine making it into a leaving group driven by the stability of 
the resulting benzhydryl carbocation. It was noticed that the characteristic deep red 
colour of the benzhydryl cation formed upon addition of the amine to the reaction 
mixture and this could account for the modest yield. 
90 ý'ý GHI/ 
02N 
H 
NN 
OH 
1 
64 
Figure 21 Docking suggests that a-branched sulfonamides could bind to MDM2 filling all three sub- 
pockets. Compound % docked in I YCR. C, Green; H, White; Cl, pink; N, blue; 0, red; S, yellow. 
G 
HO, u Nq0G 
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ONN 
Scheme 2 Synthesis of %: (a) NH2OH"HCI, NaOH, EtOH, reflex (b) CHOO' NH4*, Mg, MeOH, rt 
(c) TEA, DCM, rt. 
Unfortunately 96 exhibited 2-fold less activity than 19 indicating that this strategy 
would not work (Table 10, entry 2). This is a modest change in activity upon addition of 
a substantial group indicating that this side of the molecule plays little part in 
determining the observed activity. At the same time compound 97 was prepared. It 
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possessed no N-aryl substituent but instead the n-butyl group. This small flexible group 
would not be expected to be able to sufficiently fill one of the sub-pockets so should not 
show activity. However, it exhibited similar activity to the lead compound, 19 (Table 10, 
entry 3). This observation conclusively showed that all that was required for activity was 
the highly activated thiophene ring and unless an alternative to it was found it would not 
be possible to develop this series further. When the activity of 96 and 97 were 
determined the assay had become less sensitive, as discussed in Section 1.1 1.1. 
0 
XS %S; N. R H 
02N 
Entry Compound XR 
FP Corrected SD (IC50. PM) (, C-,; o, PM) 
1 19 Clý 80 25.15 4.7 
Cl 
2% Cl 214.2 67.4 29.6 
k 
3 97 Cl 'ý/ý 122.9 38.6 14.6 
Table 10 Both a-Branched and linear alkyl N-substituents show similar activity to 19. 
2.6 Replacing the 5-chloro-4-nitrothienylsulfonamoyl group 
All the results presented up to this point show a very flat SAR indicating that these 
inhibitors are not interacting with the binding site mainly through hydrophobic 
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interactions as is the case for the most potent literature inhibitors. It was becoming clear 
that the activity of these inhibitors was due to the highly activated thiophene system and 
that the N-substituents were playing little or no role in determining binding affinity. The 
key question was: could either the 4- or 5-substituents be replaced to give a less reactive 
species that maintained inhibitory activity? Some alternatives to the 5-chloro and 4-nitro 
investigated at Cyclacel prior to the start of this project were discussed in Section 2.3.1 
(Table 2). Some potential starting points for further investigation were identified and are 
discussed in the following sections. 
2.6.1 5-alkyl substituents 
Sterically, a suitable replacement for chlorine is the methyl group. It has 
considerably different electronic properties but will have a net electron donating effect 
as opposed to the electron with drawing effect of chlorine. Most importantly for this 
investigation it is a much poorer leaving group so analogues based on it will be of a 
similar size to (Me, 2 A; Cl, 1.8 A)195 but not react like their chloro-counterparts. While 
previous results indicated that the methyl group was not a suitable chloro-replacement it 
was thought it might be useful to examine them in the context of other N-aryl 
substituents. The results of this have been presented throughout Section 2.5, and in all 
cases 5-methyl analogues show no binding activity. If the activity of these compounds 
was based mainly on them making hydrophobic contacts with the binding site a total loss 
of activity would not be expected. No activity was observed upon increasing the size of 
the alkyl substituent to ethyl or n-propyl (Table 11). 
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RlS 20 O 
N 
02N H 
. 'R2 
Entry Compound Rt R- FP (IC5o, jM) 
1 98 Et 11 >250 
2 99 Et p-0 >250 
3 100 Et o-CF; >250 
4 101 Et m-CF >250 
5 102 Et p-CE; >250 
6 103 Et m, m-iCF: i- >250 
7 104 n-Pr 11 >500 
8 105 n-Pr p-('I >500 
9 106 n-Pr o-('f, >500 
10 107 n-Pr m-Ca ; >500 
11 108 n-Pr p-CF; >500 
12 109 n-Pr >500 
Table 11 Investigation of 5-alkyl substituents 
2.6.2 Replacing the 5-chloro group with bromine and hydrogen 
Bromine and chlorine are interchangeable within the Nutlin series of inhibitors and 
both can be used at the p-position of the phenyl groups whilst maintaining activity. An 
obvious omission from the previous work was directly replacing the 5-chloro group with 
another halogen. Whilst bromine had been tried in positions 4,5 and 4 and 5 together, 
compounds 23,24 and 25 (Table 2, entries 5,6 and 7) it had not been used in the context 
of the 4-nitrogroup. Compound 110 was prepared to test this and found to be of similar 
activity to all the other 5-chloro-4-nitro-analogues (Table 12, entry 2). As it would also 
be possible to displace bromine via SNAr, this was further evidence that the activity of 
these compounds stemmed from their reactivity. 
The des-chloro compounds, 111 and 112, were prepared along with their 5-nitro 
isomers 113 and 114. The previous work had identified the corresponding N-p-chloro 
68 
phenyl analogue 21 as a low activity, non-reactive inhibitor that warranted further 
investigation (Table 2, entry 3). Neither 111 nor 112 showed any activity in this 
investigation (Table 12, entries 2 and 3). 
The 5-nitro isomer was also formed during the synthesis of these compounds as this 
position was not blocked by another substituent so was prone to nitration in the second 
step. Rather than separate the 4- and 5-nitrothiophenesulfonyl chlorides after nitration, 
the mixture of isomers was carried through the synthesis and the sulfonamides were 
separated by reverse phase preparative HPLC. The 5-nitro analogue, 114, showed low 
activity, (45%) inhibition at 500 pM (Table 12, entry 6), which, when corrected for the 
loss of assay sensitivity would mean an IC50 of >157. This was not considered 
sufficiently active to be significant and its des-chloro counterpart, 112, showed no 
activity at this level. In the previously investigations the 5-nitro analogue, 22, (Table 2, 
entry 4) was found to be inactive too. 
2.6.3 5-amino substituents 
One of the most promising starting points in replacing the 5-chloro substituent was 
compound 31 (Table 2, entry 13) which bore a 3-hydroxypiperidine in place of chlorine. 
With activity only 2.5 fold lower than compound 19 it was the second most active 
compound that did not bear the 5-chloro-4-nitro pair. Structurally, its most similar 
analogue, 32 (Table 2, entry 14) also showed some activity albeit over 2-fold lower 
again. 
69 
X\ S/ 
N. 
R 
FP Corrected 
Entry Compound XYR (IC50, µM) (ICso, µM) SD 
I 19 Cl NO880 25.15 4.7 
Cl 
2 110 Br \O j 67.6 22.5 9.9 CI 
3 111 H NO, >500 
--- --- 
4 112 H NO, \ >500 
--- 
--- 
5 113 NO2 Ii >500 
--- --- 
6 114 NO2 11 >500 45%@500µM 
--- ý CI 
Table 12 Active compounds tested under less sensitive assay conditions showing observed and 
adjusted ICM), values. All display similar activity to all other active compounds in this study. 
A series of analogues investigating a range of structural features including alcohol 
versus ether, secondary versus tertiary amine, cyclic versus linear and various chain 
lengths were prepared. Synthesis of the above analogues utilized the reactivity of the 
highly electron deficient 5-chloro-thiophene system. Compound 68 reacted with the 
required amine nucleophile in the presence of excess potassium carbonate to give the 
corresponding 5-amino compound (Scheme 3). 
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Scheme 3 The 5-ammo analogues were prepared from 68 by SNAr with the appropriate amine. 
None of these analogues showed the expected activity (Table 13, entries 1-14). 
Some of the secondary amines showed low activity (20-30 % inhibition at 500 µM). This 
was considered too low to be significant. Most surprisingly, 115, which bore the 
previously seen to be active 3-hydroxypiperidine showed no activity (Table 13, entry 1). 
To further increase structural diversity analogues based on a range of readily 
available amines were also prepared (Table 14). But again these exhibited little or no 
activity with the most active being the unsubstituted amino group displaying 40% 
inhibition at 500µM (Table 14, entry 1). 
2.6.4 The 5-thioacetate starting point 
One analogue which had emerged from the previous work, that did not possess the 
5-chloro substituent, was the thioester 28. It actually appeared to be slightly more active 
than 19 (Table 2, entry 10). The corresponding methyl thioether, 29, was totally inactive 
(Table 2, entry II). Thioesters are not particularly stable so it was quite possible that the 
activity was due to this. To investigate this it was proposed to prepare the corresponding 
amide, 137, and ketone 140. It was thought that the ester, with such an electron deficient 
leaving group would be too unstable to be useful. The amide was prepared by acylating 
the 5-amino analogue with acetic anhydride in the acetic acid (Scheme 4). This 
extremely electron deficient amine was a poor nucleophile and did not initially react 
with either acetic anhydride or acetyl chloride. A literature procedure for acylating 
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electron deficient anilines using catalytic sulfuric acid or acetic acid as solvent 201.202 was 
employed and the latter was found to work well for this substrate too. It was also 
possible to prepare the diacetylated product 138 by increasing the quantity of acylating 
agent and using catalytic H2SO4. Unfortunately no activity was observed for either 137 
or 138 (Table 14, entries 9 and 10). 
O 
R"R'N SO 
O2N H QCI 
FP ICso % Inhibition at 500 Entry Compound R'R"N (µM) µM 
1 115 HO 
N 
>500 
2 116 HON >500 
--- 
3 117 Me() 
N 
>500 
--- 
4 118 McO-CN >500 
--- 
5 119 HOB/ýNH >500 30 
6 120 "Oý'NH >500 30 
7 121 Ho"-"-" 
.. 
- >500 
--- 
8 122 Omi N ,. >500 20 
9 123 HO-NH >500 --- 
10 124 -1 O'ý'ýNH >500 25 
11 125 HO, 
_, 
-, 
__ 
N, >500 
--- 
12 126 N, >500 17 
13 127 HO's- NH >500 20 
14 128 HO"" >500 10 
Table 13 5-Amino analogues prepared to investigate compound 115 as a potential inhibitor. 
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O R"R'N S 
ýý SAN 
02N 
CI 
Entry Compound R' R"N FP IC5o 
% 
Inhibition at (µM) 500 µM 
1 129 NH2 >500 40 
2 130 NHMe >500 20 
3 131 NMe> >500 
--- 4 132 NEt> >500 
5 133 >500 
--- 
6 134 NH >500 32 
7 135 N ýý N >500 21 
8 136 McOOCNH >500 35 
9 137 AcNH >500 
--- 
10 138 (Ac)2N >500 
--- 
11 139 H2NO00'"'NH >500 
--- 
Table 14 Investigation of diversity of 5-amino substituents. 
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Scheme 4 Acid catalysed acylation of electron deficient amine; synthesis of 137: (a) Acetic anhydride (excess) 
H2SO4 (catalytic): (b) Acetic acid (solvent). I equivalent Acetic anhydride. 
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Unfortunately, 140 was not prepared. It was proposed to install the required ketone 
on the 2-position of thiophene first then chlorosulfonate, nitrate and condense with the 
necessary amine as had been done for the chloro and alkyl analogues. The ketone was 
introduced in two steps starting from 2-acylthiophene which was converted to vinyl 
thiophene via a Wittig reaction. Vinyl thiophene was reacted with the hypervalent iodine 
compound, hydroxytosyloxyiodobenzene (HTIB or Koser's reagent), in methanol to give 
the desired ketone203 (Scheme 5). Unfortunately this compound decomposed rapidly and 
it was not possible to synthesise beyond this point. 
O 
'-i; i5 
(a) (b) 
O 
Scheme 5 Synthesis of starting material required for preparation of compound 140 (a) KO(-BU, PPb3, ether; 
(b) HTIB, McOH. 
2.7 Conclusions 
A considerable number of analogues of the bis- and tris-aryl sulfonamides were 
prepared and their binding activity determined. The work was driven by what is known 
about the structure of the PPI and how the best literature inhibitors bind and some 
potential starting points from previous work on this series. The highly activated 
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thiophene system dominated the SAR and any attempts to modify the shape of the 
molecule were void as the activity did not stem from making hydrophobic contacts with 
in the binding site. 
That 97, which posses the N-n-butyl group has the same activity as the lead 
compound 19 was strong indication that these compounds were not binding in the 
expected manner. The fact that the only active chloro replacement was another halogen 
pointed to the reactivity as the source of activity. Anything that deactivated the 
thiophene system toward nucleophilic attack also reduced activity. Apart from replacing 
the chloro leaving group removing either of the electron with drawing groups is also 
deactivating and appears as lower activity in the binding assay. This would explain why 
it was not possible to replace, reverse or extend the sulfonyl linker between the sulfur 
and thiophene, all of which would be less electron with drawing, yet any modification 
could be performed on the N-substituent with very little change in activity. As no 
non-reactive alternatives to the highly activated 5-chloro-4-nitrothienylsuffonamoyl 
moiety were found these compounds are no longer been pursued as inhibitors of the 
MDM2-p53 PPI. 
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3. Shape based virtual screening for new leads. 
3.1 Introduction 
3.1.1 Virtual screening 
Both the Nutlin and 1,4-benzodiazepiene MDM2 inhibitors were discovered by 
screening their respective companies compound libraries to find compounds that interacted 
with MDM2.135,139 Although high throughput screening (HTS) of large libraries of 
compounds for activity against a given target is widely used in industry to find new leads 
for drug discovery, most of the compounds screened will be inactive against any given 
target. Whilst this is good from a drug selectivity point of view, it means considerable 
resources will be used screening a large number of inactive compounds in the hope of 
finding a few hits that can be developed as drugs. 
Another limitation is that even the largest libraries don't sufficiently represent all 
of druglike molecular space. Large pharmaceutical companies continuously revise and 
update their compound libraries to improve the quality and diversity of their contents. 
However, even collectively considering all the largest corporate and commercial libraries 
would only represent a tiny portion of possible druglike molecular space. An often quoted 
example that puts the insignificance of any compound library into perspective is that 
chemical space is an estimated 1062 possible molecules, so many that there are not enough 
atoms in the universe to make one copy of each. 204 Therefore the Zinc Database205 
(discussed in more detail below), which currently contains about 8.5 x 106 unique, 
purchasable, drug-like compounds only represents a tiny 8.6 x 10-55 % of this chemical 
space. The fact that many of these compounds are analogues reduces its diversity further. 
Despite its insignificance in chemical space, in the context of a screening campaign 
this is still a very large number of compounds to accumulate and test. Screening the order 
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of 106 compounds is really only possible for the largest pharmaceutical companies. Small 
companies or academic investigators, with out actual compound libraries, wanting to 
screen for drugs will not normally have the resources to buy or handle this number of 
compounds. For example, to purchase one sample of each purchasable compound from the 
Zinc Database (currently around 8,500,000 compounds), at US$ 50 per sample, would cost 
in the region of US$ 425,000,000. 
Virtual screening is an increasingly popular way of selecting compounds from 
commercial libraries and focusing the actual screening effort. 206-208 Several rounds of 
computational screening, each of which removes unwanted compounds from a database 
for various specified reasons, are performed. The virtual screen culminates in a search and 
ranking based on a hypothesis that should, hopefully, identify active compounds for a 
specific target. By collating drug and lead like compounds from various sources and their 
vendor details the Zinc database205 facilitates the virtual screening and acquisition of 
compounds suitable for drug discovery. 
There are a number of different ways to perform virtual screening but broadly 
speaking it falls into two classes; ligand based and structure based. Ligand based uses 
known ligands or pharmacophore models derived from them to search for new ones and 
structure based, usually docking, uses the target protein or enzyme as a query and selects 
molecules which are judged, by one or more mathematical scoring functions to, describe 
and rank the interactions between the screened ligands and the target molecule. 
As computational power has increased so too has the ability to handle large 
amounts of data. Large numbers of molecules can be screened using more complex models 
to describe them in more detail than ever before. However, all models are approximations 
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and it is still difficult to dynamically represent a large flexible molecule, such as a protein, 
and describe its interactions with a large number of ligands in the context of a virtual 
screen. Some models work better for certain types of target than others as shown in a 
comparison study of various docking scoring functions. 
Prospective validation of virtual screening is very difficult to perform. It is easier to 
judge retrospectively and most methods are bench marked against each other using 
common test sets of known active and decoy molecules. 210' 211 Most reports on validating 
virtual screening deal with docking and in particular test the scoring functions used by 
it. 209 In real-world situations the number of unselected active compounds will remain 
unknown, unless all are tested, which would defeat the purpose of virtual screening in the 
first place. In benchmarking studies, a screening protocol or scoring function can be 
considered to work if it is significantly better than random selection, or existing protocols, 
at reducing a dataset to a smaller number of compounds with an enriched fraction of 
known actives. However, retrospective validation cannot predict how well a given 
protocol will work with new targets and datasets. In practice, a virtual screening campaign 
will ultimately be regarded as successful if it produces novel active hits. 
3.1.2 Virtual screening and p53-MDM2 
A number of MDM2 inhibitors have been discovered using computational 
modelling and virtual screening these compounds have been discussed in Section 1.8. 
3.2 Shape based virtual screening with ROCS 
One way to exploit the information carried within active compounds is to screen 
compound databases for compounds with similar shape and/or chemistry, the working 
hypothesis being, that molecules with similar 3D-shape may be active in the same targets. 
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so known actives could be used as queries to search for new ones. If they have similar 
chemical groups overlapping they may be even better. 
ROCS (Rapid Overlay of Chemical Structures) by Openeye Scientific, 212 is a 3D 
shape comparison application, based on the idea that molecules have similar shape if their 
volumes overlap well and any volume mismatch is a measure of dissimilarity. It uses a 
smooth Gaussian function to represent the molecular volume so it is possible to routinely 
minimize to the best global match. 212 Using a known active molecule as a query, 
molecules in a database can be compared to it and ranked according to their 3D shape 
and/or chemical similarity to it. The most similar compounds are regarded as hits. How the 
hitlist is populated is determined by a number of user defined parameters such as a 
minimum measure of similarity and/or number of compounds. 
Pharmacophore models are derived from a ligand, or more usually several ligands 
from different series, and based on what structural features and spatial arrangement of 
them is deemed to be important for activity. Screening based on such models is open to 
parameterization, subject to how the model is prepared and how much weighting is given 
to different structural features when scoring how well the database molecules conform to 
the model. To prepare a good pharmacophore model a considerable amount of prior 
knowledge will be required so a number of ligands from different classes with a wide 
range of activity can be used to determine what is and what is not important. The strength 
of pharmacophore-based screening compared to other ligand similarity screening 
approaches lies in the ability to detect a diverse set of putative active compounds with 
totally different chemical scaffolds. 213 Pharmacophore models can also bring together 
activity enhancing features from different molecules that do not necessarily occur together 
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in the individual ligands. Besides screening, pharmacophore models are very useful in 
other applications of drug development, like de novo design, lead optimization, 
ADME/toxicology studies, and chemogenomics. 214,215 
Shape based screening with ROCS requires only one bona fide ligand to use as a 
query and a database of molecules to compare it to. ROCS takes an holistic approach to 
ligand based virtual screening in that it considers the query molecule as a whole. A good 
ligand inherently carries the information as to what is required for binding and much of 
this information is carried within the 3D shape of the molecule. Good ligands can 
therefore be used as queries to search for other similarly shaped and hopefully, active 
molecules. 
Given that the best inhibitors of the MDM2-p53 PPI make predominantly 
hydrophobic interactions with MDM2, that are maximised by the excellent shape 
complimentarity they have with its binding site, it was decided that shape based screening 
with ROCS would be a suitable approach to finding other inhibitors that do the same. 
ROCS has been successfully employed to find new leads for the ZipA-FtsZ PPI, which is 
considered a potential antibacterial drug target. 216 To date there are no reports of ROCS 
being used to screen for ligands of the p53-MDM2 PPI. Here a ligand based screen of the 
ZINC database using ROCS is described. 
3.3 Validation of ROCS. 
Prospective validation of virtual screening is very difficult to do. Most validation is 
performed retrospectively on various known test sets of compounds for different targets 
where a screening strategy is deemed to be successful if it enriches the hitlist with known 
active compounds. However there are many variables such as diversity, size and nature of 
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the compounds in the screened database which will all affect the outcome. 210,21 Much 
work has been done to address the issues of validating virtual screening methodology. 
Most studies are aimed at benchmarking docking programs and scoring functions. ROCS 
has been compared to various docking programs using some of the same datasets used to 
retrospectively validate them. 217-219 In particular, a study by Hawkins compared the ability 
of ROCS to that of seven different docking programs at finding known actives from decoy 
sets for 21 different protein systems. ROCS consistently performed as well as and better 
than many of the docking programs showing high enrichment of the top ranked 
compounds with known actives 
. 
Z" This study also showed that very little parameterization 
is required to perform shape based screening using ROCS. The parameters used by 
Hawkins were used to perform the screens in this project. The significance of any settings 
used is dealt with in the appropriate sections below. 
3.4 Virtual screening work flow for this project. 
3.4.1 Database selection and preparation 
The early rounds of a screening campaign generally aim to remove or filter out 
unsuitable compounds and selection and preparation of the compound database is an 
extremely important part of this process. 220 What comes out as hits is ultimately a function 
of what is contained in the search database and the saying "garbage in, garbage out" is 
often used when discussing database preparation for virtual screening. The easiest way to 
ensure that undesirable hit compounds do not come out of a screen is not to put them in the 
first place. This means making sure that the database only contains compounds that are 
considered suitable for drug development reducing the possibility of obtaining false 
positives. Furthermore the type of compounds in a database will depend on whether the 
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goal is to find drugs, leads or fragments221' 222 Computationally filtering undesirable 
compounds from a database is relatively easy and non-CPU intensive. Molecules can be 
filtered out of a large database on the basis of a small number of simple molecular 
descriptors such as molecular weight, LogP, number of H-bond donors and acceptors 
number of rotatable bonds or the presence of certain atoms or functional groups. 223 It is 
important to perform filtering early so that computational time is not wasted processing 
inherently unsuitable molecules during the more CPU intensive phases of a screen. 
The Zinc database is a database of commercially available compounds from 
various vendors for virtual screening. 205 It was prepared by Shoichet and Irwin and made 
freely available to facilitate virtual screening for a wide community of scientists. All 
compounds that are added to the database are filtered by what is essentially a more lenient 
rule of six version of Lipinski's rule of five. 223' 224 Within this are a number of subsets of 
molecules filtered for different specifications of these properties. It is therefore possible to 
select a pre-filtered subset based on what one intends to do with the hits. For example, 
lead-like compounds are generally regarded as smaller than drug like compounds based on 
the idea that drug molecules tend to get larger as they are developed so it makes sense to 
start with small compounds to leave some room for this. 221 The database is available in a 
number of commonly used file formats, and each compound contains vendor and 
purchasing information to facilitate subsequent purchase of hit compounds. 
One of the main criteria for this screening campaign was that all compounds should 
be readily available. So the all purchasable subset was chosen. This would allow the 
greatest number of available compounds to be examined. It was also desirable that 
compounds of similar molecular weight to the queries were not excluded. The query 
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compounds being used in these screens are well optimized and contain a number of 
halogens, which are important in defining the overall shape and maximizing affinity. As a 
result the molecular weights of the query molecules are themselves towards the upper end 
of the range found in the database. Given that ROCS ranks hits based on how well they 
overlap the query, it was desirable that the database and queries were not mismatched with 
respect to molecular weight as a result of overly tight filtering criteria. Such a mismatch 
would lead to larger molecules having better overlap than smaller ones based on size 
rather than shape similarity. 
The database was filtered in the next step using Openeye Filter version 2.0.2212 A 
number of prewritten filter files are included with the program. These include a drug like 
filter essentially based on Lipinski's rule of five224 a corresponding lead like filter which 
only allows smaller "lead-like" molecules through221' 222 and a third filter file, known as 
"filter blockbuster" which was designed so that it just spans the range of the properties of 
141 of the best-selling non-antibiotic prescription drugs from 2005. It was shown that 
slightly narrowing all the parameters of flter_blockbuster to cover from the 2.5`h to the 
97.5`'' percentiles that only 75 of the 141 molecules pass the filter, demonstrating how 
slight changes to many filters can lead to a significant reduction in the number of 
compounds that pass all of the filters. 212 The filter files also allow molecules with certain 
numbers of particular functional groups to be removed. The filter files can be edited to 
modify any parameters or allowed functional group. 
The Blockbuster filter file was used in this screen. As it allows molecules with a 
higher molecular weight to pass than either the drug or lead like filters, it would help 
minimise any size mismatch between the query and database molecules. Being based on 
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the properties of a relatively small set of molecules this filter file does however have quite 
a restrictive list of allowed functional groups. The functional group filter of this and the 
drug-like filter file were combined to make it more lenient. 
At the time the screen was performed the all-purchasable subset of the Zinc 
database contained 2,667,437 molecules. Filtering with the above parameters reduced this 
slightly to 2,546,386 which were used in the next step. The relatively small number of 
compounds removed is a positive reflection on the criteria used for inclusion in the ZINC 
database. 
3.4.2 Database preparation; multi-conformer generation 
ROCS deals with ligand flexibility by screening multiple conformations of each 
molecule in the database. The multi-conformer database is generated prior to the screen 
using Openeye's conformer generation application, OMEGA 2.212 This is the most 
computationally intensive part of the screening process. However, once the multi 
conformer database has been generated it does not need to be repeated and can be used for 
all of the queries or for other screening campaigns without further modification. 
It is important to ensure that the multi-conformer database supplied to ROCS 
sufficiently samples conformer space. This database was prepared such that a maximum of 
1,000 conformers within 8 kcal mol-'of the minimum energy conformer, sampled at a rate 
of 0.5 RMSD for each molecule were generated for each database molecule. Bostrom 
investigated conformer generation using OMEGA and showed that the bio-active 
conformation of a number of ligands, would be contained in a multi-conformer dataset 
prepared using these parameters. 225 It was the case that the bio-active conformation of 
most ligands in this study was actually within 3.7 kcal mol" of the minimum and that by 
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sampling with a density of 0.5 RMSD the majority of conformers also had a shape 
Tanimoto co-efficient of greater than 0.9 indicating that they have a very similar overall 
shape. This result is important, considering that the main measure to be used in this screen 
is shape similarity and gives confidence that potential hits won't be missed as a result of 
insufficient sampling density. Sampling with a greater frequency is unnecessary and may 
result in poorer representation of conformer space within a given energy window if the 
maximum number of allowed conformers is achieved before a wide range is generated. 
496,216,289 conformers of the 2,546,386 compounds were generated which is on 
average 195 conformers per molecule. They were saved as gz-compressed Openeye binary 
format. To keep the file size as small as possible Open-eye multi-conformer datasets can 
be written using "off-set rotor compress". Rather than saving the coordinates for each 
individual conformer, it uses a reference conformation and implies the others as a function 
of how they deviate from it. Minimizing the size of the data in this way increases the speed 
of screening when using parallel processors by reducing traffic on the network as data is 
sent between the master and slave processors. This database was now ready to be used for 
2 
screening with either ROCS or Openeye's docking programme FRED 
. 
'2 
3.4.3 Query selection and preparation 
An example of the Nutlins, 135 1,4-benzodiazepiene-2,5-diones'22 and 
spiro-oxindoles132,141 were chosen as queries for this screen. All of these inhibitors bind 
MDM2 with low to mid nanomolar activity, exhibit clear SAR, and perform as expected in 
functional assays and in vivo. As a result these compounds carry much information about 
what is required to be a good ligand for this target and therefore all represent good points 
from which the search for new ligands can be initiated. 
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X-ray co-crystal structure data has been published for both the Nutlin135 and 
1,4-benzodiazepiene-2,5-diones122 and extensive modelling and SAR investigations 
provide very strong evidence for the proposed binding pose of the spirooxindoles. 132.141 
Although it is not necessary to have structural data to perform a ROCS screen, where it 
was available, the bioactive conformation was used as the query. In the absence of 
structural data it is suggested that the lowest energy conformer is used and has been shown 
that this has little effect on the enrichment rates in retrospective validation studies. 217 
Another benefit of having structural information is that it makes it clear which 
parts of the molecule are pharmacophoric, scaffold or solvent exposed. Given that these 
molecules are highly optimized and that their molecular weights are towards the upper end 
of the range of the data base, to minimise any mismatch in size between the query and 
database molecules the solubilising groups were removed and just the scaffold and three 
binding groups corresponding to the basic pharmacophore were used as the query. Also 
because ROCS treats the molecule as a whole it would consider overlap with these groups 
as good and non-overlap with them as bad thus causing the focus to be taken away from 
the groups known to be most important for binding. Even in the case of the 
Spiro-oxindoles, where the solubilising group is clearly pharmacophoric and considerably 
enhances activity, it was thought best to omit it to minimize mismatch between the size of 
the query and database molecules. 
3.4.3.1 Nutin-2 based query 
As discussed above, the bioactive conformation from the co-crystal x-ray structure 
(1 RV 1)135 was used without the solubilising side chain. 
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Scheme 6 Preparation of the Nudin based query (Green CPK sticks). 135 Nutlin-2 was extracted from 
its crystal structure with MDM2 (grey CPK surface) (1RV1) and its solubilising group removed 
whilst maintaining the bioactive conformation of the remaining groups. Carbon, green; oxygen, red; 
nitrogen, blue; bromine, brown. 
3.43.2 Benzodiazepienedione based query 
The structure from X-ray co-crystal structure (IT4E)'22 was used directly as a 
query. The co-crystallised analogue is one of the simpler analogues in this series and 
consists mainly of required binding groups and scaffold without the soluhilising side 
chains that are present in the optimized analogues. 
Scheme 7 The benzodiazepine query (magenta CPK sticks). was extracted from the crystal structure 
MDM2 (grey CPK surface) (1T4E) and used without further intervention. 
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3.4.3.3 Spiro-oxidole query 
As no-structural data has been published for the spiro-oxindoles, the query was 
prepared by docking the first generation analogue (MI-43)14' into (IYCR)1 using FRED. 212 
MI-43 is based on the same core as the most potent analogue MI-219 but does not have 
solubilising group or a 5-fluoro substituent on the oxindole ring. 
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Scheme 8 The spirooxindole (M1-43)1-11 was docked into MDM2 (1YCR)' (grey CPK surface) using 
FRED. " The ligand was then extracted whilst maintaining its docked pose, (Green CPK sticks). 2 
3.4.4 Performing the screen 
Using each of the query molecules described above, the multi conformer database 
was screened using ROCS. The default parameters were used, as recommended by 
Hawkins to compare ROCS with various docking programs. 217 In this work it was shown 
that matching and ranking based on both similar chemistry overlap (which Openeye call 
Color) and shape similarity was more likely to select known actives from decoy sets than 
using shape alone. 
ROCS overlays and compares every conformer of every compound in the database 
with the query. Based on the observations of Hawkins, 217 the program was set to optimize 
chemistry (Color) overlap and shape alignment. It then scores each between 0 and I where 
a score of I is a perfect match. The hits were ranked based on their combo-score which is 
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simply the sum of the shape Tanimoto and normalized Color score and has a maximum 
value of 2. Only the top scoring conformer of each database molecule is considered for 
ranking so that no compound can feature more than once. No minimum shape Tanimoto 
cut-off was specified. The top 500 hits were produced. 
3.4.5 Hit selection for actual screening. 
The 1,500 hits obtained from the three queries using ROCS were visually inspected 
and manually grouped into similar classes. Although clustering applications are available, 
given the relatively small number of hits to be examined it was decided this was the most 
efficient way to deal with them. The hits in each group were then inspected overlaid with 
the query. Hits that were rejected were typically those that only possessed two binding 
groups or those that despite having a good shape Tanimoto score only did so because the 
adopted a conformation which would cause it to clash with the binding site rather than fit 
into it in a shape complimentary manner. In total 200 hit compounds were selected from 
these groups. However, it was only possible to obtain 155 of them at the time of the 
screen. The output of the virtual screen is described in the following sections in the context 
of the queries used and the clusters into which they were divided. 
3.4.5.1 Nutlin query 
The Nutlin query returned hits which had average shape Tanimoto of 0.73 that 
ranged between 0.56-0.87 and average combo-score of 1.143 that ranged from 
1.117-1.483. The top ranked comboscore hit showed a shape Tanimoto of 0.8350 and the 
highest Tanimoto at 0.87 is shown by hit 3. The hit compounds have molecular weights 
between 268.31 and 508.57. Of all the queries this one showed the most diversity with less 
domination of the hit list by a small number of large clusters. The hit list was divided into 
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16 different clusters described in the following sections and examples from each are 
shown in Table 15. 
3.4.5.2 Nutlin query, Cluster 1 
Compounds in this cluster were typically based on pyrazole and pyrazoline 
scaffolds bearing substituents in a 2.3,5 pattern (Table 15, Entry 1). They are structurally 
similar to Nutlins but generally more planar depending on the specific scaffold. The top 
ranked hit from this cluster is shown overlaid with the query (Figure 22). 
Figure 22 The top ranked hit from \utlin query cluster I (O%er all rank 6) (Grey CPK sticks) overlaid 
with the query molecule (Green CPK sticks). This compound is typical of many of the molecules in this 
class. 
3.4.5.3 Nutlin query, Cluster 2 
These compounds have two potential binding groups cis to one another on a bicyclic 
scaffold similar to the known benzodiazepines (Table 15, Entry 2). Also some trans 
analogues show higher Tanimoto scores but overlap in a manner that would clash with the 
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protein and were not selected for testing. Examples of both cis- and trans- analogues 
overlaid with the query molecule are shown in Figure 23. 
Figure 23 Cis- (left) and trans (right) examples of molecules from cluster 2 (Grey CPI sticks) overlaid 
with the query molecule (Green CPK sticks). 
3.4.5.4 Nutlin query, rejected compounds; clusters 3-7,11 and 14. 
Compounds in these clusters were not selected for testing. They were generally 
deemed to be too flexible or lacking sufficient groups to occupy all three sub-pockets of 
the binding site. Cluster 3 consisted of linear amides and ureas. Despite possessing three 
potential binding groups and making good overlap with the query, high shape Tanimoto 
coefficients are likely a function of their flexibility. A hit from this cluster overlaid with 
the query is shown in Figure 24. 
Compounds in cluster 4 predominantly possess only two potential binding groups. 
Some molecules resemble those of cluster I but have long flexible linkers between the 
scaffold and binding group. A typical hit from this cluster is shown overlaid with the query 
(Figure 25). 
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Despite high Tanimoto coefficients and some very highly ranked hits, compounds in 
cluster 5 overlapped the query in a manner likely to clash with the protein (Figure 26). 
Cluster 6 consisted of predominantly 1,2,5-substittued imidazoles. At least one of the 
groups on these molecules is small or attached via too long a flexible linker such that it 
would not be projected into a sub-pocket (Figure 27). 
Cluster 7 consisted mainly flexible, linear molecules similar to clusters 3 and 4 and 
good Tanimoto coefficients are a function of flexibility. Clusters 11 and 14 consisted of 
phosphonate esters and flexible tertiary amines respectively. 
Figure 24 Example of molecules from cluster 3 (Grey CPK sticks) overlaid with the query molecule 
((Green CPK sticks). 
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Figure 25 Typical rejected compounds from cluster 4 only posses two potential binding groups (Grey 
CPK sticks) overlaid with the query molecule (Green CPK sticks). 
Figure 26 Typical rejected rompuund, from cluster 5 u%r"rlap .o that theN viuuld clash with the protein 
(Grey CPK sticks) overlaid with the query molecule (Green CPK sticks). 
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Figure 27 Compounds in cluster 6 typically possessed binding groups that were either to small or 
flexible or both as shown by this example (Grey CPK sticks) overlaid with the query molecule (Green 
CPK sticks). 
Figure 28 Compound 148, from cluster 8, (Gre} CPI sticks) o%erlaid µith the quer} molecule (Green 
CPK sticks). ranked 78 over all, and was active in the FP assay. 
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3.4.5.5 Nutin query, Cluster 8 
Cluster 8 consisted of mainly branched amides. These were smaller and less 
flexible than the compounds in cluster 3. Some compounds had excellent overlap with 
Tanimoto coefficients greater than 0.8 (Table 15, entry 8). One of the compounds (148) 
showed binding activity (Table 18, entry 5) and is shown overlaid with the query (Figure 
28). 
3.4.5.6 Nutlin query, Cluster 9 
Cluster 9 contains both highest ranked and best Tanimoto hits (Table 15, entry 9). It 
includes imidazoles, some cis-2,3,4-substituted imidazolines and imidazolidines very 
similar to the query. Figure 29 shows two hits from this cluster overlaid with the query. 
3.4.5.7 Nutlin query, Cluster 10 
Compounds in cluster 10 have three potential binding groups on 2,4,6-substituted 
1,2,3,4-tetrahydropyrimidine scaffolds. These compounds overlap well with the query 
molecule (Figure 30), although the adopted boat conformation with two large groups 
axially oriented will be energetically unfavourable. 
3.4.5.8 Nutlin query, Cluster 12 
Compounds in cluster 12 resemble benzodiazepines but have a tricyclic scaffold. 
These show good overlap with the query and show two possess by which they overlap the 
query (Figure 31). 
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(Grey CPK sticks) overlaid with the query molecule (Green CPK sticks) were found in cluster 9. 
Figure 311 Six membered ring stems like those seen in cluster 14) ((: res ('Pk sticks) show good 
potential overlap of the query (Green CPK sticks). 
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Figure 29 The top ranked hit (left) and the third ranked (right), which has the highest Tanimoto score 
3.4.5.9 Nutlin query, Cluster 13 
Compounds in cluster 13 were 3,5-di(furan-2-yl)-2,3,4,5-tetrahydro-6-nitro-2-phenyl- 
1,2,4-triazines (Table 15, entry 13). Although they possess three potential binding groups 
and show good overlap with the query they adopt an unfavourable conformation in doing 
so and bear an unfavourable nitro group. None were selected for testing. 
3.4.5.10 Nutlin query, Cluster 15 
Cluster 15 contains tri- and tetra-substituted piperidines that over lap the query well 
and adopt a favourable chair conformation with two of the three large substituents in 
equatorial orientations. 
3.4.5.11 Nutlin query, Cluster 16 
Cluster 16 contained whatever compounds remained. It has a variety of compounds 
most were of little interest and were rejected. However, two were a similar shape to the 
Nutlin query but based on different heterocyclic scaffolds (Figure 32) and were selected 
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Figure 31 7'No hits from cluster 12 (Grey ('YID sticks) that hale difTerent substitution patterns and 
adopt different poses when overlaid with the query molecule (Green CPK sticks). 
for testing. One of them (156) exhibits activity in the FP binding assay (Table 
lK. cntr 1O). 
Figure 32 An acti%e compound from cluster 10 it. re. N ( 1'1% Licks) o'erlaid with the query molecule 
(Green CPK sticks). 
Cluster I 
O 
N 
Compounds 
Tan ran e 
120 
0 832-0 63 N g 141 . . Highest Rank 6 
S Lowest Rank 500 
Cluster 2 QIcI Compounds 47 
N 
142 Tan range 0.78-0.643 1> Highest Rank 33 
N Lowest Rank 496 
O 
Cluster 3O 
Compounds 20 
Tan range 143 0.842-0.739 O Highest Rank 21 
N )ý17ý1 C', Lowest Rank 480 
98 
Cluster 4 HN-N Compounds 123 
144 Tan range 0.806-0.604 
Br Highest Rank 17 
HO Lowest Rank 499 
Cluster 5 
Compounds 30 
Tan range 0.837-0.692 H1/ 
p/ 
145 Highest Rank 4 
Lowest Rank 423 
/0 
Cluster 6 O' 
O, Compounds 8 
Tan range 0.781-0.702 CI /1N\/ 146 Highest Rank 64 
-NH 
"O 
Lowest Rank 464 
N 
Cluster 7 
H Compounds 48 N\ 
147 Tan range 0.785-0.617 Highest Rank 14 
Lowest Rank 494 
Cluster 8 
Compounds 46 MeO 
O 148 Tan range 0.813-0.685 IP- Highest Rank 78 
HI Lowest Rank 495 
OMe 
Cluster 9 
H CI Compounds 10 
N Tan range 0.87-0.626 149 Highest Rank I 
N- Lowest Rank 338 HF 
Cluster 10 
0 CI 
CNH Compounds 10 
150 Tan range 0.833-0.609 Highest Rank 45 
OH Lowest Rank 453 
99 
Cluster 11 
Compounds 10 
O O 
Tan range 151 Highest Rank 
0.806-0.787 
206 
Z P k R 438 N Lowest an O H\ 
Cluster 12 
0\ d 8 Compoun s 
HN-N Tan range 152 0.772-0.65 
Br 
Highest Rank 
Lowest Rank 
295 
414 
O 
Cluster 13 
02N N, 
N 
Compounds 
Tan range 
3 
0.649-0.646 153 Highest Rank 28 
H Lowest Rank 32 
0 / 
Cluster 14 
Cluster 15 
Cluster 16 
Compounds 2 
154 Tan range 0.75-0.700 Highest Rank 167 
Lowest Rank 177 
Compounds 2 
155 Tan range 0.682-0.656 Highest Rank 173 
Lowest Rank 437 
Compounds II 
156 Tan range 0.816-0.615 Highest Rank 173 
Lowest Rank 437 
Table 15 Representative hits and statistics from each of the 16 clusters round by the Nutlin query. 
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3.4.5.12 Spiro-oidndole query 
The spiro-oxindole query returned hits with an average shape Tanimoto of 0.692, 
ranging between 0.569-0.799 and comboscore that averaged 1.23 and ranged between 
1.194-1.381. The top ranked comboscore hit had a shape Tanimoto of 0.7710 and the 
highest Tanimoto at 0.799 was shown by the hit ranked 203 overall. The hit compounds 
have molecular weights between 233.20 and 546.39. 
The hit with the highest Tanimoto coefficient scored low overall showing that the 
Color score was playing a large role in determining these hits. This is not surprising given 
the number of indole and oxindole based hits that were found which would match aspects 
of the query chemistry perfectly. This compound has an N-methyl group on the indole 
nitrogen which would make it unable to act as a H-bond donor (Figure 34) showing that 
minor structural features could drastically alter a compounds overall rank. 
3.4.5.13 Spiro-oxindole query, Cluster 1 
The largest cluster of compounds for this query are also spiro-oxindoles but with a 
4H-pyran as the other ring. There was a considerable variety of substituents. Hit selection 
focused on compounds with 3 binding groups. Figure 33 shows two of these compounds 
overlaid with the query. A number of hits from this cluster were selected for testing and 
two (179 and 181) showed binding activity in the FP assay (Table 18, entries 14 and 16). 
3.4.5.14 Spiro-oxindole query, Cluster 2 
Another large cluster of spiro-oxindoles with a thiaziolidine ring were also hits. 
These compounds only bore two potential binding groups and were not selected for 
testing. This very uniform group of compounds dominated the top 100 hits. 
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3.4.5.15 Spiro-oxindole query, Cluster 3 
These were also spiro-oxindoles. As they only possess two potential binding groups 
they were not selected for testing (Table 16, entry 3). 
3.4.5.16 Spiro-oxindole query, Cluster 4 
This cluster consisted of spiro-oxindoles with either pyrazole, isoxazole or 
pyrazolidinone as the second ring. Many only possess two potential binding groups but 
some possess three groups and were selected for testing. The molecule with the highest 
Tanimoto coefficient was found in this cluster however it has an N-methyl substituent 
which would prevent it from mimicking the H-bond interaction made by W23 of p53 
(Figure 34). 
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Figure 33 TNo examples of compounds from cluster I of the spiro-oxindole query screen (Grey CPK 
sticks) overlaid with the query molecule (Green CPK sticks). 
3.4.5.17 Spiro-oxindole query, Cluster 5 
This cluster did not contain any Spiro cycles. It mainly consisted of 3-substituted 
indoles attached to five membered nitrogen heterocycles which bore two potential binding 
groups. A number of these possessed three potential binding groups and showed good 
overlap with the query (Figure 35). 
3.4.5.18 Spiro-oxindole query, Cluster 6 
Cluster 6 consisted of tetrazole and triazole pyrimidine based scaffolds with two other 
potential binding groups bearing some shape similarity to benzodiazepine series and 
cluster 2 from the Nutlin screen. 
3.4.5.19 Spiro-oxindole query, Cluster 7 
Cluster 7 is a small group of compounds some of which are similar to Nutlins. Most 
of these are based on pyrolidine or imidazoline scaffolds with substituents attached in a 
1,2,3-pattern. 
3.4.5.20 Spiro-oxindole query, Cluster 8 
These compounds do not particularly belonging to any group and are linear or possess 
insufficient groups to completely fill the binding site. 
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sticks). Both show excellent overlap but one contains a nitro substituent (left). The best Tanimoto hit 
(right) is N-methylated and therefore not be able to act as a tryptophan mimic. 
sticks) overlaid with the query molecule (Green CPK sticks). 
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I-igure 34 1 Ho hits From cluster 4 ((; rei CPK sticks) oserlaid with the quere molecule (Green C1'K 
Figure 35 TNo non-spiroc%clie hits possessing 3 potential binding groups, from cluster 5 ((; re% CPK 
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Table 16 The bits from the spiro-oxindole query were grouped into eight clusters. 
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3.4.5.21 Benzodiazepine query. 
The hits obtained using the benzodiazepine query showed shape-Tanimoto 
coefficients and combo-scores ranging between 0.509-0.791 and 1.1122-1.315 
respectively. With the top ranked comboscore hit having a shape Tanimoto of 0.74 and the 
highest Tanimoto at 0.791 was shown by hit 287. The hit compounds have molecular 
weights between 266.29 and 546.41. 
The benzodiazepine query returned a large number of hits with good chemistry 
overlap. Many of the hits possess bicyclic-nitrogen heterocycles which show good Color 
overlap with the benzodiazepine. These included a group of other benzodiazepines and 
many compounds with bicyclic, nitrogen heterocycles such as quinolines and quinoxilines 
but little shape similarity to the query (cluster 2). However, some compounds with this 
type of chemistry that overlap the query well were found (cluster 4). Some of these also 
show binding activity and are discussed in the following sections. 
3.4.5.22 Benzodiazepine query, cluster 1 
With 176 compounds, that were relatively close analogues, based on a 
1,4-benzodiazepiene-2-one scaffold very similar to the query this cluster was very 
dominant in the hit list. This cluster contained the top ranked hit but hits from it were 
distributed throughout the hitlist with the lowest being ranked at 476 (Table 17, entry 1). 
The main difference between the hit compounds and the query was that their phenyl 
substituent was on the 5 rather than 4-position. This substitution pattern is likely to cause a 
clash with the protein but as it was the dominant class of compound in the hit list some 
examples were selected for testing. The top ranking hit, a typical example of the 
compounds in this cluster, is shown overlaid with the query (Figure 36). 
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Figure 36 The top hit found using the benzodiazepine query (Grey CPK sticks) overlaid with the 
query molecule (Green CPK sticks). This was typical of the compounds in this large cluster which 
dominated this hit list. They exhibit good shape and Color overlap. 
3.4.5.23 Benzodiazepine query, cluster 2 
With 181 compounds this cluster was also very dominant in the hit list. It is 
predominantly populated with molecules based on quinoline and quinolinone ring systems 
that exhibit very good chemistry overlap with the benzodiazepine ring of the query. Apart 
from this common feature molecules in this cluster are quite varied and less homogeneous 
than those in cluster 1. Members of this cluster were rejected as they only contain two 
potential binding groups. The top ranked hit (ranked 11) from this cluster is shown 
overlaid with the query (Figure 37). It is typical of the molecules in this group. The 
quinolinone ring system overlaps well with the benzodiazepine of the query but it only 
contains two potential binding groups and its shape overlap is maximised by a relatively 
long linker adopting the necessary conformation. 
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Figure 37 The top ranked compound from cluster 2 (Grey CPK sticks) overlaid with the query 
molecule (Green CPK sticks). shows good Color overlap but only possesses two potential binding 
groups. 
3.4.5.24 Benzodiazepine query, cluster 3 
The compounds in this cluster are predominantly tertiary sulfonamides. Many of these 
possess quinoline and quinolinone ring systems similar to the compounds in cluster 2. 
Some possess 3 potential binding groups and are of interest. Testing some of these would 
also be interesting with respect to Chapter 2. Two of the compounds from this cluster, 
(167 and 175) show binding activity (Table 18, entries 3 and 8). Within this cluster there 
are examples of hits in which either Color or shape matching are dominant. An example of 
each is shown in Figure 38. Both compounds are tertiary sulfonamides but overlap the 
query very differently. The compound on the left possesses a quinazolin-2-one, as seen in 
the compounds in cluster 2, which is quite similar to the benzodiazepine ring system. As a 
result it overlaps the query in a manner that matches the similar chemistry at the expense 
of overall shape overlap and this hit achieves a high colour score. This is clearly not the 
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optimum shape overlap and it only achieves a low shape Tanimoto score. The similar 
compound on the right, that does not bear the quinazolin-2-one ring, shows overlap that is 
clearly dominated by shape matching and its higher Tanimoto coefficient is the main 
contributor to its overall score. The Color matching in this example is sufficiently strong 
that the compound on the left, with the lowest Tanimoto score, actually ranks higher 
overall than the one on the right which has a considerably higher Tanimoto coefficient. 
00 0 
S, 
N NH 
CI 
*Shape Tanimoto 0.509 
" Color score 0.698 
0 Combo score 1.207 
i N 
00 NJ 
S`NO 
'Shape Tanimoto 0.782 
'Color score 0.342 
Combo score 1.124 
Figure 38 Sulfonamides from cluster 3 are a clear example of dominance of Color score over shape to 
such an extent that the molecule with the best over lap is the one with the lowest overall rank. 
(Carbons: grey) overlaid with the query molecule (Carbons: green). 
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3.4.5.25 Benzodiazepine query, cluster 4 
This is the most interesting cluster from this query. It consists of 32 molecules 
predominantly based on dihydroquinolinone and dihydroquinazolinone ring systems. Like 
cluster 2, the compounds show good chemistry overlap with the benzodiazepine ring of the 
query. Unlike cluster 2, a number of compounds possess three potential binding groups 
and make very good shape and Color overlap with the query. Two such hits (176 and 168) 
show binding activity (Table 18, entries 9 and 12) and a previously described inhibitor, 8, 
(Figure 39) was also a hit. 161 These compounds show excellent overlap with the query 
(Figure 40). Furthermore, these hits are small "lead like" compounds that show potential 
for further investigation and are discussed in Section 3.5.2 
OyOH 
, 
ON, 
N 
O 
F 
Figure 39 Compound 8 is a previously described inhibitor" and was a hit in this screen 
3.4.5.26 Benzodiazepine query, cluster 5 
Compounds in this cluster did not fit into any of the classes discussed above. Most did 
not show potential as ligands. However some bear three potential binding groups on a 
rigid scaffold and the imidazoles based compound, 169, was the most active compound in 
the FP assay (Table 18, entry 1). 
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Table 17 The hits from the benzodiazepine query were grouped into five dusters. 
Figure 40 Compound 168 the top ranked hit from cluster 4, (Grey CPK sticks) overlaid with the query 
molecule (Green CPK sticks). 
3.4.6 Screening: binding and cell assays 
The 155 purchased compounds were screened at Cyclacel for activity using the FP 
assay. At the time of the screen the assay was performing with lower sensitivity as 
discussed in Section 1.11.1. The first round of screening included all compounds and a 
cut-off point of 50% activity at 500µM was set. Using the correction factor of 3.18 this 
would mean 50% at 157µM with the sensitivity of the original assay. Sixteen compounds 
showed greater than 50% inhibition at 500 M. The corrected IC50 values of these 
compounds were determined. They ranged between 48.22 µM and 140.42 p. M (Table 18). 
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169 95.811 153.34 48.22 
170 81.239 172.66 54.29 
167 65.58 232.94 73.25 
171 76.867 246.06 77.38 
172 82.696 313.59 98.61 
173 57.923 268.16 84.33 
113 
7 
8 
cL 
N OMe 
' 
NH 
Me0 
i RSO 
N\ ý cr ý1-o 
9H 
NO 
Br "N ' 
CI 
10 
11 
/\ 
O 
O 
OPh 
N 
H 
OH 12 
" 
Q: 
o> ý Ný ,IiN 
O 
174 
175 
176 
156 
177 
168 
114 
65.938 267.80 84.21 
52.095 272.01 85.54 
52.095 334.40 105.16 
59.058 318.20 100.06 
65.938 387.09 121.73 
52.095 429.39 135.03 
13 
178 
14 ONH2 
t-Bu000 r 
8OOMe 179 
H 
15 P--r 
/ 
HN 
,N , Ph 
180 
O 
N 
H 
16 
-O NH2 
Br \ I"' 8OOBn 
181 
H 
Table 18 Binding activity of the active bit compounds. 
55.435 373.18 117.35 
61.566 379.40 119.31 
61.566 446.53 140.42 
52.095 436.70 137.33 
3.4.7 Functional assays 
In order to determine if the hit compounds could induce a p53 response in cells 
they were assayed using a p53 Luciferase reporter gene assay at Cyclacel. Nutlin-3 was 
used as a control and showed 9-fold induction of p53 at 10 µM. This value is very much in 
agreement with what had been shown previously and demonstrated that the assay was 
functioning normally. Very little induction was observed for the test compounds. 
However, three compounds, 156,168 and 180, showed some p53 induction (Figure 41) 
156 Showed 2.93 fold induction at 6.58 µM, 168 showed 2.24 fold at 9.88 pM and 180 
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showed 5.75 fold at 8.89 µM. 156 and 180 show some indication of dose dependency up to 
these concentrations. 
Nutlin-3 is a highly potent, validated MDM2 inhibitor and the test compounds 
have already been shown to have a much lower affinity than it for the target. However, 
that any p53 induction is observed with such low affinity inhibitors is encouraging. If it is 
possible to prepare any analogues of these compounds that exhibit higher affinity and 
show increased p53 induction in this assay it will be strong evidence that they are indeed 
genuine MDM2-p53 PPI inhibitors. 
p53 Induction Luciferese Reporter Gene U2OS cells 
10.00 
9.00 
8.00 
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2.00 
1.00 
0.00 
0.00 
Figure 41 Three of the sixteen hits that show binding activity also show low levels of p53 induction. 
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3.5 Conclusions and future work 
Out of 155 screened compounds 16 that bind the target with moderate to low µM 
affinity were discovered. These are representative of 9 unique chemo types. Three of these 
show low to moderate p53 induction in a Luciferase reporter gene assay. Although distinct 
from them, the hits all bear structural similarities to the known inhibitors that were used as 
queries to find them. However, they are clearly un-optimised and a number of them are 
quite small and "lead-like" which leaves considerable scope for further development and 
are candidates for further hit to lead investigation. 
3.5.1 Evaluation of the ROCS screen 
Having selected 155 compounds for screening that produced a number of low activity 
hits that are suitable for drug development and a known inhibitor compound 8, the ROCS 
shape based screen can be considered a success. Each of the queries produced some hits 
that were similar both to themselves and the other queries. The compounds that showed 
activity were sufficiently different to the known chemo types and ROCS demonstrates a 
definite ability to scaffold hop. However, having seen how it performs on a large database, 
it is possible to suggest some ways in which improvements to future screens could be 
made. 
Combo scoring does give better quality hits than shape alone. However there were 
times when Color scoring clearly dominated the hit selection. This lead to high ranking 
compounds with low shape Tanimoto coefficients and was probably accountable for the 
domination of the hitlists of the benzodiazepines and spiro-oxindoles by only a few classes 
of very similar molecules. The example from cluster 3 (section 3.4.5.24) of the 
benzodiazepine hitlist is a good example of a case where Color score dominated over the 
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shape score in hit selection (Figure 38). For a hydrophobic target such as MDM2 where 
shape complimentarity is important in determining affinity, shape would need to be 
prioritised over Color. This could be done by specifying a minimum shape Tanimoto 
requirement of 0.7 or 0.75 so all compounds would have to have a better measure of shape 
similarity to be considered as hits. 
Another observation was that a considerable number of linear and flexible hits were 
generated and ultimately discarded during the visual inspection. While some of these were 
a function of Color-score dominance and would be eliminated by setting a minimum 
Tanimoto requirement, others may have resulted from the lenient approach to database 
preparation. Finding rigid molecules that are the correct shape is preferable to finding 
flexible molecules that may adopt the correct shape. Flexible molecules could be removed 
by using tighter filter parameters with respect to number of allowed rotatable bonds and 
reducing the energy window during conformer generation from 8 to 5 kcal mol-' which 
would take higher energy conformers out of the database so ROCS would not be able to 
consider them. 
The Zinc database proved to be a very useful tool for this screening campaign. It is 
often the case that screening libraries that originate from medicinal chemistry campaigns 
and combinatorial synthesis contain large numbers of very similar compounds. This 
reduces the diversity of chemical space they represent. This was evident as large clusters 
of very similar compounds dominated some of the hit lists in this screen. Reducing the size 
of large clusters before screening or performing subsequent rounds of screening in which 
clusters that dominate the hitlists have been removed could potentially allow more of 
chemical space to be represented. The Zinc database has grown considerably since this 
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screen was performed. The all purchasable dataset is now in excess of 13,500,000 
compounds over 8,500,000 of which are unique and available only from a single vendor. 
As the database grows it will represent more diverse classes of compounds. Performing a 
similar screen on this larger database using the tighter parameters, outlined above, to 
reduce the numbers of hits that are either too flexible or do not have sufficient shape 
similarity to be deemed useful and taking steps to deal with dominant clusters may be a 
very attractive prospect for finding new leads. 
3.5.2 Developing the hits 
In order to determine if these are genuine MDM2 inhibitors and if they can be 
developed further it will be necessary to test more analogues to determine if activity can 
be improved or any SAR is exhibited. How this might be achieved for the particularly 
leadlike compound 168 is discussed in the following section. 
3.5.2.1 Investigation of 168 
Compound 168 was identified in the recent shape based virtual screening using the 
Johnson and Johnson Benzodiazepine core structure as a query. Although not the most 
active hit in the FP assay it showed some p53 induction and is structurally very similar to 
the recently discovered inhibitor, 8.161 making it very attractive for further development. 
Furthermore the core structure of this compound is extremely "lead-like" and a range of 
desirable analogues are synthetically accessible. This section is an overview how this 
compound could be investigated further as an MDM2 inhibitor. 
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Figure 42 Other analogues of 168 show low binding activity (% inhibition at 500µM). 
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Four similar compounds to 168 were also purchased and tested in the in the initial 
screen (Figure 42) Only the IC50 of 168 was determined. However one of the other 
analogues, 182, was only just outside the threshold for selection for IC50 determination, 
showing 49.18% inhibition at 500 pM as opposed to 52.1 % shown by 168. Given the 
issues with the binding assay this compound may need to be looked at in the SAR study. 
These compounds also become progressively less active as their substituents become 
smaller which suggests that the smaller analogues are making less contact with the binding 
site. Although little more can be gained from this information it does provides some 
evidence that varying substituent size affects activity as expected. 
Variation of the ring substituents R, R' and R" will allow the overall size and shape 
of the molecule to be optimised to better fill all three sub-pockets of the binding site. This 
would allow known SAR features to be investigated. The chemistry assessment below 
indicates that it should be possible to prepare a number of analogues to facilitate such an 
investigation (Figure 43). It would be very desirable to investigate substituents on the 
fused benzene ring. The core molecule is too small to fill the MDM2 site without 
substitution here. This is clearly evident when overlaid with the benzodiazepine core 
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structure (Figure 37). Given the emerging importance of MDMX as a target, that it is 
known to have a similar but smaller binding site than MDM2 and that MDM2 inhibitors 
show considerably less affinity for it, 171,187 small "lead-like" compounds, like 168, could 
also be an attractive starting point for the investigation of the requirements of MDMX 
inhibitors. It would be desirable to simultaneously investigate these compounds with 
respect to both proteins. 
Solubilising Groups cotAd 
be attached here in the 
final synthetic step 
Chirality here could 
potentially control the 
other centre by facilitating 
assymetric synthesis or 
resolution. This group 
could also act as a 
geometric constraint 
Figure 43 Potential sites for development of these compounds. 
The three well developed classes of inhibitors all have solubilising groups attached. 
From the published SAR of the spiro-oxindoles it is clear that appropriately placed 
solubilising groups can make additional binding interactions and enhance affinity and 
should therefore be considered as part of the overall pharmacophore and not just an 
appendage to improve properties. However, it is convenient to investigate this after the 
classical pharmacophore has been optimised. There is a free amino group in the ring which 
would facilitate attachment of pendant solubilising groups. Furthermore, the position of 
this attachment point coincides with that of the benzodiazepine (see overlay, Figure 37) 
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which is precedence that it may be well tolerated. This is a positive consequence of using 
the Color-score chemistry matching in ROCS. The chemistry assessment below shows that 
this group can be added in the last synthetic step greatly facilitating its investigation. 
Compound 168 has one chiral centre. It was tested as the racemate, but it can be 
expected that only one enantiomer will be responsible for the bulk of the activity and each 
enantiomer would need to be investigated. The easiest way to do this would be to use 
a-methyl benzyl amines to prepare diastereomeric compounds which could easily be 
separated. This substituent could also act as a geometric constraint that helps the 
compound favour the binding conformation, hence reducing the entropy penalty upon 
binding. This has been shown to be the case both for the benzodiazepienes139" 140 and this 
type of compound for which there is literature precedent for inducing stereochemistry and 
constraining geometry. 226 If this is successful the methyl group could be replaced and 
derivatives of phenyl glycine used to (a) mimic the carboxylate group of the 
benzodiazepines or (b) provide an alternative attachment point for solubilising groups that 
are chemically and spatially more similar to the activity enhancing ones seen on the 
spiro-oxindoles. 133 
It will only be possible to investigate these compounds if a number of analogues 
can be obtained. While it is possible to purchase analogues with the desired substitution on 
the benzyl and phenyl groups, suitable analogues substituted on the fused ring are not 
available. Scheme 9 shows a short route that allows variation in the diversity at all of the 
main pharmacophore and solubilising groups to be easily investigated. 226 By using readily 
available chiral benzyl amines or amino acids it should be possible to investigate the role 
of stereochemistry in the SAR. 
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Scheme 9A synthetic route that would give access to a range of analogues. 
3.5.3 Investigating the other hits 
The other hit compounds could be further investigated by testing more analogues 
of them. The analogues chosen would be based on the known SAR of the literature 
inhibitors and would mainly be those with halide substituents at various positions of their 
aryl groups. It would be particularly interesting to investigate 156 and 180 which showed 
some p53 induction in the Luciferase reporter gene assay and 169, the most active 
compound in the FP binding assay. Although 169 does not show any p53 induction it does 
bear an acid group which would reduce its cell permeability. It would therefore be 
desirable to test analogues in which the acid is blocked or absent. 
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4. Scaffold Hopping 
4.1 Introduction 
Scaffold hopping is a very important aspect of drug discovery. The goal is generally 
to find new chemo types of the same pharmacophore. The reasons for this are manifold 
and may include trying to improve the inherent physico-chemical properties, to move 
away from toxic or reactive species or from a competitors IP space. There is usually 
more than one type of ligand for any given target. This is clearly seen in the case of 
MDM2, where over 20 diverse chemo types have now been described. 125.134 Of those for 
which there is structural or computational evidence that supports them binding in a mode 
compatible with the accepted pharmacophore model, they utilise different scaffolds to 
present their binding groups to the sub-pockets of the binding site. 
' 22,135 Although, 
proven as a concept in mouse models with the three most potent inhibitors, the MDM2- 
p53 PPI is still to be validated in the clinic. Whether or not this can be done may be 
dependent on the pharmaco properties of the inhibitors used, and whether they have any 
undesirable off-target activity. Therefore, finding and investigating novel classes of 
inhibitors remains an important area of research. 
Scaffold hopping usually involves virtual screening or in-silico de novo design or 
fragment based drug discovery206.221.227 which was the subject of Chapter 3. In this 
chapter, initial investigations on two scaffolds are initiated. One is based on a variation 
of the known benzodiazepine inhibitors the second is conceptually novel but has 
sufficient basis to warrant investigation. 
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4.2 1,5-Benzodiazepiene-2-ones 
Based on the successful development of the 1,4-benzodiazepiene-2,5-diones by 
Johnson and Johnson and because our collaborators at Cyclacel Ltd were working on a 
similar chemo type for another target it was suggested that a series of 
1,5-benzodiazepiene-2-ones be investigated as MDM2 inhibitors (Scheme 10). These 
compounds were relatively free of IP particularly with respect to use as cancer 
therapeutics. 
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Scaffold Hop 
Scheme 10 The proposed scaffold hop from the well established 1,4-benzodiazepine-2,5-dione to a 
novel 1,5-benzodiazepine-2-one scaffold 
4.2.1 Computational Docking 
This scaffold hop is moving one of the potential binding groups from the 4- to the 
5-position of the diazepiene ring. In an inhibitor like this where the overall shape of the 
molecule is likely to be critical to its binding it would be expected that such a change 
would cause the binding groups to clash with the protein rather than fill its sub pockets 
and hence be detrimental to activity. 
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The proposed structure was docked into the binding site of the X-ray co-crystal 
structure of MDM2 with the p53-peptide (1YCR)' using FRED. The 21 top poses, as 
ranked by Openeye's scoring function, Chemgauss 3,212 were examined. The ligand does 
not occupy the binding site in a shape complimentary manner or even fill the W23 sub 
pocket in any of the poses. However it was decided that a small number of simple 
analogues should be prepared. 
4.2.2 Synthesis and testing 
Extensive data detailing the medicinal chemistry and SAR development of the 
1,4-benzodiazapien-2,5-diones has been published. 136-140,154 In this work it has been 
shown that only one of the two oxo groups on the benzodiazepine ring is required to 
maintain activity and that the carboxylic acid and solubilising groups can also be 
removed without total loss of activity. 139' 40 On this basis some analogues of the core 
structures, not bearing these features, were prepared (Table 19). 
The synthetic route used (Scheme 11) was based on that of Lee et a] who prepared a 
number of similar compounds using solid supported synthesis (SPS) methodology. 228 
Direct implementation of the SPS synthesis was not suitable for these compounds as it 
required an amide group at the 8-position for attachment to the resin which would still be 
present on the molecule after cleavage. This route was particularly suitable for 
examining various benzyl/benzoyl substituents where diversity here could be varied in 
the last step using a common core. Because of this, analogues were based on variations 
of this group (Table 19). Exploring substituents on other parts of the molecule would 
however, require that the diversity was introduced earlier such that each analogue would 
involve multistep synthesis. 
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The synthesis shown in Scheme 11 worked well. The fl-amino ester, ethyl 3-amino- 
2-phenylpropanoate, was prepared by Claisen condensation between phenylacetonitrile 
and diethylcarbonate followed by hydrogenation of the nitrile. The fl-amino ester was 
coupled with 2-fluoronitrobenzene by nucleophilic aromatic substitution. It was found 
that a3 fold excess of 2-fluoronitrobenzene and DIPEA were required to drive product 
formation in the third step. Performing the fourth and fifth steps in the order shown in 
Scheme 11 greatly facilitated isolation of the product. If the nitro group was reduced 
prior to ester hydrolysis, as was the case in the SPS on which this synthesis was based, 228 
the solution phase work up was tedious with emulsion formation and partitioning of the 
product between both aqueous and organic phases, problems not associated with SPS. 
However hydrolysis of the ester prior to reduction of the nitro group allowed facile 
isolation of the product. When the cyclisation step was performed with the peptide 
coupling reagent, HBTU, the reaction proceeded quicker and products were easier to 
isolate than when using carbodiimide chemistry. A one-pot reduction-cyclisation using 
zinc or iron in aqueous acid was unsuccessful although some reduction of the nitro group 
occurred no cyclisation was observed. Had this been successful it would have merged 
the three previous steps into one and allowed formation of core cyclised product directly 
from the nitro ester. Formation of a seven membered ring was probably not sufficient 
driving force for the cyclisation. The final step of the synthesis worked well using 
stoichiometric benzyl chloride and excess cesium carbonate base. The use of benzyl 
bromide leads to formation of the bis-benzyl quaternary ammonium salt. Benzoylation 
with the necessary benzoylchloride gave the required product but required catalytic 
DMAP to be added for the reaction to proceed. 
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Scheme 11 Synthesis of 1,5-benzodiazepiene-2-ones. 
When tested in the FP assay, all of these compounds were found to be inactive and 
showed no activity at the highest concentration. This result demonstrated that it was not 
possible to change the overall shape of the molecule in this way. Had any appreciable 
activity been shown analogues examining substituents on the phenyl and fused benzene 
ring would have been investigated. 
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OH 
/\ 
Ný 
N 
Y 
X/1 
Entry Compound Y h Yield FPICso (µM) 
1 186 
-CH2- H 69% >500 
2 187 
-CH2- o-(] 48% >500 
3 188 
-CHF- rn-Cl 54% >500 
4 189 
-CH2- /p-C'l 63% >500 
5 190 C=O H 58% >500 
6 191 C=O o-Cl 48% >500 
7 192 C=O m-Cl 43% >500 
8 193 C=O /)-('1 56% >500 
Table 19 All of this series were inactive using the less sensitive assay cond itions so much so that it 
was not possible to apply the correction factor pre viously used. Yields are of isolated material after 
purification. 
4.2.3 Conclusion 
If inhibitors based on a 1,5-benzodiazepiene-2-one scaffold were to be developed 
they would be required to carry their substituents at the same positions as the known 
active 1,4-benzodiazepiene-2,5-diones (Figure 44). This initially appeared to be an 
attractive proposition that would represent a novel class of inhibitor, based on a 
privileged structure scaffold, 229 with essentially identical shape to one of the best known 
inhibitors. Moreover carrying substituents at these positions, 
1,5-benzodiazepiene-2-diones such as 194, are almost totally free of any IP. It was 
therefore, decided to do some preliminary investigations into preparing similar 
compounds. 
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Figure 44 1,5-benzodiazepiene-2-diones, 194, with the same substitution pattern as the known active 
1,4-benzodiazepiene-2,5-diones would be more likely to be active. qfl-Substituted fl-amino esters, 
195, are the key intermediate required for their preparation. 
If analogues of 194 were to be prepared using a similar strategy to that in Scheme 
11 the key intermediates would be aß-substituted-, 6-amino esters like 195 (Figure 44). It 
quickly became apparent that these were not subject to IP for a reason. Synthesis of this 
intermediate would not be as straightforward as it first appeared. There was no literature 
precedent for the preparation of a, ß-substituted ß-amino esters with such large 
substituents at both a and ß positions. Other obstacles to the investigation of these 
compounds were that all diversity would need to be added at the start of the synthesis so 
several steps would be required to prepare each analogue and not all of the materials 
were readily available to investigate the range of analogues required for a 
comprehensive SAR study. The idea of investigating these compounds was abandoned 
in favour of a simpler, more drug like and completely novel scaffold as described in the 
following section. 
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1,3-Dihydrobenzimidazol-2-one based inhibitors 
4.2.4 Background 
It is well accepted that drug-like chemical space is limited to molecules with a 
certain acceptable range of properties, 223.223,224 Privileged structures are molecular scaffolds 
capable of interacting with a variety of cellular targets. 229 These same structures are 
repeatedly seen in various bioactive compounds and are therefore excellent starting 
points from which to initiate drug discovery programs. A number of nitrogen 
heterocycles are considered privileged structures and occur in a wide spectrum 
biologically active compounds. 
At a presentation by Lipinski0 and in a recent paper by Ertl, 231 that the 
occurrence of rings in bioactive compounds is concentrated to discreet clusters, based on 
these privileged structures, was discussed. One such privileged ring system, 
1,3-dihydrobenzimidazol-2-one, 1% 197, (Figure 45). It occurs in many important 
pharmaceutical compounds. Examples shown in Figure 46 include the Hl receptor 
antagonist, Oxatomide, 198,232 the anti dopaminergic, Domperidone sold as Motilium, 
199,233 Filbanserin, the 5-HTIA and 5-HT2A receptor agonist, 200,234 the ORL-I 
receptor antagonist, J-113,397,201,235 the non-nucleoside HIV inhibitor, 202,236 the 
progesterone receptor antagonist 203,237 the p38 MAP kinase inhibitor, 204,238 and 
BIMU8, the 5-HT-4 receptor agonist, 205.239 
The 1,3-dihydrobenzimidazol-2-one ring system, 1%, could conceivably act as a 
potential tryptophan mimic and be a good starting point from which to design novel 
MDM2 inhibitors with the general structure of 197. Branching at the 3-position, using a 
minimalistic scaffold (a single sp3 carbon) to project groups into the F19 and L26 
sub-pockets would result in molecules possessing few, if any, superfluous atoms and 
131 
potentially be very ligand-efficient, 240 which would contribute to their inherent 
"drug-likeness". 
H 
196 197 
Figure 45 The privileged structure Dihydrobenzimidazol-2-one, 1%, could potentially mimic the 
W23 residue of p53 and be the basis of potential ligands with the general structure of 197 X: H, Cl 
or Br; R. R": alkyl or aryl. 
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Figure 46 The 1,3-dihydrobenzimidazol-2-one ring system is found in many important 
pharmaceutical compounds. 
132 
There is precedent for 1,3-dihydrobenzimidazol-2-one based inhibitors within the 
context of what is already known about p-53-MDM2 PPI inhibitors. The 
1,3-dihydrobenzimidazol-2-one is very similar to the oxindole ring which is the basis of 
the most potent spiro-oxindole inhibitors such as MI-291 132,141 and a number of 
inhibitors such as 206 in the patent literature (Figure 47). 241 The indole based inhibitor, 
6, recently reported by Wang et al, 143 with the same branching as proposed here that 
shows low µM affinity and as of yet is totally unoptimised (Figure 47). Probably most 
convincing was a report, in which the W23 indole of the p53 peptide is replaced with a 
1,3-dihydrobenzimidazol-2-one ring with very little loss of affinity for MDM2.242 
R 
c'o 
N 
H 
6 206 
Figure 47 Known inhibitors provide precedent for various aspects of the proposed investigation of 
1,3-dihydrobenzimidazoi-2-one as the basis for MDM2-p53 PPI inhibitors. 14'''2°2 
4.2.5 Ligand design and synthesis. 
A recent report described a one-pot synthesis of some 3-substituted 
1,3-dihydrobenzimidazol-2-ones (Scheme 12). 243 It was decided to use this synthesis as 
it facilitated varying the molecule in the final step and suitable 2-haloanilines were 
available from which both the unsubstituted and the all important 6-Cl-substituted 
analogues could be prepared. Observation of SAR at the 6-position, as observed for the 
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optimised peptides131 and spirooxindoles, 132" 141 would be very indicative of these 
molecules binding in the predicted manner. The other starting materials that would be 
required were a-branched primary amines possessing the other two binding groups. The 
limited availability of amines of this type played a role in deciding what initial analogues 
would be prepared. Most of the desired amines were not readily available so it was 
decided to base the analogues on amino acids. 
The L-enantiomers of tryptophan, phenylalanine and leucine were selected for the 
first analogues not because of their relationship to this binding site but more so because 
they would simultaneously represent a small medium and large and aliphatic, aromatic 
and heteroaromatic binding groups (Table 20). 
YyR r-R 
RrR 
O HZNN CICOOMe 
X NHZ Pyridine XI HAO- Cul/(L)-proline X 
I/ ýO 
Base/DMSO 
Scheme 12 X: H, Cl; R, R": alkyl, aryl 
The amino acids were converted to their corresponding N, N-dimethyl and pyrolidyl 
amides. Amides were chosen as they are the most stable carboxylic acid derivatives and 
could be modified to vary the size of the third binding group. Also their carbonyl group 
would reduce the number of rotatable bonds increasing the overall rigidity of these 
molecules. The N-substituents chosen were selected as they are of a similar size to 
groups used in other inhibitors. 
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4.2.6 Physico property prediction 
Given that this series of molecules were being designed around a privileged 
structure, it was decided to monitor their pharmaco properties from the outset using the 
OSIRIS property explorer by Actelion Pharmaceuticals Ltd. 244 This is an online property 
prediction program, available at the Organic Chemistry Portal website. 245 For a given 
structure, this program measures molecular weight and predicts properties associated 
with drug likeness namely the partition coefficient (cLogP) and aqueous solubility 
(LogS). 223 Figure 48 shows how these properties are distributed among commercial drug 
compounds. The molecular weight, cLogP and LogS values determined for the test 
compounds (Table 20) are all values shown by the majority of commercial drug 
compounds. 
Drug-likeness, a measure of similarity between a given molecule and commercial 
drug compounds on the basis of it containing substructure fragments found in 3,300 
traded drugs, is also determined. A positive drug-likeness score is indicative that a 
molecule contains fragments frequently found in commercial drug compounds. With 
values ranging from 6.09 to 7.48 the compounds in this study are predominantly 
composed from such fragments. Comparing these values to the distribution of 
drug-likeness in traded compounds shown in Figure 48, it is clear that they exceed the 
value normally found. This is good providing that properties such as cLogP are not 
adversely affected. 
The program also recognises and flags functionality associated with toxicity. An 
overall drug score is also determined. This score is a combination of drug-likeness, 
cLogP, LogS, molecular weight and toxicity risks and is a measure of compound's 
overall potential to qualify as a drug. Drug-scores close to l indicate a high probability 
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that a compound will have good drug properties. All of the initial analogues scored very 
well (Table 20) and did not flag up any toxicity risks. Although the OSIRIS property 
explorer does not measure all of the Lipinski rule-of-five descriptors of drug likeness 
such as numbers of H-bond donors and acceptors, rotatable bonds or chiral centres it is 
clear that all of these compounds comply with these guidelines too. 223 
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Figure 48 Distribution of properties calculated by OSIRIS property explorerud among traded drugs. 
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O R 
N-NR2. \ 
N 
H 
Drug Drug 
Entry Compound X R NR'2 Mw cLogP LogS likeness score 
1 207 H i Pr NMe2 275.35 2.27 
-3.02 6.13 0.88 
2 208 H i Pr Py 301.38 3.08 
-3.7 6.09 0.8 
3 209 H Ph NMe2 309.36 2.28 
-3.45 6.83 0.84 
4 210 H Ph Py 335.40 3.09 
-4.14 6.78 0.75 
5 211 H In Py 374.44 3.15 
-4.66 6.75 0.67 
6 212 Cl iPr NMe2 309.79 2.88 
-3.75 6.8 0.8 
7 213 Cl iPr Py 335.83 3.69 
-4.44 6.73 0.69 
8 214 Cl Ph NMe2 343.80 2.89 
-4.19 7.48 0.75 
9 215 Cl Ph Py 369.84 3.70 
-4.87 7.4 0.62 
10 216 Cl In Py 408.88 3.77 
-5.4 7.36 0.54 
Table 20 Predicted drug prope rties. Key In, indole; Py, pyrolidine 
4.2.7 Docking into MDM2 
All of the synthesized ligands and a number of conceptual ones, based on 
commercially unavailable amines, were docked in MDM2, from the X-ray co-crystal 
structure with the p53 peptide (1 YCR), ' using FRED. 2 Z The top pose for the majority of 
these ligands was as expected with the 1,3-dihydrobenzimidazol-2-one ring mimicking 
tryptophan and the other two groups mimicking phenylalanine and leucine. In the case of 
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compound 216, where the amino amide was pyrolidyl L-tryptophan the indole is 
predicted to make an additional H-bond with MDM2 (Figure 49). 
Figure 49 Compound 216 docked into MDM2 from IYCR' using FRED212 binds as expected 
mimicking the H-bond donor ability of W' and showing the possibility to make additional H-bonds. 
4.2.8 Synthesis 
The t-boc-protected amino acids were coupled with either dimethylamine or 
pyrolidine using the peptide coupling reagent HBTU and DIPEA and deprotected in 
TFA to give the required amino amides. 246 The required o-halophenylcarbamates were 
prepared by condensation of the corresponding o-haloaniline with methyl chloroformate. 
The o-halophenylcarbamates and amino amides were converted into the desired 
3-substituted-1,3-dihydrobenzimidazol-2-ones (Table 21) using the cascade 
coupling/cyclisation methodology described by Zou et al (Scheme 13). 243 
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Scheme 13 All compounds were prepared using this convergent synthetic route which is very 
amenable to analogue synthesis. Coupling/Cyclisation Conditions: 10% Cul / L-proline, K3P04, 
DMSO, 70°C then 130°C 
4.2.9 FP Binding Assay and SAR 
The results described here are again based on the less sensitive assay and binding 
affinity is corrected by a factor of 3.18 as previously discussed (Section 1.1 1.1). 
On initial inspection these compounds were all thought to be inactive with 
uncorrected IC50 > 500µM. However, upon closer inspection some analogues showed 
some, albeit low, dose dependant activity approaching 500µM. These were mostly the 
analogues with the 6-chloro substituent which had been shown to greatly enhance the 
potency of the ultra potent peptides 13' and spiro-oxindoles132.141. Despite the low 
activity, this implied that a well established SAR feature was exerting some influence on 
their affinity for the target. To confirm and quantify this, the assay was performed with a 
much higher top concentration of 5mM. Interestingly at this high concentration the 
compounds remained soluble. IC5o values were determined and corrected (Table 21). 
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Once again the 6-chloro analogues showed activity and the corresponding 
des-chloro counterparts remained mainly inactive with only two slight exceptions, 
neither of which detract from the possible 6-chloro SAR. Firstly the tryptophan based 
des-chloro analogue 211, showed some activity, albeit considerably less than the 
corresponding 6-chloro analogue 216 (Table 21 entries 5 and 10). Secondly the only 
6-chloro analogue that was inactive was 212, the N, N-dimethyl leucine derivative, which 
is the smallest analogue (Table 21 entry 6). 
There also appears to be some SAR based on the size of the side chains. As the size 
of the molecules 212,213 and 214 increases so too does binding activity. Activity is 
considerably reduced for the next largest analogue, 215, indicating that the optimum 
volume may have been exceeded (Table 21 entries 6-9). However, the largest and the 
second most active compound, 216, appears to buck this trend and showing the second 
highest activity of the series (Table 21, entry 10). That 216 is less active than 214 
suggests that its increased bulk is reducing its ability to ft into the binding site but its 
increased activity over 215 indicates that its different functionality is allowing it to make 
interactions that compounds 212-215 cannot. This is supported by docking that shows its 
indole making a second H-bond interaction with MDM2 (Figure 49), the fact that its des- 
chloro counterpart 212 also shows some activity and that it is structurally similar to the 
previously described inhibitor, 6, which bears two indole groups. 143 
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O 
RýR'2 
aN 
N 
H 
FP IC50 
Entry Compound X R NR'2 Yield 
Adjusted 
1 207 H iPr NMe2 55 % Inactive 
2 208 H iPr Pyrolidine 27% Inactive 
3 209 H Ph NMe2 61 % Inactive 
4 210 H Ph Pyrolidine 69 % Inactive 
5 211 H Indole Pyrolidine 12 % 753.11 
6 212 Cl iPr NMe2 49% Inactive 
7 213 Cl iPr Pyrolidine 42 % 588.73 
8 214 Cl Ph NMe2 58% 196.18 
9 215 Cl Ph Pyrolidine 41 % 456.63 
10 216 Cl Indolc Pyrolidine 21 % 239.08 
Table 21 Yields and binding activities of the 1,3-dihydrobenzimidazol-2-one compounds as 
determined by FP competitive binding assay. 
4.2.10 Conclusions and Future work 
A number of very drug like but low affinity ligands have been found in a very 
preliminary investigation using a low sensitivity assay. While SAR consistent with 
known MDM2 inhibitors shown by these analogues is evidence that they may well be 
bona-fide ligands, they are never the less low affinity ones. However, the analogues that 
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were investigated were based on a small number of amides derived from natural amino 
acids there are a number of things to be taken into account when considering these 
results and planning future work. 
As these compounds are chiral and only one enantiomer was prepared it is likely 
that the other one will bind with different affinity. So analogues of the general type 217, 
based on the corresponding D-amino acids, will need to be tested. The corresponding 
enantiomers of 213,215 and 216 have been prepared but are not yet tested. 
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Although using amino amides as the branched amines for this investigation have 
some advantages such as stability, ease of variation and rigidity there are also some 
limitations. In particular, the rigidity provided by the amide carbonyl group will extend 
to the its nitrogen and be a barrier to rotation. While rigidity is considered a good thing it 
would probably be beneficial to allow rotation in the bond immediately adjacent to the 
binding groups so that it could adopt the most favourable conformation and fine tune its 
interaction with the protein, rather than be locked in to one which may reduce its ability 
to bind. Given the lack of available a-branched primary amines it would be necessary to 
prepare these. However this should be possible by addition to sulfonylimines using 
organometalics such as Grignard reagents, a route that could be employed stereo 
selectively, 247-249 or by reduction of the amino amides already used, which would 
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provide compounds like 218 that would be directly comparable to the work already 
done. 
R 
N N 
XN H 
218 
While the compounds discussed here warrant further investigation as outlined new 
analogues would need to show much enhanced binding activity and SAR. Probably the 
most important requirement will be to improve the sensitivity of the binding assay so 
that accurate affinities can be determined. If any better ligands are developed they would 
need to be tested using functional assays to show that they do indeed induce a 
non-genotoxic p53 response. 
143 
5. Experimental 
5.1 Synthesis, General Methods 
Standard syringe techniques were applied for transfer of air sensitive reagents. Solvents 
and reagents were purchased from Aldrich, Fisher Scientific, Fluorochem, or Alfa Aesar 
and were used as received. 1H and 13C NMR spectra were recorded on a Bruker Avance 
400 spectrometer at 400 MHz and 100 MHz respectively at ambient temperature. 
Chemical shift values are reported in ppm relative to external TMS. High resolution 
mass spectra (HRMS) were recorded on a Micromass LCT spectrometer, ionization 
mode: ESI. Optical rotation was measured on a Bellingham and Stanley ADP410 
polarimeter. Flash chromatography was performed with the indicated solvent mixture on 
Fluorochem Silica gel 60 (35-70 gm). Thin layer chromatography was performed using 
Merck silica gel 60 F254 aluminum backed plates visualized by UV irradiation and 
permanganate staining. All tested compounds show > 95 % purity as determined by 
HPLC. For all compounds except the benzodiazepine series (compounds 186-193) and 
the deschloro sulfonamdes (compounds 111 and 114) a Waters, Symmetry column (C18, 
3.5 um, 120 A, 4.6 x 50 mm), mobile phase water with 0.1 % formic acid and 
acetonitrile, gradient 5-100 % acetonitrile over 10 min, at a flowrate of I mUmin and 
detection wavelength 254 nm. HPLC of the benzodiazepienes was performed using a 
Phenomenex Onyx monolith column (C18,4.6 x 100 mm), mobile phase water with 
0.1% formic acid and acetonitrile isocratic 45% acetonitrile 3 mUmin and detection 
wavelength 254 nm 
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General Procedure A: 5-Chlorothiophene-2-sulfonyl chloride 20 
CI S SCI C/ 
PCl5 (100 g) was added portionwise to chlorosulfonic acid (80 mL). The mixture was 
stirred until gas evolution ceased (15 min) and then cooled to 0 T. 2-Chlorothiophene 
(11 mL, 120 mmol) was added dropwise with cooling. The reaction mixture was stirred 
at ambient temperature for 5h and then carefully added with stirring to of ice/1-120 (2 L). 
After stirring overnight, the aqueous solution was extracted with ether (3 x 500 mL). The 
ether extract was washed with H2O (500 mL) and brine (500 mL), dried (MgSO4), 
filtered, and concentrated under reduced pressure to yield 34.14 g (72%) of the desired 
product: Orange oil; 'H NMR (400 MHz, CDC13) 5 7.66 (d, J=4.2 Hz, 1 H), 7.00 (d, J= 
4.2 Hz, 1 H). 
5-Bromothiophene-2-sulfonyl chloride 
Br 
1S/ 
S 
2-Bromothiophene (22.53 mL, 23 mmol) was converted to the desired product using the 
General Procedure A as employed for the analogous chloro compound. The solid that 
precipitated upon addition to ice and was collected, washed and dried by vacuum 
filtration to yield 53.38 g (89 %) of the product as a cream crystalline solid: 'H NMR 
(400 MHz, CDC13) 5 7.66 (d, J=4.2 Hz, 1 H), 7.19 (d, J=4.2 Hz, 1 H). 
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Thiophene-2-sulfonyl chloride 
0 
S 
/ 
SCI 
Thiophene (19.1 mL, 230 mmol) was converted to the desired product using the General 
Procedure A as employed for the analogous chloro compound. The brown oil that 
separated upon pouring the reaction mixture on to ice was dissolved in ether (250 mL), 
dried (MgSO4) and the solvent removed under reduced pressure to yield the desired 
product as a low melting, brown solid 31.3 g (75%): 1H NMR (400 MHz, CDC13) 8 7.9 
(dd, J, 
=4 Hz, J2 = 1.3 Hz, 1 H), 7.85 (dd, J, =5 Hz, J2 = 1.3 Hz, 1 H), 7.21 (dd, Ji =5 
Hz, J2=4Hz, 1H). 
General Procedure B: nitration of thienyl sulfonyl chlorides 250 
The crude sulfonyl chloride was added dropwise to 100% fuming nitric acid (100 mL) 
while maintaining the temperature below 60 °C and stirred at ambient temperature for 4 
hours. The reaction mixture was added slowly with stirring to of ice/H20 (1 Q. Solid 
products were separated and dried by filtration. Oils were separated, dissolved in diethyl 
ether and dried (MgSO4) and the solvent was removed under reduced pressure. 
5-chloro-4-nitrothiophene-2-sulfonyl chloride 
90 
02N 
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Using General Procedure B, 5-chlorothiophene-2-sulfonyl chloride (17.07 g, 80 mmol) 
yielded the desired product. Pale yellow solid 15.1 g (73 %). 1H NMR (400 MHz, 
CDCl3) 6 8.31 (s, I H). 
5-Bromo-4-nitrothiophene-2-sulfonyl 
chloride 
Br S9O S-CI 
02N 
Using General Procedure B, 5-bromothiophene-2-sulfonyl chloride (53.38 g, 204 mmol) 
yielded the desired product. Cream solid (42.5 g, 70 %) 'H NMR (400 MHz, CDCl3) 8 
8.29 (s, I H). 
4-Nitrothiophene-2-sulfonyl chloride 
S 
\/S, CI 
02N 
Using General Procedure B, thiophene-2-sulfonyl chloride (31.3 g, 171 mmol) Orange 
oil 26.88 g (69 %) as a 2: 1 mixture of the 4-nitro and 5-nitro isomers in favour of the 
desired 4-nitro product. The mixture of isomers was used in the next step with out 
further purification. 1H NMR (400 MHz, CDC13) 4-Nitro isomer (desired) 5 8.77 (d, J= 
1.7 Hz, I H), 8.4 (d, J=1.7 Hz, I H). 5-nitro isomer 7.99 (d, J=4.3 Hz, 1H (0.54 relative 
to 4-isomer)), 7.88 (d, J=4.3 Hz, IH (0.54 relative to 4-isomer)). 
General Procedure C: 5-Alkyl-4-nitro-2-sulfonyl chlorides 251 
Chlorosulfonic acid (54.5 mL, 816 mmol) in chloroform (500 mL) was cooled a salt / ice 
bath. A solution of 2-alkylthiophene (267 mmol) in chloroform (200 mL) was added 
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dropwise and the reaction was stirred for 30 min. The solution was poured on to ice and 
the product was extracted with diethyl ether (3 x 100 mL). The combined organic layers 
were dried (MgSO4) and the solvent removed under reduced pressure to yield the crude 
sulfonyl chloride as brown oil. The crude sulfonyl chloride was added dropwise to 100% 
fuming nitric acid (100 mL) while maintaining the temperature below 60 °C and stirred 
at ambient temperature for 4 h. The reaction mixture was added slowly with stirring to 
ice1H20 (I L). The solid products were separated by filtration and dried under reduced 
pressure. 
5-Methyl-4-nitrothiophene-2-sulfonyl chloride 
S0 ýO 
- CI 
02N 
Using General Procedure C, 2-methylsulfonamide (25.7 mL, 267 mmol) yielded 6.6 g 
(27 %) of the desired product as a cream solid: 'H NMR (400 MHz, CDC13) S 8.33 
(s, IH), 2.94 (s, 3H). 
5-Ethyl-4-nitrothiophene-2-sulfonyl chloride 
S 
9ýO 
SICI 
11*'-ýý/ 
02N 
Using General Procedure C, 2-ethylsulfonamide (25 g, 223 mmol) yielded 18.2 g of the 
desired product Cream solid (32 %) 1H NMR (400 MHz, CDC13) 8 8.33 (s, IH), 3.41 (q, 
J=7.38 Hz, 2H), 1.48 (t, J=7.38 Hz, 3H). 
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S-n-Propyl4-nitrothiophene-2"sulfonyl 
chloride 
SQ "O S0CI 
02N 
Using General Procedure C, 2-propylsulfonamide (18.69 mL, 223 mmol) yielded 15.6 g 
(26 %) of the desired product as a cream solid: 1H NMR (400 MHz, CDC13) 8 8.33 
(s, I H), 3.32 (t, J=7.4 Hz, 2H), 1.85 (sx, J=7.4 Hz, 2H), 1.12 (t, J=7.4 Hz, 3H). 
General Procedure D: N-benzylsulfonamide synthesis 
Up to twelve compounds were prepared in parallel using a general sulfonamide synthesis 
adapted from literature procedures. u°' 252 The required sulfonylchloride (1.1 eq) and 
DCM were added to a clean dry reaction tube, ice cooled and stirred. Over 5 minutes, the 
required benzylamine (I eq) and TEA (1 eq) in DCM were added. The reaction was 
stirred on ice for 5 minutes then allowed to warm to room temperature for 1 hour with 
stirring. IM aqueous HCl (10 mL) was added followed by DCM (10 mL). The organic 
layer was separated washed with water (2 x 20 mL), brine (1 x 20 mL), dried (MgSO4) 
and the solvent was removed under reduced pressure. The crude material was purified by 
flash chromatography and/or recrystalisation as detailed below. 
N-Benzyl-5-chloro-4-nitrothiophenesulfonamide (67) 
CI S 
S` 
/W 
/ 
- 
ý\ 
02N 
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Benzylamine (541 mg, 5 mmol), TEA (505 mg, 5 mmol) in DCM (5 mL) was added to 
5-chloro-4-nitrothiophene-2-sulfonyl chloride (1.44 g, 5.5 mmol) in DCM (5 mL) as per 
General Procedure D. The crude product was purified by flash chromatography (silica 
gel; hexane/EtOAc, 10: 2), recrystallised in hexane, EtOAc and dried under high vacuum 
at 60 °C overnight yielded 0.8 g (48 %) of 67 as pale yellow crystals: mp 130-131 °C; 1H 
NMR (400 MHz, CDC13) 8 7.84 (s, I H), 7.28 (m, 5H), 5.09 (br t, J=6 Hz, I H), 4.32 (d, 
J=6.0 Hz, 2H); 13C NMR (100 MHz, DMSO-d6) 6 142.8,138.6,137.0,136.3,128.7, 
128.3,127.8,127.0,46.9; HRMS (ESI) m/z calcd for C,, H8CINZO4S2 [M-H]-: 330.9614, 
found: 330.9579; HPLC TR: 10.45 min. 
N-(4-Chlorobenzyl)-5-chloro-4-nitrothiophenesulfonamide (68) 
CI S S: 
O 
/HIj 
02N CI 
4-Chlorobenzylamine (713 mg, 5 mmol), TEA (505 mg, 5 mmol) in DCM (5 mL) was 
added to 5-chloro-4-nitrothiophene-2-sulfonyl chloride (1.44 g, 5.5 mmol) in DCM 
(5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 10: 2), recrystallised in hexane, EtOAc and 
dried under high vacuum at 60°C overnight yielded 0.74 g (40 %) of 68 as pale yellow 
crystals: mp 98-99 °C; 1H NMR (400 MHz, CDC13) 6 7.91 (s, 1 H), 7.3 (dt, JAB = 8.5 Hz, 
2H), 7.23 (dt, JAB 
= 
8.5 Hz, 2H), 5.05 (br t, i=6.0 Hz, 1 H), 4.28 (d, J=6.0 Hz, 2H); 13C 
NMR (100 MHz, CDC13) S 137.8,137.5,134.9,128.9,128.5,128.1,127.2,47.7; HRMS 
(ESI) m/z calcd for C11H7C12N204S2 [M-H]': 364.9224, found: 364.9216; HPLC TR: 
10.96 min. 
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N-(2-Trifluoromethylbenzyl)-5-chloro-4-nitrothiophenesulfonamide (69) 
CI S0 
CF., 
O2N 
2-Trifluoromethylbenzylamine (881 mg, 5 mmol), TEA (505 mg, 5 mmol) in DCM 
(5 mL) was added to 5-chloro-4-nitrothiophene-2-sulfonyl chloride (1.44 g, 5.5 mmol) in 
DCM (5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexaneJEtOAc, 10: 2), recrystallised in hexane, EtOAc and 
dried under high vacuum at 60 °C overnight yielded 0.8 g (40 %) of 69 as pale yellow 
crystals: mp 98-99 °C; 1H NMR (400 MHz, CDC13) 6 7.88 (s, 1H), 7.66 (m, IH), 7.57 
(m, 2H), 7.46 (m, 1 H), 5.21 (t, J=6.2 Hz, I H), 4.48 (d, J=6.2 Hz, 2H); HRMS (ESI) 
m/z calcd for C12H7CIFý3N2O4S2 [M-H]': 398.9488, found: 398.9483; HPLC TR: 11 min. 
N-(3-Trifluoromethybenzyl). 5-chloro4-nitrothiophenesulfonandde (70) 
S 
q0 
CI 0 S, CF3 
02N 
3-Trifluoromethylbenzylamine (881 mg, 5 mmol), TEA (505 mg, 5 mmol) in DCM 
(5 mL) was added to 5-chloro-4-nitrothiophene-2-sulfonyl chloride (1.44 g, 5.5 mmol) in 
DCM (5 ml-) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane EtOAc, 10: 2), recrystallised in hexane, EtOAc and 
dried under high vacuum at 60 °C overnight yielded 1.1 g (55 %) of 70 as pale yellow 
crystals: mp 130-131 °C; 'H NMR (400 MHz, DMSO-d6) 8 9.04 (t, J=6 Hz, 1 H), 7.83 
(s, 1 H), 7.60-7.51 (m, 4H), 4.33 (d, J=6 Hz, 2H); 13 C NMR (100 MHz, DMSO-d6) 6 
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142.7,138.7,138.5,136.5,132.6,129.9,129.5 (q, J= 32.7 Hz), 127.0,124.6 (q, J= 
4.1 Hz), 124.6 (q, J= 272.5 Hz), 124.5 (q, J=3.8 Hz), 46.2; HRMS (ESI) m/z calcd for 
Ci2H7C1F3N204S2 IM-H]": 398.9488, found: 398.9482; HPLC TR: 11.03 min. 
N-(4-Trifluoromethybenzyl)-5-chloro4-nitrothiophenesulfonamide (71) 
CI S 
9,, 0 
- 
ý\ / SH ýj 
02N CF3 
4-Trifluoromethylbenzylamine (881 mg, 5 mmol), TEA (505 mg, 5 mmol) in DCM 
(5 ml-) was added to 5-chloro-4-nitrothiophene-2-sulfonyl chloride (1.44 g, 5.5 mmol) in 
DCM (5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 10: 2), recrystallised in hexane, EtOAc and 
dried under high vacuum at 60 °C overnight yielded 1.1 g (55 %) of 71 as pale yellow 
crystals: mp 123-124 °C; 1H NMR (400 MHz, CDC13) S 7.94 (s, I H), 7.65 (d, J=8.1 Hz, 
2H), 7.42 (d, J=8.1 2H), 5.14 (t, J=6.0 Hz, I H), 4.38 (d, J=6.0 Hz, 2H); HRMS (ESI) 
m/z calcd for C12H7C1F3N2O4S2 [M-H]': 398.9488, found: 398.9488; HPLC 
TR: 11.05 min. 
N-(3,5-Bistrifuoromethybenzyl)-5-chloro-4-uitrothiophenesulfonamide (72) 
0 
CI 
O S/ %ý,; CF3 
H 
02N 
CF3 
3,5-Bistrifluoromethylbenzylamine (1.22 g, 5 mmol), TEA (505 mg, 5 mmol) in DCM 
(5 mL) was added to 5-chloro-4-nitrothiophene-2-sulfonyl chloride (1.44 g, 5.5 mmol) in 
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DCM (5 ml-) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexanelEtOAc, 10: 2), recrystallised in hexane, EtOAc and 
dried under high vacuum at 60 °C overnight yielded 0.65 g (35 %) of 72 as pale yellow 
crystals: mp 169-170 °C; 1H NMR (400 MHz, CDCl3) S 7.93 (s, 1H), 7.84 (s, 1H), 7.75 
(s, 2H), 4.46 (s, J=6.0 Hz, 1 H), 4.38 (d, J=6.1 Hz, 2H); 13C NMR (100 MHz, DMSO- 
d6) S 142.7,140.9,138.5,136.7,130.6 (q, JF 
= 
33 Hz), 129.1,127.2,123.7 (q, JF" 
= 
272.3 Hz), 121.5,45.6; HRMS (ESI) m/z calcd for C13H6C1F6N204S2 [M-H]": 466.9462, 
found: 466.9369; HPLC TR: 11.55 min. 
N-Benzyl-5-methyl-4-nitrothiophenesulfonanlide (74) 
S SO 
\/ 
02N 
Benzylamine (541 mg, 5 mmol), TEA (505 mg, 5 mmol) in DCM (5 mL) was added to 
5-methyl-4-nitrothiophene-2-sulfonyl chloride (1.33 g, 5.5 mmol) in DCM (5 mL) as per 
General Procedure D. The crude product was purified by flash chromatography (silica 
gel; hexane/EtOAc, 10: 6), recrystallised from chloroform and dried under high vacuum 
at 60 °C overnight yielded 0.85g (54 %) of 74 as a cream crystalline solid: mp 
109-110 °C; 1H NMR (400 MHz. CDC13) 6 7.94 (s, 1 H), 7.3-7.23 (m, 5H), 4.9 (br t, J= 
6 Hz, 1 H), 4.29 (d, J=6.0 Hz, 2H), 2.83 (s, 3H); 13C NMR (100 MHz, CDC13) 8 149.3, 
136.7,135.4,128.8,128.2,128.2,128.0,47.7,15.9; HRMS (ESI) m/z calcd for 
C12H, 1N204S2 [M-H]-: 311.0160, found: 311.0418; HPLC TR: 10.14 min. 
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N-(4-Chlorobenzyl)-5-methyl-4-nitrothiophenesulfonamide (75) 
S0 /O 
/ 
S" 
HIj 
02N CI 
4-Chlorobenzylamine (713 mg, 5 mmol), TEA (505 mg, 5 mmoi) in DCM (5 mL) was 
added to 5-methyl-4-nitrothiophene-2-sulfonyl chloride (1.33 g, 5.5 mmol) in DCM 
(5 mL) as per General Procedure D. The crude product was crystallised from chloroform 
and dried under high vacuum at 60 °C overnight yielded 0.5 g (29 %) of 75 as a cream 
crystalline solid: mp 130-131 °C; 'H NMR (400 MHz, DMSO-d6) 6 8.77 (t, 6 Hz, 1H), 
7.82 (s, I H) 7.35 (dt, JAR 
= 
8.5 Hz, 2H), 7.28 (dt, J, B = 8.5 Hz, 2H), 4.15 (d, J=6.0 Hz, 
2H), 2.78 (s, 3H); 13C NMR (100 MHz, DMSO-d6) 6 149.8,143.2,137.6,136.4,132.5, 
130.0,128.9,128.6,127.3,46.1,15.9; HRMS (ESI) m/z calcd for C, 2Hi0C1N204S2 
(M-H]': 344.9771, found: 344.9771; HPLC TR: 10.58 min.. 
N-(2-Trifluoromethylbenzyl)-5-methyl-4-nitrothiophenesulfonamide (76) 
S`O 
OF3 
/H 
02N 
2-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-methyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 8: 3), recrystallised in 
hexane, EtOAc and dried under high vacuum at 60 °C overnight yielded 0.58 g (61 %) of 
76 as a cream solid: mp 118-119 °C; 1H NMR (400 MHz, CDC13) S 7.95 (s, IH), 7.65 
(m, I H), 7.58 (m, 2H), 7.44 (m, 1 H), 5.05 (t, J=6.1 Hz, I H), 4.45 (d, J=6.1 Hz, 2H), 
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2.84 (s, 3H); 13C NMR (100 MHz, CDC13) 8 149.6,143.2,136.5,136.5,131.4,131.1 
(q, JF 
= 3.7 Hz), 129.4,128.3,127.8,125.0 (q, JF = 3.7 Hz), 124.5 (q, JF. = 3.8 Hz), 
123.8 (q, Jr, 
= 
272.3 Hz), 47.0,15.8; HRMS (ESI) m/z calcd for C13HioF3N204S2 [M-Hl' 
: 379.0034, found: 379.0039; HPLC TR: 10.72 min. 
N-(3-Trifluoromethybenzyt)-5-methyl4-nitrothiophenesulfonamide (77) 
00 
S S, CF3 N 
02N 
3-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-methyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 8: 3), recrystallised in 
hexane, EtOAc and dried under high vacuum at 60 °C overnight yielded 0.55 g (58 %) of 
77 as a cream crystaline solid: mp 109-110 °C; 'H NMR (400 MHz, CDCl3) S 7.90 
(s, 1 H), 7.55-7.45 (m, 4H), 5.31 (t, J=6 Hz, 1 H), 4.36 (d, J=6 Hz, 2H), 2.81 (s, 3H); 
HRMS (ESI) m/z calcd for C13Hi0F3N204S2 IM-H]': 379.0034, found: 379.0046; HPLC 
TR: 10.14 min. 
N-(4-Trifluoromethybenzyi)-5-methyl-4-nitrothiophenesulfonamide (78) 
S SO 
02N CF3 
4-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-methyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
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2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 8: 3), recrystallised in 
hexane, EtOAc and dried under high vacuum at 60 °C overnight yielded 0.66 g (69 %) of 
78 as a cream crystaline solid: mp: 125-130 °C; 1H NMR (400 MHz, CDC13) S 7.98 
(s, I H), 7.59 (d, J=8.2 Hz, 2H), 7.41 (d, J=8.2 Hz, 2H), 5.15 (t, J=6.0 Hz, I H), 4.35 
(d, J=6.0 Hz, 2H) 2.83 (s, 3H); HRMS (ESI) m/z calcd for C13H1oF3N204S2 [M-H]-- 
379.0034, found: 379.041; HPLC TR: 10.72 min. 
N-(3,5-Bistrifuoromethybenzyl)-5-methyl-4-nitrothiophenesulfonamide (79) 
SJ CF3 
H 02N 
CF3 
3,5-Bistrifluoromethylbenzylamine (610 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in 
DCM (2.5 mL) was added to 5-methyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by recrystallisation from chloroform and dried under high vacuum at 60 °C 
overnight yielded 0.75g (68 %) of 79 as a cream crystaline solid: mp 170.8-171.5 °C; 'H 
NMR (400 MHz, CDCI3) 6 7.95 (s, 1 H), 7.82 (m, 1 H), 7.73 (m, 2H), 5.12 (br t, J=6.5 
Hz, I H), 4.45 (d, J=6.5 Hz, 2H), 2.86 (s, 3H); HRMS (ESI) m/z calcd for 
C14H9F6N204S2 f M-H]-: 446.9908, found: 446.9926; HPLC TR: 11.26 min. 
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N-Benzyl-5-ethyl-4-nitrothiophenesulfonamide (98) 
S "x S, 
N "ýo 
02N 
Benzylamine (261 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM (2.5 mL) was 
added to 5-ethyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 2.75 mmol) in DCM 
(2.5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 7: 3), recrystallised from chloroform and 
dried under high vacuum at 60 °C overnight yielded 0.63 g (77 %) of 98 as a cream 
solid: mp 88.5-89.6 °C; 'H NMR (400 MHz, CDC13) S 7.95 (s, I H), 7.31-7.19 (m, 5H), 
4.9 (br t, J=6 Hz, 1 H), 4.29 (d, J=6.0 Hz, 2H), 3.29 (q, J=7.4 Hz, 2H), 1.36 (t, J= 
7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) S 157.0,142.4,136.8,135.4,128.8,128.4, 
128.2,128.0,128.0,47.6,23.7,14.2; HRMS (ESI) m/z calcd for C13H13N204S2 [M-H]-: 
325.0317, found: 325.0334; HPLC TR: 10.91 min. 
N44-Chlorobenzyl)-5-ethyl4-nitrothiophenesuffonamide (99) 
0 
H Iý 
02N C1 
4-Chlorobenzylamine (357 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM (2.5 mL) 
was added to 5-ethyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 2.75 mmol) in DCM 
(2.5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 7: 3), recrystallised from chloroform yielded 
0.71 g (79 %) of 99 cream crystaline solid mp: 130.7-133 °C; 'H NMR (400 MHz, 
CDCI3) 6 7.95 (s, 1 H), 7.32-7.23 (m, 5H), 4.93 (t, 5.9 Hz, 1 H) 4.30 (d, J=5.9 Hz, 2H), 
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3.30 (q, J=7.4 Hz, 2H), 1.39 (t, 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) 8 157.1, 
142.4,136.7,134.3,133.9,129.4,129.0,128.5,46.9,23.7,14.2; HRMS (ESI) m/z calcd 
for CH12C1N204S2 [M-H]-: 358.9917, found: 358.9917; HPLC TR: 10.54 min. 
N-(2-Tritluoromethylbenzyl)-5-ethyl-4-nitrothiophenesulfonamide (100) 
S 
S0 CF3 
H/ 
02N 
2-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-ethyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 7: 3), recrystallised in 
hexane, EtOAc and dried under high vacuum at 60 °C overnight yielded 0.58 g (59 %) of 
100 as a cream solid: mp 95-95.8 °C; 1H NMR (400 MHz, CDCI3) S 7.94 (s, IH), 
7.64-7.40 (m, 4H), 5.39 (t, J=6.1 Hz, 1 H), 4.45 (d, J=6.1 Hz, 2H), 3.29 (q, J=7.6 Hz, 
2H), 1.38 (t, J=7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) S 157.1,142.4,136.6,133.9, 
132.5,131.1,128.5,128.4,128.3 (q, JF 
= 
30.3 Hz), 126.3 (q, J): = 5.6 Hz), 124.2 (q, jr = 
273.8 Hz), 44.3,23.7,14.2; HRMS (ESI) m/z calcd for C14H, 2F3N204S2 [M-H]-: 
393.0191, found: 393.0224; HPLC TR: 11.06 min. 
N-(3-Trifiuoromethybenzyl)-S-ethyl-4-nitrothiophenesulfonamide (101) 
00 S/ 1S; 
H 
CF3 
02N 
I 
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3-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-ethyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 7: 3), recrystallised in 
hexane, EtOAc and dried under high vacuum at 60 °C overnight yielded 0.55 g (56 %) of 
101 as a cream solid: mp 86-88.5 °C; 1H NMR (400 MHz, CDC13) S 7.89 (s, IH), 7.52- 
7.42 (m, 4H), 5.77 (t, J=6.2 Hz, I H), 4.37 (d, J=6.2 Hz, 2H), 3.25 (q, J=7.5 Hz 2H), 
1.36 (t, J=7.5 Hz, 3H); 13C NMR (100 MHz, CDCI3) S 157.3,142.4,136.6,131.4, 
131.1 (q, JF = 32.9 Hz), 129.4,128.6,125.0 (q, JF = 3.7 Hz), 124.5 (q, JF = 3.7 Hz), 
123.8 (q, Jk- 
= 
272.8 Hz), 47.0,23.7,14.0; HRMS (ESI) m/z calcd for C14H, 2F3N204S2 
[M-H]-: 393.0191, found: 393.0160; HPLC TR: 11.05 min. 
N-(4-Trifuoromethybenzyl)-5-ethyl4-nitrothiophenesulfonamide (102) 
S" S\H 
02N CF3 
4-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-ethyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 7: 3), recrystallised in 
hexane, EtOAc and dried under high vacuum at 60 °C overnight yielded 0.66 g (67 %) of 
102 as cream solid: mp 92.4-94.6 °C; 1H NMR (400 MHz, CDC13) 8 7.94 (s, IH), 7.53 
(d, j=8.2 Hz, 2H), 7.40 (d, J=8.2 Hz, 2H), 6.01 (t, J=6.2 Hz, I H), 4.34 (d, J=6.2 
Hz, 2H), 3.25 (q, J=7.5 Hz, 2H), 1.36 (t, J=7.5 Hz, 3H); 13C NMR (100 MHz, CDC13) 
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S 157.3,142.4,139.6,136.4,130.4 (q, J,. 
- 
= 
31.8 Hz), 128.6,128.2,125.7 (q, J,., = 3.8 
Hz), 123.8 (q, Jr 
= 
271 Hz), 46.9,23.6,14.1; HRMS (ESI) m/z calcd for 
C14H12F3N204S2 [M-H]': 393.0191, found: 393.2028; HPLC TR: 11.04 min. 
N-(3,5-Bistritluoromethybenzyl)-5-ethyl-4-nitrothiophenesulfonamide (103) 
0O S/ CF3 
02N 
CF3 
3,5-Bistrifluoromethylbenzylamine (610 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in 
DCM (2.5 nil. ) was added to 5-ethyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 7: 3), recrystallised in 
hexane, EtOAc and dried under high vacuum at 60 °C overnight yielded 0.75 g (65 %) of 
103 as a cream solid: mp 152.9-155.9 °C; 'H NMR (400 MHz, CDC13) S 7.98 (s, IH), 
7.82 (s, 1 H), 7.74 (s, 2H), 5.17 (br t, J=6.2 Hz, I H), 4.46 (d, J=6.2 Hz, 2H), 3.30 (q, J 
= 7.5 Hz, 2H), 1.39 (t, J=7.5 Hz, 3H); 13C NMR (100 MHz, CDC13) S 157.5,138.4, 
136.4,132.4,132.1,128.7,128.0,123.0 (q, JF = 272.2 Hz), 122.2 (q, JF, = 3.8 Hz), 46.5, 
23.7,14.0; HRMS (ESI) m/z calcd for C15H11F6N204S2 [M-H]-: 461.0064, found: 
461.0096; HPLC TR: 11.57 min. 
N-Benzyl-5-propyl-4-nitrothiophenesulfonamide (104) 
0 
S/ ýL0N 
02N 
160 
Benzylamine (261 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM (2.5 mL) was 
added to S-n-propyl-4-nitrothiophene-2-sulfonyl chloride (742 mg, 2.75 mmol) in DCM 
(2.5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 10: 2) and dried under high vacuum at 60 °C 
overnight yielded 0.25 g (29 %) of 104 as a cream solid: mp 104.2-106.5 °C; 'H NMR 
(400 MHz, CDC13) 6 7.94 (s, I H), 7.33-7.24 (m, 5H), 4.94 (br t, J=6 Hz, I H), 4.29 (d, J 
= 6.0 Hz, 2H), 3.21 (t, 7.7 Hz, 2H), 1.78 (m, 2H), 1.07 (t, J=7.3 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) S 155.0,142.6,136.9,135.4,128.8,128.4,128.2,128.0,47.6,31.6, 
23.5,13.8; HRMS (ESI) m/z calcd for Ci4H, 5N204S2 [M-H]': 339.4120, found: 
339.0441; HPLC TR: 10.94 min. 
N-(4-Chlorobenzyi)-5-propyl4-nitrothiophenesulfonamide (105) 
0 
02N v CI 
4-Chlorobenzylamine (357 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM (2.5 mL) 
was added to 5-n-propyl-4-nitrothiophene-2-sulfonyl chloride (742 mg, 2.75 mmol) in 
DCM (2.5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 10: 2) and dried under high vacuum at 60 °C 
overnight yielded 0.32 g (34 %) of 105 as a cream crystaline soild: mp 92.1-94.8 °C; 'H 
NMR (400 MHz, CDCI1) 6 7.97 (s, I H), 7.29 (dt, JAR = 8.4 Hz, 2H), 7.20 (dt, JAR = 8.4 
Hz, 2H), 4.98 (t, J=6 Hz, 1 H), 4.26 (d, J=6.0 Hz, 2H). 3.22 (m, 2H), 1.79 (m, 2H), 
1.07 (t, J=7.3,3H); 13C NMR (100 MHz, CDC13) 8 155.3,142.6,136.7,134.2,134.0, 
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129.4,128.9,128.4,46.8,31.6,23.5,13.8; HRMS (ESI) m/z calcd for Ci4Hi4C1N204S2 
(M-H)-: 373.0084, found: 373.0102; HPLC TR: 11.27 min. 
N-(2-Trifluoromethylbenzyl)-5-propyl-4-nitrothiophenesulfonamide (106) 
S0 
CF3 
02N 
2-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-n-propyl-4-nitrothiophene-2-sulfonyl chloride (742 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 10: 2) and dried under high 
vacuum at 60 °C overnight yielded 0.25 g (25 %) of 106 as a cream microcrystaline 
solid: mp 97.8-99.5 °C; 'H NMR (400 MHz, CDC13) 6 7.95 (s, IH), 7.64 (m, 1H), 7.57 
(m, 2H), 7.43 (m, I H), 5.01 (t, J=6.4 Hz, I H), 4.6 (d, J=6.4 Hz, 2H), 3.22 (m, 2H), 
1.78 (m, 2H), 1.07 (t, J=7.3 Hz, 3H); 13C NMR (100 MHz, CDC13) S 155.2,142.6, 
136.6,133.9,132.4,130.9,128.6,128.4,128.2 (q, JF = 30.2 Hz), 126.2 (q, JF = 4.7 Hz), 
124.1 (q, JF- = 273.8 Hz), 44.1,31.6,23.5,13.7; HRMS (ESI) m/z calcd for 
Ci5H, 4F3N204S2 [M-H)-: 407.4100, found: 407.0307; HPLC TR: 11.45 min. 
N-(3-Tritluoromethybenzyl)-5"propyl4-nitrothiophenesulfonamide (107) 
1 
S/ S; O 
N CF3 
H 02N 
3-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-n-propyl-4-nitrothiophene-2-sulfonyl chloride (742 mg, 
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2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 10: 2) and dried under high 
vacuum at 60 °C overnight yielded 0.20 g (20 %) of 107 as cream needles: mp 
76.4-77.5 °C; 1H NMR (400 MHz, CDC13) S 7.93 (s, IH), 7.55-7.45 (m, 4H), 5.08 (t, J= 
6.2 Hz, I H), 4.37 (d, J=6.2 Hz, 2H), 3.21 (m, 2H), 1.77 (m, 2H), 1.07 (t, J=7.3,3H); 
13C NMR (100 MHz, CDC13) S 155.4,142.5,136.6,136.6,131.4,131.2 
(q" f 
= 31.7 Hz), 129.4,128.5,125.0 (q, JF = 3.7 Hz), 124.5 (q, JF = 3.7 Hz), 122.4 
(q, 
r 
= 
272.4 Hz), 47.0,31.6,23.4,13.8; HRMS (ESI) m/z calcd for C, 5Hi4F3N204S2 
[M-H]-: 407.4100, found: 407.0300; HPLC TR: 11.41 min. 
N-(4-Trifluoromethybenzyl)-5-propyl4-nitrothiophenesulfonamide (108) 
S0,, O 
\ "H j 
02N CF3 
4-Trifluoromethylbenzylamine (441 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM 
(2.5 mL) was added to 5-n-propyl-4-nitrothiophene-2-sulfonyl chloride (742 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 10: 2) and dried under high 
vacuum at 60 °C overnight yielded 0.19 g (19 %) of 108 as a cream microcrystaline 
solid: mp 92.2-93.8 °C; 1H NMR (400 MHz, CDC13) S 7.99 (s, IH), 7.59 (d, 2H), 7.42 
(d, 2H), 5.02 (t, J=6.2 Hz, I H), 4.36 (d, J=6.2 Hz, 2H), 3.21 (t, J=7.3 Hz, 2H), 1.77 
(s, J=7.3 Hz, 2H), 1.07 (t, J=7.3,3H); 13C NMR (100 MHz, DMSO-d6) 8 155.3, 
142.6,139.6,136.6,130.7 (q, JF 
= 
32.9 Hz), 128.5,128.2,125.8 (q, JF- = 3.9 Hz), 123.8 
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(9, 
F 
= 
271.6 Hz), 46.9,31.6,23.5,13.8; HRIVIS (ESI) m/z calcd for C15Hi4F3N204S2 
[M-H)": 407.4100, found: 407.0307; HPLC TR: 11.4 min. 
N-(3,5-Bistrifluoromethybenzyl)-5-propyl-4-nitrothiophenesulfonamide (109) 
1O 
H CF3 
02N 
CF3 
3,5-Bistrifluoromethylbenzylamine (610 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in 
DCM (2.5 mL) was added to 5-n-propyl-4-nitrothiophene-2-sulfonyl chloride (742 mg, 
2.75 mmol) in DCM (2.5 mL) as per General Procedure D. The crude product was 
purified by flash chromatography (silica gel; hexane/EtOAc, 10: 2) and dried under high 
vacuum at 60 °C overnight yielded 0.65 g (55 %) of 109 as a cream solid: mp 
150-153.5 °C; 'H NMR (400 MHz, CDC13) S 7.96 (s, 1H), 7.59 (s, IH), 7.73 (s, 2H), 
5.33 (t, J=6.2 Hz, 1 H), 4.44 (d, J=6.2 Hz, 2H), 3.21 (t, J=7.3 Hz, 2H), 1.76 (s, J= 
7.3 Hz, 2H), 1.0 (t, J=7.3,3H); 13C NMR (100 MHz, DMSO-d6) S HRMS (ESI) m/z 
calcd for C16H13F6N204S2 [M-H]-: 475.0221, found: 475.0035; HPLC TR: 11.92 min. 
General procedure 4-nitro and 5-nitrothiophenesulfonamides 
To a solution of the mixture of 4- and 5-nitro thienylsulfonyl chlorides (455 mg, 
2 mmol) in DCM (2 mL) benzyl amine (216 mg) or 4-chlorobenzyl amine (285 mg, 
2 mmol) and triethylamine (202, leq) in DCM (2ml) as per the General Procedure D. 
The products were purified by flash chromatography (silica gel; hexane/EtOAc, 10: 2) to 
yield 0.20 g (33 %) of a 5: 4 mixture of the 4-nitro (111): 5-nitro (113) regioisomers ('H 
NMR) and 0.20 g (30 %) of a 5: 4 mixture of the 4-nitro (112): 5-nitro (114) regioisomers 
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(IH NMR). The isomers were resolved using reverse phase preparative hplc 
(Phenomenex Onyx Cis monolithic column 100mm x 10mm; isocratic 40% MeCN/ 
60%H20,23.5 ml min-'). 
N-Benzyl-4-nitrothiophenesulfonamide (111) 
S 
02N 
Colourless crystaline solid; 'H NMR (400 MHz, CDCl3) S 8.43 (d, J=1.6 Hz, I H), 7.97 
(d, J=1.6 Hz, I H), 7.32-7.22 (m, 5H), 4.95 (t, J=6.0 Hz, I H), 4.95 (d, J=6 Hz, 2H); 
HRMS (ESI) motz calcd for C, I H9N204S2 [M-H]-: 297.0004, found: 297.0012; HPLC TR: 
5.39 min. 
N-Benzyl-5-nitrothiophenesulfonamide (113) 
02N 
`S/ 
,HN t 
i 
Colourless crystaline solid; 1H NMR (400 MHz, CDC13) 5 7.81 (d, J=4.3 Hz, 1 H), 7.43 
(d, J=4.3 Hz, 1 H), 7.35-7.2 (m, 5H), 5.07 (brs, 1 H), 4.31 (d, J=3.3 Hz, 2H); HRMS 
(EST) m/z calcd for Cj'H9N204S2 IM-H] -: 297.0004, found: 296.9908; HPLC TR: 
3.72 min. 
N-(4-Chlorobenzyl)-4-nitrothiophenesulfonamide (112) 
S 
S` 
/H 
02N CI 
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Colourless crystaline solid; 1H NMR (400 MHz, CDCl3) S 8.47 (d, J=1.6 Hz, I H), 8.02 
(d, J=1.6 Hz, I H), 7.33-7.29 (m, 2H), 7.22-7.18 (m, 2H), 4.98 (brs, I H), 4.28 (brs, 2H); 
HRMS (ESI) m/z calcd for C,, H$C1N204S2 [M-H]": 330.9614, found: 330.9602; HPLC 
TR: 7.18 min. 
N-(4-Chlorobenzyl)-5-nitrothiophenesulfonamide (114) 
OZN S 
ý'O 
/ 
ýýN 
CA 
Colourless crystaline solid; 'H NMR (400 MHz, CDCl3) 8 7.85 (d, J=4.2 Hz, I H), 7.47 
(d, J=4.2 Hz, I H), 7.32 (m, 2H), 7.20 (m, 2H) 4.99 (brs, I H), 4.28 (brs, 2H). HRMS 
(ESI) m/z calcd for C11HgCIN204S2 [M-H]-: 330.9614, found: 330.9620; HPLC TR: 
3.98 min. 
N-(4-Chlorobenzyl)-5-bromo-4-nitrothiophenesulfonamide (110) 
Br S ,O 
'-ý / S, H 
02N CI 
4-Chlorobenzylamine (357 mg, 2.5 mmol), TEA (253 mg, 2.5 mmol) in DCM (2.5 mL) 
was added to 5-bromo-4-nitrothiophene-2-sulfonyl chloride (766 mg, 2.75 mmol) in 
DCM (2.5 mL) as per General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 10: 2) yielded 0.48 g (47 %) of 110 as a pale 
yellow microcrystalline solid: mp 134-137 °C; 1H NMR (400 MHz, CDCl3) 8 7.84 
(s, I H), 7.28 (m, 5H), 5.09 (br t, J=6 Hz, I H), 4.32 (d, J=6.0 Hz, 2H); '3C NMR (100 
MHz, DMSO-d6) 6 145.1,141.9,136.2,132.6,130.2,128.7,127.5,121.4,46.1; HRMS 
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(ESI) m/z calcd for Cj1H7BrNZO4S2 [M-H]-: 408.8719, found: 408.8625; HPLC TR: 
12.4 min. 
N-Benzyl-N-methyl-5-chloro-4-nitrothlophenesulfonamide (87) 
ýS C1 ý° SA / 
O2N 
A solution of N-methyl-benzylamine (0.31 g, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in 
DCM (3 mL) was added dropwise to a solution of 5-chloro-4-nitrothiophene-2-sulfonyl 
chloride (0.72 g, 2.75 mmol) in DCM (2 mL) as per General Procedure D. 
Crystallisation from hexane and EtOAc yielded 0.29 g (33 %) of 87 as off white crystals: 
mp 96.5-98.5 °C; 1H NMR (400 MHz, CDC13) 6 7.93 (s, IH), 7.40-7.31 (m, 5H), 4.27 (s, 
2H), 2.76 (s, 3H); HPLC TR: 11.03 min. 
N, N-Dibenzyl-5-chloro4-nitrothiophenesulfonamide (86) 
0 
CI S S', 
/NI 
02N 
A solution of dibenzylamine (0.986 g, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM 
(3 mL) was added to to a solution of 5-chloro-4-nitrothiophene-2-sulfonyl chloride 
(0.72 g, 2.75 mmol) in DCM (2 mL) as per General Procedure D. Crystallisation twice 
from hexane/EtOAc yielded 0.25 g (24 %) of 86 as a yellow solid: mp 116-118.5 °C; 'H 
NMR (400 MHz, CDC13) 8 8.17 (s, IH), 7.60-7.19 (m, IOH), 4.41 (s, 4H); HPLC TR: 
14.4 min. 
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(S)-N-(1-Phenylethyl)-5-chloro4-nitrothiophenesulfonamide (92) 
0 
CI O 
02N 
A solution of (S)-a-methylbenzylamine (305 mg, 2.5 mmol) and TEA (253 mg, 2.5 
mmol) in DCM (3 mL) was added to to a solution of 5-chloro-4-nitrothiophene-2- 
sulfonyl chloride (0.72 g, 2.75 mmol) in DCM (2 mL) as per General Procedure D. 
Crystalisation from DCM yielded 0.79 g (79 %) of 92 as cream crystals: mp 
159.1-160.7 °C; 1H NMR (400 MHz, DMSO-d6) S 8.98 (brs, 1 H), 7.50 (s, I H), 7.25- 
7.11 (m, 5H), 4.52 (q, J=7.2 Hz, IH), 1.37 (d, J=7.2 Hz, 3H); 1 3C NMR (100 MHz, 
CDC13) S 140.6,138.2,137.2,128.8,128.2,127.3,126.3,54.7,23.6; HRMS (ESI) m/z 
calcd for CI2H, oCIN2O4S2 [M-H]': 344.9771, found: 344.9741; [a] 20 = -50 (c 0.52, 
McOH); HPLC TR: 10.02 min. 
(R)-N-(1-Phenylethyl)-5-chloro4-nitrothiophenesulfonamide (93) 
CI S S: O 
N""'o 
02N 
A solution of (R)-a-methylbenzylamine (305 mg, 2.5 mmol) and TEA (253 mg, 2.5 
mmol) in DCM (3 mL) was added to to a solution of 5-chloro-4-nitrothiophene-2- 
sulfonyl chloride (0.72 g, 2.75 mmol) in DCM (2 mL) as per General Procedure D. 
Crystalisation from DCM yielded 0.71 g (82 %) of 93 cream crystals: mp 159-160 °C; 
'H NMR (400 MHz, DMSO-d6) S 8.97 (brs, I H), 7.50 (s, IH), 7.25-7.11 (m, 5H), 4.52 
(q, J=7.2 Hz, IH), 1.37 (d, J=7.2 Hz, 3H); 13 C NMR (100 MHz, CDC13) 5 140.6, 
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138.2,137.2,128.8,128.2,127.3,126.3,54.7,23.6; HRMS (ESI) m/z calcd for 
C12HioC1N204S2 [M-H]-: 344.9771, found: 344.9773; [a] m 20 = +42.6° (c 0.47, MeOH); 
HPLC TR: 10.66 min. 
(S)-N-(I-Phenylerhyl)-5-methyl-4-nitrothiophenesulfonamide (94) 
SO 
/ 
SýN 
02N 
A solution of (S)-a-methylbenzylamine (305 mg, 2.5 mmol) and TEA (253 mg, 2.5 
mmol) in DCM (3 mL) was added to to a solution of 5-methyl-4-nitrothiophene-2- 
sulfonyl chloride (665 mg, 2.75 mmol) in DCM (2 mL) as per General Procedure D. 
Crystalisation from DCM yielded 0.68 g (83 %) of 94 as cream crystals: mp 
101.6-104 °C; 'H NMR (400 MHz, CDC13) 8 7.62 (s, 1 H), 7.25-7.12 (m, 5H), 4.97 (d J= 
7,1 H), 4.63 (qn, J=7.0 Hz, 1 H), 1.37 (d, J=7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
S 148.9,142.9,141.0,137.2,128.6,128.8,127.8,126.2,54.5,23.6,15.8; HRMS (ESI) 
m/z calcd for C, 3Hi3N204S2 [M-H]": 325.0317, found: 324.3018; [a] m= -51.63° (c 0.47, 
DCM); HPLC TR: 10.33 min. 
(R)-N-(1-Phenylethyl)-5-methyl-4-nitrothiophenesulfonamide (95) 
S 
S`O 
HI/ 
02N 
A solution of (R)-a-methylbenzylamine (305 mg, 2.5 mmol) and TEA (253 mg, 2.5 
mmol) in DCM (3 mL) was added to to a solution of 5-methyl-4-nitrothiophene-2- 
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sulfonyl chloride (665 mg, 2.75 mmol) in DCM (2 mL) as per General Procedure D. 
Crystalisation from DCM yielded 0.66 g (81 %) of 95 as cream crystals: mp 101.6- 
104.2 °C; 1H NMR (400 MHz, CDCl3) S 7.62 (s, IH), 7.25-7.12 (m, 5H), 4.97 (d, J=7.0 
Hz, I H), 4.63 (qn, J=7.0 Hz, I H), 1.37 (d, J=7.0 Hz, 3H); HRMS (ESI) m/z calcd for 
C, 1H13N, 04S2 [M-HF: 325.0317, found: 324.2574; [a] n 20 = +53.6° (c 0.47, DCM) 
N-(2-Picolyi)-5-chloro4-nitrothiophenesulfonamide (80) 
CI O 
N U" 
OZN 
2-Picolylamine (273 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM (3 mL) was 
added to to a solution of 5-chloro-4-nitrothiophene-2-sulfonyl chloride (0.72 g, 
2.75 mmol) in DCM (2 mL) as per General Procedure D. Crystalisation from ethanol 
yielded 0.71 g (85 %) of 80 as a brown solid: mp 170-172 °C; 'H NMR (400 MHz, 
DMSO-d6) S 9.10 (t, J=5.8 Hz, 1 H), 8.44 (ddd, Jj = 4.8 Hz, J2 = 1.7 Hz, J3 = 0.7 Hz, 
1 H), 7.91 (s, I H), 7.76 (td, J, 
= 
7.8 Hz, J2 = 1.8 Hz, I H), 7.39 (d, J=7.7 Hz, I H), 7.26 
(qd, J, = 4.8 Hz, J2 =1 Hz, IH), 4.30 (d, J=6.1 Hz, 2H); 13C NMR (100 MHz, 
DMSO-d6) S 156.6,149.3,142.8,138.6,137.3,136.3,127.0,123.0,122.5,48.5; HRMS 
(ESI) m/z calcd for C, oH7CJN304S2 [M-H]-: 331.9566, found: 331.9468; HPLC TR: 
10.32 min. 
N-(3-Picolyl)-5-chloco-4-nitrothiophenesulfonamide (81) 
CI O 
Iý 1ST HN 
02N 
170 
3-Picolylamine (273 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM (3 mL) was 
added to to a solution of 5-chloro-4-nitrothiophene-2-sulfonyl chloride (0.72 g, 
2.75 mmol) in DCM (2 mL) as per General Procedure D. Crystalisation from ethanol 
yielded 0.65 g (78 %) of 81 as a beige solid: mp 180-184 °C; 'H NMR (400 MHz, 
DMSO-d6) S 9.19 (brs, I H), 8.48 (d, J=1.7 Hz, I H), 8.44 (dd, J, = 4.8 Hz, J2 = 1.7 Hz, 
1 H), 7.96 (s, I H), 7.71 (dt, J, 
= 
7.8 Hz, J2 
= 
1.8 Hz, I H), 7.32 (dd, J, = 4.8 Hz, J2 = 
1 Hz, IH), 4.23 (s, 2H); 13C NMR (100 MHz, DMSO-d6) S 194.3,148.8,142.9,138.3, 
136.5,136.4,133.1,127.2,123.9,44.3; HRMS (ESI) m/z calcd for C10H7C1N304S2 
EM-H]-: 331.9566, found: 331.9541; HPLC TR: 8.97 min. 
N-(4-Picolyl)-5-chloro-4-nitrothiophenesulfonamide (82) 
CI S 
9S10 
02N 
HN 
4-Picolylamine (273 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM (3 mL) was 
added to to a solution of 5-chloro-4-nitrothiophene-2-sulfonyl chloride (0.72 g, 
2.75 mmol) in DCM (2 mL) as per General Procedure D. Crystalisation from ethanol 
yielded 0.66 g (79 %) of 82 as a dark brown solid: mp 148-150 °C; 'H NMR (400 MHz, 
DMSO-d6) 8 9.06 (t, J=6 Hz, 1 H), 8.50 (d, J=4.3 Hz, 2H), 7.96 (s, 1 H), 7.31 (d, Jj = 
6.3 Hz, 2H), 4.25 (d, J=6 Hz, 2H); ' 3C NMR (100 MHz, DMSO-d6) S 152.7,145.9, 
143.0,137.8,136.7,127.4,124.3,45.5; HRMS (ESI) m/z calcd for CioH7C1N304S2 
[M-H]-: 331.9566, found: 331.9554; HPLC TR: 8.03 min. 
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N-(2-Picolyl)-5-methyl-4-nitrnthiophenesalfonamide (83) 
O S0 S: 
N N 
02N 
2-Picolylamine (273 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM (3 mL) was 
added to to a solution of 5-methyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2 mL) as per General Procedure D. Crystalisation from ethanol 
yielded 0.70 g (89 %) of 83 as a beige solid: mp 125.4-126.4 °C; 1H NMR (400 MHz, 
DMSO-d6) S 8.87 (brs, I H), 8.44 (ddd, Jl = 4.8 Hz, J2 = 1.8 Hz, J3 =I Hz, I H) 7.83 
(s, I H), 7.73 (td, J, 
= 
7.8 Hz, J2 
= 
1.8 Hz, 1 H), 7.36 (d, J=7.8 Hz, 1 H) 7.24 (9d, J, = 
4.8 Hz, J2 
=1 Hz, I H), 4.25 (s, 2H), 2.76 (s, 3H); 13C NMR (100 MHz, DMSO-d6) S 
156.9,149.8,149.3,143.2,137.6,137.2,127.3,123.0,122.4,48.5,15.9; HRMS (ESI) 
m/z calcd for C, IHION3O4S2 [M-H]': 312.0113, found: 312.0110; HPLC TR: 7.4 min. 
N-(3-Picolyi)-5-methyl-4-nitrothiophenesulfonamide (84) 
S 
00 
SAH N 
02N 
3-Picolylamine (273 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM (3 mL) was 
added to to a solution of 5-methyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2 mL) as per General Procedure D. Crystalisation from ethanol 
yielded 0.65 g (83 %) 84 as a beige solid: mp 160-162.5 °C; 1H NMR (400 MHz, 
DMSO-d6) 6 8.80 (brs, I H), 8.46 (d, J=1.7 Hz, I H), 8.44 (dd, J, = 4.8 Hz, J2 = 1.7 Hz, 
I H), 7.88 (s, I H), 7.67 (dt, Ji = 7.8 Hz, Jz = 1.7 Hz, 1 H), 7.32 (dd, J1 = 4.8 Hz, J2 = 
1 Hz, IH), 4.18 (s, 2H), 2.77 (s, 3H); 13C NMR (100 MHz, DMSO-d6) 5 149.9,149.5, 
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149.0,143.3,137.4,136.0,133.1,127.4,123.8,44.4,15.9; HRMS (ESI) m/z calcd for 
CIIHION304S2 [M-H]-: 312.0113, found: 312.0105; HPLC TR: 7.51 min. 
N-(4-Picolyl)-5-methyl4-nitrothiophenesulfonamide (85) 
0 
S %O S. H( 
N 02N 
4-Picolylamine (273 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM (3 mL) was 
added to to a solution of 5-methyl-4-nitrothiophene-2-sulfonyl chloride (665 mg, 
2.75 mmol) in DCM (2 mL) as per General Procedure D. Crystalisation from ethanol 
yielded 0.68 g (87 %) of 85 as a beige solid: mp 177-179 °C; 'H NMR (400 MHz, 
DMSO-d6) 8 8.88 (brs, I H), 8.48 (d, J=5.5 Hz, 2H), 7.91 (s, 1 H), 7.29 (d, Jj = 5.5 Hz, 
2H), 4.20 (s, 2H), 2.78 (s, 3H); 13C NMR (100 MHz, DMSO-d6) 8 150.0,146.7,143.3, 
137.2,127.5,122.9,45.5,15.9; FIRMS (ESI) m/z calcd for Ci, H, 0N304S2 [M-HF: 
312.0113, found: 312.0111; HPLC TR: 7.44 min. 
Benzophenone oxime'" 
i 
HO. N 
A mixture of of benzophenone (100 g, 550 mmol), hydroxylamine hydrochloride (60 g, 
860 mmol) 95 per cent ethyl alcohol (200 mL) and water (40 mL) was added to a 2-L. 
round-bottomed flask. Powdered sodium hydroxide (110 g, 2.75 moles) was added in 
portions, with stirring. The vigorous reaction was cooled in a water bath. After all the 
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sodium hydroxide addition the mixture was refluxed for five minutes. After cooling, the 
contents werre poured into a solution of concentrated hydrochloric acid (300 mL) in H2O 
(2 L). The precipitate was filtered with suction, thoroughly washed with water, and dried 
to yield 106g (98 %) of benzophenone oxime as a white solid: mp 140-142 °C, 
141-142 °C (lit). 1H NMR (400 MHz, DMSO-d6) S 11.36 (s, 1H), 7.49-7.27 (m, 10H). 
HRMS (ES! ) m /z calcd for C13H12NO [M+H]+: 198.0919, found: 198.0932. 
Diphenylmethanandne 2" 
i 
H2N 
i 
Ammonium formate (9.46 g 200 mmol) and magnesium powder (5 g, 41 mmol) were 
added to a solution of benzophenone oxime (9.65 g, 50 mmol) in methanol (50 mL). The 
mixture was stirred under a nitrogen atmosphere at room temperature. After the 
completion of reaction (monitored by TLC), the reaction mixture was filtered through 
celite. The solvent was evaporated under reduced pressure and the residue dissolved in 
DCM (200 mL) and washed with brine (2 x 100 mL). The organic layer was dried 
(MgSO4) and the solvent removed under reduced pressure. The residue was dissolved in 
ether (100 mL) and poured into a solution of HCl in ether (100 mL). The precipitate was 
filtered, washed with ether, dissolved in 2M NaOH and extracted with DCM (3 x 50 
mL). The organic layer was dried (MgSO4) and the solvent removed under reduced 
pressure to yield 2.1 g (23 %) of the desired product as a colourless oil 'H NMR 
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(DMSO-d6) 8 8.44 (s, 1 H), 7.43-7.27 (m, 1 OH). 13C NMR (400 MHz, CDC13) 8 145.05, 
128.55,127.09,126.91,59.65. 
N-(Dip6enylamine)-5-c61oro4-nitrothiophenesulfonamide (96) 
ci ss H 
Ph 
Diphenylmethanamine (458 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM 
(3 ml-) were added to to a solution of the sulfoyl chloride (0.72 g, 2.75 mmol) in DCM 
(2 mL) as in General Procedure D. The crude product was purified by flash 
chromatography (silica gel; hexane/EtOAc, 9: 1), recrystalised in hexane/EtOAc and 
dried under high vacuum at 60 °C overnight to yield 200 mg (20 %) of 96 as a white 
crystalline solid: mp 191.8-193.1 °C; 'H NMR (400 MHz, CDCI3) 7.49 (s, IH), 
7.33-7.25 (m, 6H), 7.22-7.18 (m, 4H), 5.76 (d, J=7.8 Hz, 1 H), 5.42 (d, J=7.8 Hz, 1 H); 
13C NMR (100 MHz, CDC13) S 141.8,139.6,139.1,136.1,128.3,127.7,127.5,126.5, 
61.9; HRMS (ESI) m/z calcd for C»H12CIN204S2 [M-H]-: 406.9927, found: 406.9926; 
HPLC TR: 11.31 min. 
N-n-But-1-yi-S-chloro-4-nitrothiophenesulfonamide (97) 
cl s ;° 
N"ý-Pr H 
02N 
n-Butylamine (185 mg, 2.5 mmol) and TEA (253 mg, 2.5 mmol) in DCM (3 mL) were 
added to to a solution of the sulfonyl chloride (0.72 g, 2.75 mmol) in DCM (2 mL) as in 
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General Procedure D. The crude product was purified by flash chromatography (silica 
gel; hexane/EtOAc, 9: 1), recrystalised in hexane/EtOAc and dried under high vacuum at 
600 C overnight to yield 0.65 g (87 %) of 97 as a cream crystaline solid: mp 81-82.3 °C; 
1H NMR (400 MHz, CDCl3) 8 8.02 (s, 1 H), 4.65 (t, J=5.7 Hz, I H), 3.14 (q, J=7.1 Hz, 
2H), 1.57 (m, 2H), 1.39 (s, J=7.5 Hz, 2H), 0.95 (t, J=7.5 Hz, 3H); 13C NMR (100 
MHz, CDC13) 6 142.6,137.7,137.4,126.8,43.4,31.5,19.7,13.5; HRMS (ESI) m/z 
calcd for C8HioCIN204S2 [M-H]": 296.9771, found: 296.9746; HPLC TR: 10.48 min. 
N-Methylamines 
N-(2-Methoxy)ethyl-1"formamide 253 
H 
-, D-, i N 
0 
2-Methoxyethyl-l-amine (35 mL, 400 mmol) was refluxed in ethylformate (80 mL 
,I 
mole) overnight. Excess ethylformate was removed by rotary evaporation to give the 
desired product as a colourless oil in quantitative yield (41.25 g). 1H NMR (400 MHz, 
CDCI; ) 6 8.17 (s, IH), 6.72 (brs, IH), 3.50-3.44 (m, 4H), 3.37 (s, 3H). 
N-(2-metboxy)propyl-l-formamide 253 
H 
3, 
O, 
_,,,, ýN) 
O 
-Methoxypropyl-l-amine (41 mL, 400 mmol) was refluxed in ethylformate (80 mL, I 
mole) overnight. Excess ethylformate was removed by rotary evaporation to give the 
desired product as a colourless oil in quantitative yield (46.9 g). 1H NMR (400 MHz, 
CDC13) 8 8.15 (s, I H), 6.21 (brs, I H), 3.52-3.39 (m, 4H), 3.35 (s, 3H), 1.8 (m, 2H). 
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N 43-hydroxy)propyl-l-formamide 253 
HOý, N 
O 
3-Amino-l-propanol (31 mL, 400 mmol) was refluxed in ethylformate (80.5 mL, I 
mole) overnight. Excess ethylformate was removed by rotary evaporation to give the 
desired product as a colourless oil in quantitative yield (41.24 g). 'H NMR (400 MHz, 
CDC13) S 8.13 (s, IH), 6.67 (brs, IH), 3.68-3.60 (m, 2H), 3.43-3.32 (m, 2H), 1.75-1.66 
(m, 2H). 
2-methoxy-N-roethylethan-1-amine 
H 
N-(2-Methoxyethyl)formamide (5.16 g, 50 mmol) and LiAIH4 (2.1 g, 55 mmol) were 
refluxed in anhydrous TIW (25 mL). The reaction was quenched by careful addition of 
water (5 mL). The solvent was removed under reduced pressure 1M NaOH (20 mL was 
added and the aqueous layer washed with DCM (3 x 20 mL). The combined organic 
layers were dried (MgSO4) and the sovent was removed under reduced pressure to yield 
the product as a colourless oil 3.52 g (79%): 1H NMR (400 MHz, CDC13) S 3.50 (t, J= 
5.1 HZ, 2H), 3.36 (s, 3H), 2.74 (t, J=5.1 Hz, 2H), 2.44 (s, 3H). 
3-Methoxy-N-methylpropan-l-amine 
H 
ýOýýNý 
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N-{3-Methoxypropyl)formamide (5.85 g, 50 mmol) and LiAIHL (2.1 g, 55 mmol) were 
refluxed in anhydrous THE (25 mL). The reaction was quenched by careful addition of 
water (5 mL). The solvent was removed under reduced pressure IM NaOH (20 mL was 
added and the aqueous layer washed with DCM (3 x 20 mL). The combined organic 
layers were dried (MgSO4) and the sovent was removed under reduced pressure to yield 
the product as a colourless oil 3.3 g (64%): 'H NMR (400 MHz, CDC13) 6 3.80 (t, J= 
6.2 Hz, 2H), 3.28 (s, 3H), 2.60 (t, J=6.8 Hz, 2H), 2.37 (s, 3H), 1.71 (qn, J=6.8 Hz; 
2H); HRMS (ESI) m/z calcd for C5H14NO [M+H]+: 104.1075, found: 104.1089. 
N-Methylpropan-3-ol-1-amine 
H 
HO, N 
N-(3-hydroxy)propyl-l-formamide (5.16 g, 50 mmol) and LiAIH4 (2.1 g, 55 mmol) 
were refluxed in anhydrous THE (25 mL). The reaction was quenched by careful 
addition of water (5 mL). The solvent was removed under reduced pressure IM NaOH 
(20 mL was added and the aqueous layer washed with DCM (3 x 20 mL). The combined 
organic layers were dried (MgSO4) and the sovent was removed under reduced pressure 
to yield the product as a colourless oil 3.2 g (72%): 1H NMR (400 MHz, CDC13) 6 3.76 
(t, J=5.5 Hz, 2H), 2.80 (t, J=5.9 Hz, 2H), 2.39 (s, 3H), 1.67 (qn, J=5.5 Hz, 2H). 
General Procedure E: 5-amination of N-(4-chlorobenzyl)-5-chloro-4- 
nitrothiophenesulfonamide (68) 
The required amine nucleophile (2.2 mmol) was added to a solution of 
N-(4-chlorobenzyl)-5-chloro-4-nitrothiophenesulfonamide (68) (734 mg, 2 mmol) in 
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MeCN (5 mL) and K2CO3 (829 mg, 6 mmol). The reaction was stirred at room 
temperature and monitored by TLC until 68 was consumed. The solids were removed by 
filtration and the solvent removed under reduced pressure. The crude products were 
purified by dry flash chromatography on a plug of silica gel. 
N-(4Chlorobenryl)-5-(4hydroxypiperidin-1-yl)-4-nitrothiophenesulfonamide (116) 
HO NS 
H 
v 'G 
4-Hydroxypiperidine (220 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAcfMeOH, 10: 2: 1) to yield 600 mg (70 %) of 116 as a bright yellow solid: 
mp 167.5-169.4 °C; 'H NMR (400 MHz, DMSO-d6) S 8.6 (t, J=6 Hz, IH), 7.62 (s, 
1 H), 7.34-7.27 (m, 4H), 4.90 (d, J=4.1 Hz, 1 H), 4.13 (d, J=6 Hz, 2H), 3.79 (m, I H), 
3.48 (m, 2H), 3.20 (m, 2H), 1.9 (m, 2H), 1.61 (m, 2H); 13C NMR (100 MHz, DMSO-d6) 
163.3,136.6,132.4,130.1,129.2 128.7,128.5,123.7,64.4,51.3,46.0,33.6; HRMS 
(ESI) m/z calcd for C16H»CJN305S2 [M-H]-: 430.0298, found: 430.0280; HPLC TR: 
9.55 min. 
N-(4-Chlorobenzyl)-5-(3-hydroxypiperidin-1-yl)-4-nitrothiophenesulfonamide (115) 
OH 
NSP S' HIý 
O2N CI 
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3-Hydroxypiperidine (220 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc/MeOH, 10: 2: 1) to yield 530 mg (62 %) of 115 as a bright yellow 
crystalline solid: mp 133.5-136.8 °C; 'H NMR (400 MHz, CDCI3) 8 7.89 (s, 1H), 7.30- 
7.20 (m, 4H), 4.93 (t, J=6.4 Hz, 1 H), 4.23 (d, J=6.4 Hz, 2H), 4.09 (m, 1 H), 3.49 (dd, 
J1 
= 12.4 Hz, J2 = 3.5 Hz, 1 H), 3.29 (m, 2H), 2.10 (m, 2H), 1.95 (m, 1 H), 1.76 (m, 2H); 
13C NMR (100 MHz, DMSO-d6) 8 163.4,136.6,132.4,130.1,129.2,128.5,128.4, 
123.2,65.2,60.4,54.1,46.0,31.8,21.9; HRMS (ESI) m/z calcd for C16H17C1N3O5S2 
[M-H]-: 430.0298, found: 430.0309; HPLC TR: 9.75 min 
N-(4-Chlorobenzyl)-5-(4-methoxypiperidin-1-yl)-4-nitrothiophenesulfonamide 
(118) 
/O oS1. 
%O 
. 
7, 
H 
02N CI 
4-Methoxypiperidine (253 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 
10: 2) to yield 350 mg (39 %) of 118 as a bright yellow crystalline solid: mp 167-169 °C; 
'H NMR (400 MHz, CDCI3) S 7.93 (s, I H), 7.33-7.22 (m, 4H), 4.85 (t, J=6.4 Hz, I H), 
4.25 (d, J=6.4 Hz, 2H), 3.61-3.50 (m, 3H), 3.41 (s, 3H), 3.33-3.26 (m, 2H), 2.13-2.04 
(m, 2H), 1.99-1.90 (m, 2H); 13C NMR (100 MHz, CDCI3) 6 172.2,134.3,134.2,130.6, 
130.4,129.4,128.9,122.6,56.0,50.5,46.8,29.6; HRMS (ESI) m/z calcd for 
C»H19C1N305S2 [M-H]-: 444.0455, found: 444.0477; HPLC TR: 10.62 min 
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N-(4-Chlorobenzyl)-5-(3-methoxypipei idin-1-yl)-4-nitrothiophenesulfonamide 
(117) 
ýO 
CýN 
S ,O S, 
H 
O2N 
ýcj 
3-Methoxypiperidine (253 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 
10: 2) to yield 450 mg (50 %) of 117 as a bright yellow crystalline solid: mp 80.6-82.5 
°C; 1H NMR (400 MHz, CDCI1) S 7.89 (s, 1H), 7.33-7.18 (m, 4H), 4.85 (t, J=6.5 
Hz, IH), 4.25 (d, J=6.5 Hz, 2H), 3.70-3.64 (m, 1H), 3.58-3.51 (m, IH), 3.47-3.40 
(m, 1 H), 3.39 (s, 3H), 3.23-3.16 (m, 1 H), 3.13-2.07 (m, 1 H), 2.11-1.95 (m, 2H), 1.81- 
1.70 (m, 1 H), 1.66-1.57 (m, 1 H); 13C NMR (100 MHz, CDC13) 6 163.6,134.3,134.0, 
130.5,129.4,129.3,128.9,122.6,57.4,56.6,54.3,46.8,28.7,21.9; HRMS (ESI) m/z 
calcd for C»H, 9C1N3O5S2 [M-H]': 444.0455, found: 444.0471; HPLC TR: 10.65 min. 
N-(4-Chlorobenzyl)-5-(N-methyl-N-propan-l-ol-3-amino)-4- 
nitrothiophenesutfonamide (125) 
HO, 
-ýN s S: O 
/H 
02N CI 
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N-Methyl-N-propan-l-ol-3-amine (194 mg, 2.2 mmol) was used as in General Procedure 
E. The crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc/MeOH, 10: 2: 1) to yield 460 mg (55 %) of 125 as a bright yellow 
crystalline solid: mp 84.2-86.9 °C; 'H NMR (400 MHz, CDCI3) S 7.84 (s, IH), 7.31-7.27 
(m, 4H), 4.94 (t, J=6.3 Hz, 1 H), 4.23 (d, J=6.3 Hz, 2H), 3.73 (m, 2H), 3.56 (m, 2H), 
3.12 (s, 3H), 1.97 (m, 2H), 1.49 (t, J=4.9 Hz, I H); 13C NMR (100 MHz, CDC13) S 
163.2,134.5,133.9,130.8,129.4,128.8,128.1,121.2,59.5,55.3,46.7,43.9,29.6; 
HRMS (ESI) m /z calcd for C15H17CIN3O5S2 [M-H]': 418.0298, found: 418.0290; HPLC 
TR: 9.53 min. 
N-(4-Chlorobenzyl)-5-(N-3-methoxypropyl-N-methylamino)-4- 
nitrothiophenesulfonamide (126) 
- 
N- NSp 
/H 
C 2N CI 
N-3-Methoxypropyl-N-methylamine (227 mg, 2.2 mmol) was used as in General 
Procedure E. The crude material was purified by dry flash chromatography (silica gel; 
hexanelEtOAc, 10: 2) to yield 430 mg (50 %) of 126 as a bright yellow crystalline solid: 
mp 65.4-67.3 °C; 1H NMR (400 MHz, CDC13) S 7.85 (s, I H), 7.31-7.19 (m, 4H), 4.84 (t, 
J=6.7 Hz, 1 H), 4.23 (d, J=6.7 Hz, 2H), 3.55 (m, 2H), 3.41 (m, 2H), 3.31 (s, 3H), 3.11 
(s, 3H), 1.97 (m, 2H); 13C NMR (100 MHz, CDC13) 6 162.9,134.4,134.0,130.9,129.4, 
128.9,128.1,121.0,69.1,58.8,55.5,46.8,44.0,27.2; HRMS (ESI) m/z calcd for 
C16H19C1N305S2 [M-H]-: 432.0455, found: 432.0456; HPLC TR: 10.49 min. 
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N-(4-Chlorobenryl)-5-(N-3-methoxypropylamino)-4-nitrothiophenesulfonamide 
(124) 
NSc 
,o 
02NCI 
N-3-Methoxypropylamine (196 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 
10: 2) to yield 720mg (86 %) of 124 as a bright yellow crystalline solid: mp 126-127.3 
°C; 'H NMR (400 MHz, CDC13) 8 7.85 (s, IH), 7.31-7.19 (m, 4H), 4.84 (t, J=6.7 
Hz, 1 H), 4.23 (d, J=6.7 Hz, 2H), 3.55 (m, 2H), 3.41 (m, 2H), 3.31 (s, 3H), 1.97 (m, 
2H); 13C NMR (100 MHz, CDC13) S 162.4,134.4 134.0 129.4,128.9,128.7,124.6, 
119.0,71.1,59.0,47.3,46.8,28.0; HRMS (ESI) m/z calcd for C15H17C1N305S2 [M-H]-- 
418.0298, found: 418.0309; HPLC TR: 10.39 min. 
N-(4-Chlorobenzyl)-5-(N-propan-l-ol-3-amino)-4-nitrothiophenesulfonamide (123) 
HON HS 00 
OiN v C1 
N-Propan-1-ol-3-amine (163 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 
10: 2) to yield 740 mg (91 %) of 123 as a bright yellow crystalline solid: mp 
133.2-135.9 °C; 'H NMR (400 MHz, CDCl3) 5 7.82 (s, IH), 7.32-7.19 (m, 4H), 4.22 (s, 
2H), 3.91 (t, i=5.4 Hz, 2H), 3.49 (t, J=6.3 Hz, 2H), 2.04 (m, 2H); 13C NMR (100 
MHz, DMSO-4) 162.5,136.7,132.4,130.1,128.5,127.4,123.9,120.1,59.0,46.9,46.0, 
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30.7; HRMS (ESI) m/z calcd for C14H15C1N305S2 [M-H]-: 404.0142, found: 404.0074; 
HPLC TR: 11.38 min. 
N-(4Chlorobenzyl)-5-(N-ethan-l-ol-2-amino)-4-nitrothiophenesulfonamide (119) 
HOýý NSO 
H 
02N ci 
N-Propan- I 
-ol-3-amine (134 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc/MeOH, 10: 2: 1) to yield 740 mg (94 %) 119 as a bright yellow crystalline 
solid: mp 170.7-172 °C; 'H NMR (400 MHz, CDCI3) 8 7.52 (s, IH), 7.39-7.29 (m, 4H), 
5.08 (t, J=6, IH), 4.11 (s, 2H), 3.39 (m, 2H); 13C NMR (100 MHz, DMSO-d6) 163.3, 
136.7,132.4,130.0,128.6,127.1,124.2,120.0,59.3,51.7,46.0; HRMS (ESI) m/z calcd 
for C13H13CIN30552 [M-H] : 389.9985, found: 389.9984; HPLC TR: 9.36 min. 
N-(4-chlorobenzy)-5-(N-2-methoxyethylamino)-4-nitrothiophenesulfonamide (120) 
H 00 
02N CI 
N-2-Methoxyethylamine (165 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 
10: 2) to yield 720 mg (91 %) of 120 as a bright yellow crystalline solid: mp 153-155.2 
°C; 1H NMR (400 MHz, CDCI3) 6 8.57 (brs, I H), 7.82 (s, I H), 7.33-7.21 (m, 4H), 5.08 
(t, J=6.2 Hz, I H), 4.22 (d, J=6.2 Hz, 2H), 3.68 (q, J=5.3 Hz, 2H), 3.49 (t, J=5.3 Hz, 
2H), 3.49 (s, 3H); '3C NMR (100 MHz, CDC13) 6 162.6,134.3,134.1,129.4,129.0, 
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128.6,125.0,119.4,69.4,59.2,48.0,46.8; HRMS (ESI) m/z calcd for C14H15C1N305S2 
[M-H]': 404.0142, found: 404.0120; HPLC TR: 10.84 min. 
N-(4-Chlorobenzyl)-5-(N-3-methoxyethyl-N-methylamino)-4- 
nitrothiophenesulfonamide (122) 
10--l-,, N S% 
HI/ 
O2N CI 
N-3-Methoxyethyl-N-methylamine (196 mg, 2.2 mmol) was used as in General 
Procedure E. The crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc, 10: 2) to yield 510 mg (61 %) of 122 as a bright yellow crystalline solid: 
mp 100-101.7 °C; 1H NMR (400 MHz, CDC13) S 7.87 (s, IH), 7.34-7.21 (m, 4H), 4.86 
(t, J=6.1 Hz, I H), 4.23 (d, J=6.1 Hz, 2H), 3.65 (m, 4H), 3.34 (s, 3H), 3.18 (s, 3H), 13C 
NMR (100 MHz, CDCI3) S 163.5,134.4,133.9,130.8,129.4,128.9,128.2,121.4,70.1, 
59.0,57.6,46.7,44.2; HRMS (ESI) m /z calcd for C15H17C1N305S2 [M-H]': 418.0298, 
found: 418.0265; HPLC TR: 10.39 min. 
N-(4-Chlorobenzyl)-5-(N-methyl-N-ethan-l-ol-2-amino)- 
4-nitrothiophenesulfonamide (121) 
N, 
_--, 
NS 9'O S, H 
02N CI 
N-Methyl-N-ethan- I 
-ol-2-amine (196 mg, 2.2 mmol) was used as in General Procedure 
E. The crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc/MeOH, 10: 2: 1) to yield 480 mg (59 %) of 121 as a bright yellow 
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crystalline solid: mp 76-79 °C; 'H NMR (400 MHz, CDC13) 6 7.85 (s, 1H), 7.32-7.19 
(m, 4H), 4.86 (t, J=6 Hz, 1 H), 4.26 (d, J=6 Hz, 2H), 3.97 (q, J=5.3 Hz, 2H), 3.65 (t, J 
= 5.3 Hz, 2H), 3.22 (s, 3H); 13C NMR (100 MHz, DMSO-d6) 8 163.5,136.7,132.4, 
130.0,129.4,128.6,127.4,122.0,60.1,58.5,46.0,44.0; HRMS (ESI) m/z calcd for 
C14H15C1N305S2 [M-H]': 404.0142, found: 403.9974; HPLC TR: 9.56 min. 
N-(4-Chlorober yl)-5-(N-hexan-l-ol-6-amino)-4-nitrothiophenesulfonandde (128) 
HO NS 
H 
02N CI 
N-Hexan-l-ol-6-amine (256 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc/MeOH, 10: 2: 1) to yield 302 mg (34 %) of 128 as a bright yellow 
crystalline solid: mp 102-104.2 °C; IH NMR (400 MHz, CDC13) S 8.43 (t, J=6 Hz, 
I H), 7.82 (s, I H), 7.53-7.22 (m, 4H), 4.88 (t, J=6.5 Hz, I H), 4.22 (d, J=6.5 Hz, 2H), 
3.68 (m, 2H), 3.34 (m, 2H), 1.81 (m, 2H), 1.61 (m, 2H), 1.48 (m, 4H); 13C NMR (100 
MHz, DMSO-d6) S 162.4,136.7,132.4,130.1,128.5,127.4,123.9,120.0,61.1,49.0, 
46.0,32.8,27.9,26.6,25.6; HRMS (ESI) m/z calcd for C17H21C1N3OSS2 [M-H]': 
446.0611, found: 446.0619; HPLC TR: 10.01 min. 
N-(4-Chlorobenzyl)-5-(N-2-methoxypentanol-5-amino)-4- 
nitrothiophenesulfonamide (127) 
HO H 00 
S %l* 
H 
02N CI 
186 
N-2-Methoxypentanol-5-amine (225 mg, 2.2 mmol) was used as in General Procedure E. 
The crude material was purified by dry flash chromatography (silica gel; 
hexanefEtOAc/MeOH, 10: 2: 1) to yield 480 mg (55 %) of 127 as a bright yellow 
crystalline solid: mp 123.2-125.8 °C; 1H NMR (400 MHz, DMSO-d6) 8 9.32 (brs, IH), 
8.58 (brs, 1 H), 7.49 (s, 1 H), 7.34-7.28 (m, 4H), 4.41 (t, J=4.5 Hz, 1 H), 4.12 (s, 2H), 
3.41 (m, 2H), 3.32 (m, 2H), 1.65 (m, 2H), 1.46 (m, 2H), 1.35 (m, 2H); 13C NMR (100 
MHz, DMSO-d6) S 162.5,136.7,132.4,130.1,128.5,127.4,123.9,120.0,61.0,49.0, 
46.0,32.5,27.7,23.3; HRMS (ESI) m/z calcd for C16H19ClN3O5S2 [M-H]-: 432.0455, 
found: 432.0438; HPLC TR: 9.74 min. 
N-(4-Chlorobenzy1)-S-(N-propargylamino)-4-nitrothiophenesulfonamide (134) 
k, 
N 0 S 
02N CI 
Propargylamine (121 mg, 2.2 mmol) was used as in General Procedure E. The crude 
material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 10: 2) to 
yield 450 mg (58 %) of 134 as a bright yellow crystalline solid: mp 150-152.1 °C; 
1H NMR (400 MHz, DMSO-d6) 8 9.55 (brs, 1 H), 8.59 (brs, 1 H), 7.53 (s, 1 H), 7.37-7.28 
(m, 4H), 4.23 (d, J=2.5 Hz, 2H), 4.13 (s, 2H), 3.50 (t, IH); HRMS (ESI) m/z calcd for 
C14H, IC1N304S2 [M-H]": 383.9879, found: 383.9859; HPLC TR: 9.44 min. 
N-(4-Chlorobenzyl)-5-(N-allylamino)-4-nitrothiophenesulfonamide (133) 
H 
NSS; 0 
C2N CI 
187 
Allylamine (125 mg, 2.2 mmol) was used as in General Procedure E. The crude material 
was purified by dry flash chromatography (silica gel; hexane/EtOAc, 10: 2) to yield 493 
mg (64 %) of 133 as a bright yellow crystalline solid: mp 141.5-144.9 °C; IH NMR (400 
MHz, DMSO-d6) S 9.51 (brs, 1 H), 8.54 (brs, 1 H), 7.51 (s, 1 H), 7.34-7.27 (m, 4H), 5.86- 
5.77 (m, 1 H), 5.32-5.27 (m, 2H), 4.11 (d, J=4.8 Hz, 2H), 4.00 (s, 2H); 13C NMR (100 
MHz, CDC13) S 162.2,134.2,134.1,129.9,129.4,129.0,128.4,125.1,120.1,120.0, 
50.2,46.8; HRMS (ESI) m/z calcd for C14H13C1N304S2 [M-H]-: 386.0036, found: 
385.9993; HPLC TR: 10.49 min. 
N-(4-Chlorobenzyl)-5-(N-methyl-N-(2-cyano)ethan-l-amino)-4- 
nitrothiophenesulfonamide (135) 
O 
N/N-N S S` 
02N Cl 
N-(2-Cyano)ethan-N-methyl-l-amine (183 mg, 2.2 mmol) was used as in General 
Procedure E. The crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc, 10: 2) to yield 484 mg (58 %) of 135 as a bright yellow crystalline solid: 
mp 145.7-147.3 °C; 'H NMR (400 MHz, CDC13) S 7.85 (s, IH), 7.32-7.19 (m, 4H), 4.86 
(t, J=6 Hz, I H), 4.26 (d, J=6 Hz, 2H), 3.97 (q, J=5.3 Hz, 2H), 3.65 (t, J=5.3 Hz, 
2H), 3.22 (s, 3H); 162.8,136.6,132.4,130.1,129.3,128.6,128.5,123.7,119.0,53.1, 
46.0,43.0,16.0; HRMS (ESI) m/z calcd for CJ5H14CJN404S2 [M-H]: 413.0145, found: 
412.9505; HPLC TR: 10.13 min. 
N-(4-Chlorobenzyl)-5-amino-4-nitrothiophenesulfonamide (129) 
188 
112N S 
9, O 
SAH 
02N CI 
Ammonia was bubbled through a solution of N-(4-chlorobenzyl)-5-chloro4- 
nitrothiophenesulfonamide (68) (734 mg, 2 mmol) in MeCN (5 mL) and K2CO3 (829 
mg, 6 mmol). The reaction was stirred at room temperature and monitored by TLC until 
68 was consumed. Nitrogen wass bubbled through the solution, the solids were removed 
by filtration and the solvent removed under reduced pressure. The crude products were 
purified by dry flash chromatography on a plug of silica gel to yield 696 mg (80 %) of 
129 as a yellow solid: mp: 179-182.1 °C; 1H NMR (400 MHz, DMSO-d6) S 8.84 (brs 
3H), 7.43 (s, IH), 7.33 (m, 4H), 4.1 (s, 2H); 13C NMR (100 MHz, DMSO-d6) S 162.6, 
136.8,132.3,130.0,128.6,126.5,124.6,119.9,45.9; HRMS (ESI) m/z calcd for 
C, IH9C1N304S2 [M-H]-: 345.9723, found: 345.9730; HPLC TR: 7.82 min. 
N-(4-Chlorobenzyl)-5-methylamino-4-nitrothiophenesulfonamide (130) 
, -N g 
%00 
H 
02N CI 
Methylamonium hydrochloride (146 mg, 2.2 mmol) was used as in General Procedure E. 
The crude material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 
10: 2) to yield 424 mg (59 %) of 130 as a bright yellow crystalline solid; IH NMR (400 
MHz, DMSO-d6) 8 9.36 (q, J=4.8 Hz, I H), 8.54 (t, J=6.3 Hz, 1 H), 7.53 (s, I H), 7.36- 
7.29 (m, 4H), 4.11 (d, J=6.3 Hz, 2H), 3.01 (d, J=4.8 Hz, 3H); HRMS (ESI) m/z calcd 
for C12Hi1C1N304S2 [M-H]-: 359.9879, found: 359.9939 HPLC TR: 9.97 min. 
189 
N-(4Chlorobenzyl)-5-dimethylandno-4-nitrothiophenesulfonamide (131) 
,NSo, ý 
Nzý / S, H 
02N CI 
Dimethylamonium hydrochloride (179 mg, 2.2 mmol) was used as in General Procedure 
E. The crude material was purified by dry flash chromatography (silica gel; 
hexane/EtOAc, 10: 2) to yield 442 mg (59 %) of 131 as a bright yellow crystalline solid: 
mp 130.7-133 °C; 1H NMR (400 MHz, CDC13) 5 7.87 (s, 1 H), 7.31-7.20 (m, 4H), 4.84 
(t, J=6.5 Hz, 1 H), 4.22 (d, J=6.5 Hz, 2H), 3.16 (s, 6H); HRMS (ESI) m/z calcd for 
C13H14C1N3O4S2 [M-H]-: 374.0036, found: 374.0029; HPLC TR: 10.86 min. 
N-(4-Chlorobenzyl)-5-diethylamino-4-nitrothiophenesulfonamide (132) 
Et2N s S, 
H 
0rN CI 
Diethylamonium chloride (242 mg, 2.2 mmol) was used as in General Procedure E. The 
crude material was purified by dry flash chromatography (silica gel; hexane/EtOAc, 
10: 2) to yield 44 mg (55 %) of 132 as a bright yellow crystalline solid: IH NMR (400 
MHz, CDCIO S 8.57 (s, 1 H), 7.55 (s, 1 H), 7.32-7.26 (m, 4H), 4.14 (s, 2H), 3.44 (q, i= 
7.1 Hz, 4H), 1.12 (t, J=7.1 Hz, 6H); HRMS (ESI) m/z calcd for C15H17C1N304S2 
[M-H]-: 402.0349, found: 402.0323; HPLC TR: 10.88 min. 
N-(4-Chlorobenzyl)-5-(N-acetyl)-4-nitrothiophenesulfonamide (137)201.202 
190 
H ýN S OHO 
O/ 
SAH 
02N CI 
129 (70 mg, 0.2 mmol) and acetic anhydride (22 mg, 0.22 mmol) were refluxed in 
glacial acetic acid until] no more 129 was observed by tic. The reaction was cooled and 
water added (2 mL). The pale yellow precipitate was separated by filtration washed with 
water and dried to yield 50 mg (64 %) pale yellow crystals: 'H NMR (400 MHz, DMSO- 
d6) S 11.60 (s, I H), 8.64 (t, i=6.5 Hz, I H), 7.70 (s, I H), 7.35-7.27 (m, 4H), 4.12 (d, J= 
6.5 Hz, 2H), 2.42 (s, 3H); HRMS (ESI) m/z calcd for C13Hi1C1N3O5S2 [M-H]-: 
387.9827, found: 387.9838; HPLC TR: 10.16 min. 
Ethyl Phenylcyanoacetate 2M 
O Ný 
O^ 
i 
Sodium ethoxide (15.1 mL, 25 wt% in ethanol, 66 mmol, 2.0 equiv. ) was added slowly 
by syringe to a solution of benzyl cyanide (3.80 mL, 33 mmol) and diethyl carbonate 
(31.99 mL, 264 mmol, 8.0 equiv. ) in toluene at 0 °C. The resulting solution was stirred 
at 0°C for 10 minutes, then heated to 80 °C and stirred for 12 hours. After quenching 
with IM aqueous hydrochloric acid (75 mL), the mixture was extracted with diethyl 
ether (2 x 200 mL). The combined organic extracts were washed with brine (100 mL), 
dried (Mg2SO4), and concentrated under reduced pressure. The residue was purified by 
flash chromatography (silica gel, pet ether/EtOAc 9: 1), to yield a colorless oil 4.77g, 
191 
(76%). 'H NMR (400 MHz, CDCl3) 8 7.48-7.4 (m, 5H), 4.71 (s, I H), 4.25 (qd, Jj 
=7.2 
Hz, J2= 1.5 Hz, 2H), 1.29 (t, J=7.2 Hz, 3H). 
Ethyl 3-amino-2-phenylpropanoate 
O 
H2N 
A solution of ethyl phenylcyanoacetate (4.77 g, 25.24 mmol) in ethanol (30 mL) was 
degassed by sonication under aspirator vacuum for 5 minutes and backfilled with 
nitrogen. 10% palladium on charcoal was carefully added under a blanket of nitrogen. A 
septum was fitted and 3.5m1 conc HCl injected. The flask was evacuated under aspirator 
vacuum for 5 minutes. A H2 balloon and needle was inserted into the septum. The 
reaction was stirred vigorously at room temperature and the balloon was refilled until no 
further consumption of hydrogen was apparent. The reaction mixture filtered through 
celite. The solvent was evaporated to yield a yellow waxy solid which was washed with 
EtOAc to give 2.96g (51 %) of the desired product as a white crystalline soild: 
mp 158-159 °C, literature: 160-161 °C; 'H NMR (400 MHz, CD3OD) 8 7.46-7.28 (m, 
5H), 4.71 (s, 1 H), 4.21 (qd, Jj =6.9 Hz, Jz= 2.8 Hz, 2H), 4.01 (m, 1 H), 3.6 (m, I H), 3.25 
(m, 1H), 1.21 (t, J=6.9 Hz, 3H); HRMS (ESI) m /z calcd for C,, H16NO2 [M+H]+: 
194.1181, found: 194.1193. 
Ethyl 3-(2-nitrophenylamino)-2-phenylpropanoate 
192 
NO2 
O NZý 
iH Oý 
Z 
1 
Ethyl 3-amino-2-phenylpropanoate (2.28 g, 11 mmol), 2-fluoronitrobenzene (25 mL, 
22 mmol) and DIPEA (39.8 mL, 22 mmol) in THE (150m1) were refluxed until no more 
was Ethyl 3-amino-2-phenylpropanoate detected by TLC. The solvent was removed 
under reduced pressure and the orange residue purified by flash chromatography (silica 
gel; DCM/Pet ether, 4: 6). Two orange bands were observed on the column the second 
contained the product as a yellow oil (1.7 g, 49 %): 'H NMR (400 MHz, CDCl3) 8 8.16 
(m, 2H), 7.42-7.31 (m, 5H), 6.86 (dd, J, 
= 
8.6 Hz, J2 = 6.3 Hz, 1 H), 6.66 (m, 1 H), 4.26- 
4.12 (m, 2H), 4.04-3.93 (m, 2H), 3.68-3.62 (m, 1H), 1.23 (t, J=7.1 Hz, 3H); HRMS 
(ESI) m/z calcd for C17H, 9N204 [M+H] : 315.1345, found: 315.1303. 
3-(2-Nitrophenylamino)-2-phenylpropanoic acid 
NO2 (0 ýN 
OH H 
Ethyl 3-(2-nitrophenylamino)-2-phenylpropanoate (2 g, 6 mmol) and lithium hydroxide 
(1.1 g, 24 mmol) was refluxed in 1: 1 THE and water (60 ml) until no more starting 
material was detected by TLC. THE was removed under reduced pressure the solution 
was neutralised with 2M HCl and extracted with DCM (2 x 50 mL). The organic layer 
was dried (MgSO4) and evaporated under reduced pressure to yield 1.5 g (87 %) of the 
product as an orange solid: 'H NMR (400 MHz, CDC13) 8 8.17 (m, 2H), 7.49-7.33 (m, 
193 
5H), 6.89 (dd, J, =8.6 Hz, J2= 6.3 Hz, 1H), 6.69 (m, 1H), 4.02 (m, IH), 3.74-3.68 (m, 
2H); HRMS (ESI) m/z calcd for C15Hi5N204 [M+H]+: 287.1032, found: 287.1027. 
3-(2-Aminophenylamino)-2-phenylpropanoic 
acid 
NH2 
O aN 
OH 
A solution of 3-(2-Nitrophenylamino)-2-phenylpropanoic acid (1.5 g, 5.24 mmol) in 
THE (30 mL) was degassed by sonication under aspirator vacuum for 5 minutes and 
backfilled with nitrogen. 10% palladium on charcoal was carefully added under a 
blanket of nitrogen. A septum was fitted and conc HCl (1 mL) was injected. The flask 
was evacuated under aspirator vacuum for 5 minutes. A H2 balloon and needle were as 
inserted into the septum. The reaction was stirred vigorously at room temperature and 
the balloon was refilled until no further consumption of hydrogen was apparent. The 
reaction mixture was filtered through celite. Removal of the solvent under reduced 
pressure yielded 0.86 g (64 %) of the the product as a white solid: 1H NMR (400 MHz, 
CDC13) 6 7.42-7.19 (m, 7H), 6.89 (d, J=7.8 Hz, 1 H), 6.73 (m, 1 H), 4.02 (m, 1 H), 3.94 
(m, 1 H), 3.78 (m, 1 H), 3.61 (m, 1 H) 3.29 (m, 1 H); HRMS (ESI) m/z calcd for 
C, 5H, 6N202 [M+H]': 257.1290, found: 257.1239. 
4,5-Dihydro-3-phenyl-1 H-benzo[b][1,4]diazepin-2(3H)-one 
194 
N_ 
ýiN\/ 
H 
3-(2-Aminophenylamino)-2-phenylpropanoic acid (450 mg, 1.75 mmol), DIPEA 
(0.68 mL, 4.0 mmol) and HBTU (759 mg, 2.0 mmol) were stirred in THE (5 mL) at 
room temperature until no more starting material was observed by TLC and MS. The 
solvent was removed under reduced pressure. The residue was dissolved in DCM 
(50 mL) washed with saturated sodium bicarbonate (50 mL) and brine (50 mL), dried ( 
MgSO4) and concentrated under reduced pressure. Purification by flash chromatography 
(silica gel; pet ether/EtOAc, 1: 1) yielded 160 mg (38 %) of the desired product as a 
beige solid: 1H NMR (400 MHz, CDC13) S 7.38-7.35 (m, 12H), 7.10 (td, J, = 7.6 Hz, J2 
= 1.5 Hz, 1 H), 7.02 (td, J, = 7.6 Hz, J2 = 1.5 Hz, 1H), 6.90 (dd, Jj = 7.6 Hz, J2 = 1.5 Hz, 
1H), 5.15 (d, J= 15.6 Hz, 1 H), 5.04 (d, J= 15.6 Hz, 1 H), 4.08 (s, 1 H), 3.79 (d, J= 
3.8 Hz, 1 H), 3.78 (m, I H), 3.48 (brs, I H); HRMS (ESI) m/z calcd for C15H16N202 
[M+H]+: 239.1184, found: 239.1254. 
S-Benzyl-4,5-dihydro-3-phenyl-lH-benzo[b][1,4]diazepin-2(3H)-ones 
General Procedure F 
4,5-Dihydro-3-phenyl-]H-benzo[b][1,4]diazepin-2(3H)-one (50 mg, 0.2 mmol), the 
appropriate benzylchloride (0.2 mmol) and cesium carbonate (520 mg, 1.6 mmol) were 
refluxed in acetonitrile until no starting material was observed by TLC and MS. The 
reaction mixture was filtered and the solvent removed under reduced pressure. The crude 
products were purified by flash chromatography. 
195 
5-Benzyl-4,5-dihydro-3-phenyl-lH-benzo[b][1,4]diazepin-2(3H)-one (186) 
(i 
NN 
,0 
Using benzylamine (25 mg, 0.2 mmol) as per General Procedure F yielded 45 mg of 186 
(69 %) as a cream solid: mp 223-224 °C; 1H NMR (400 MHz, CDCl3) 6 7.38-7.35 (m, 
12H), 7.10 (td, J, 
= 
7.6 Hz, J2 = 1.5 Hz, 1 H), 7.02 (td, J, = 7.6 Hz, J2 = 1.5 Hz, 1 H), 
6.90 (dd, J, = 7.6 Hz, J2 = 1.5 Hz, 1H), 5.15 (d, J= 15.6 Hz, 1 H), 5.04 (d, 15.6 Hz, 1 H), 
4.08 (m, 2H), 3.79 (d, J=3.8 Hz, 2H), 3.78 (m, IH), 3.48 (brs, IH); 13 C NMR (100 
MHz, CDCl3) 6 172.8,140.9,137.9,136.2,135.8,129.6,128.3,128.2,127.5,127.2, 
126.9,126.8,123.3,123.1,122.1,57.9,52.2,47.5; 13C NMR (100 MHz, CDCl3) 8 
HRMS (ESI) m/z calcd for C22H21N20 [M+H]+: 329.1654, found: 329.1664; HPLC TR: 
2.52 min. 
5-(4-Chlorobenzyl)-4,5-dihydro-3-phenyl-lH-benzo[b][1,4]diazepin-2(3H)-one (189) 
Using 4-chlorobenzylamine (32 mg, 0.2 mmol) as per General Procedure F yielded 
46 mg of 189 (63 %) as a cream solid: mp 172-174.8 °C; 'H NMR (400 MHz, CDCl3) 5 
7.51 (m, 1 H), 7.38-7.09 (m, 1 OH), 7.10 (td, J1= 7.6 Hz, J2 = 1.5 Hz, 1 H), 6.93 (dd, Ji = 
196 
7.6 Hz, J2 
= 1.5Hz, 1H), 5.30 (d, J= 16.9 Hz, 1 H), 5.17 (d, J= 16.9 Hz, 1 H), 4.12 (m, 
2H), 3.82 (m, 1H), 3.62 (brs, 1H); 13 C NMR (100 MHz, CDC13) S 172.9,141.0,136.3, 
136.0,135.4,132.7,129.6,128.7,128.5,128.3,127.6,127.0,123.3,123.2,122.2,57.9, 
51.5,47.4; HRMS (ESI) m/z calcd for C22H2oC1N20 [M+H]+: 363.1264, found: 
363.1120; HPLC TR: 3.99 min. 
5-(2-Chlorobenzyl)-4,5-dihydro-3-phenyl-lH-benzo[b][1,4]diazepin-2(3H)-one (187) 
Using 2-chlorobenzylamine (32 mg, 0.2 mmol) as per General Procedure F yielded 
35 mg of 187 (48 %) as a cream solid: mp: 148-150 °C; 'H NMR (400 MHz, CDCI3) 8 
7.38-7.09 (m, II H), 7.10 (td, J, = 7.8 Hz, J2 = 1.6 Hz, I H), 6.93 (dd, J1= 7.8 Hz, J2 = 
1.6 Hz, I H), 5.30 (d, J= 15.6 Hz, I H), 5.17 (d, J= 15.6 Hz, I H), 4.06 (m, 2H), 3.78 (m, 
I H), 3.47 (brs, I H); 13C NMR (100 MHz, CDC13) 6 172.9,141.0,139.9,136.0,135.4, 
134.2,129.6,128.3,127.6,127.2,127.1,127.0,125.3,123.3,123.2,122.3,58.0,51.7, 
47.4; HRMS (ESI) m/z calcd for C22H20C1N20 [M+H]+: 363.1264, found: 363.1117; 
HPLC TR: 4.12 min. 
5-(3-Chlorobenzyl)-4,5-dihydro-3-phenyl-lH-benzo[b][1,4]diazepin-2(3H)-one (188) 
197 
NN 
co 
CI 
Using 4-chlorobenzylamine (32 mg, 0.2 mmol) as per General Procedure F yielded 
39 mg of 188 (54 %) as a cream solid: mp 129-131 °C; 1H NMR (400 MHz, CDC13) S 
7.38-7.09 (m, I1 H), 7.10 (td, J, = 7.8 Hz, J2 = 1.6 Hz, 1 H), 6.93 (dd, Jj = 7.8 Hz, J2 = 
1.6 Hz, IH), 5.30 (d, J= 15.8 Hz, IH), 5.17 (d, 15.8 Hz, IH), 4.08 (m, 2H), 3.80 (m, 
I H), 3.53 (brs, I H); 13C NMR (100 MHz, CDC13) 6 172.8,140.8,136.0,135.5,134.9, 
132.4,129.6,129.2,128.2,128.0,127.6,127.0,123.3,123.0,122.2,58.1,50.1,47.5; 
HRMS (ESI) m/z calcd for C22H20C1N20 [M+H]+: 363.1264, found: 363.1130; HPLC 
TR: 4.17 min. 
General Procedure G synthesis of 5-benzoyl-4,5-dihydro-3-phenyl-lH- 
benzo[b][ 1,4]diazepin-2(3H)-ones 
4,5-Dihydro-3-phenyl-IH-benzo[b][1,4]diazepin-2(3H)-one (50 mg, 0.2 mmol), the 
appropriate benzoylchloride (0.2 mmol) and DMAP (catalytic) were refluxed in pyridine 
until no starting material was observed by TLC and MS. The reaction mixture was 
filtered and the solvent removed under reduced pressure. The crude products were 
purified by flash chromatography. 
5-Benzoyl-4,5-dihydro-3-phenyl-lH-benzo[b][1,4]diazepin-2(3H)-one (190) 
198 
atN 
0 
Using benzoylchloride (28 mg, 0.2 mmol) as per General Procedure G yielded 40 mg 
(58 %) of 190 as a cream solid: mp 214-217.5 °C; 1H NMR (400 MHz, CDC13) S 8.7 
(brs, IH), 7.44-6.72 (m, 14H), 5.09 (t, J= 11.6 Hz, IH), 4.01 (m, 2H); 13 C NMR (100 
MHz, CDC13) S 173.5,171.3,135.2,135.2,135.1,134.6,130.3,129.8,128.7,128.5, 
128.3,128.0,126.3,122.7,56.0,46.8; HRMS (ESI) m/z calcd for C22H, 9N202 [M+H]+: 
343.1447, found: 343.1463; HPLC TR: 1.06 min. 
5-(2-Chlorobenzyl) 4,5-dihydro-3-phenyl-lH-benzo[b][l, 4]diazepin-2(3H)-one (191) 
Using 2-chlorobenzoylchloride (35 mg, 0.2 mmol) as per General Procedure G yielded 
36 mg (48 %) of 191 as a cream solid: mp 210.5-212.3 °C; 1H NMR (400 MHz, CDC13) 
S 8.08 (brs, 1 H), 7.49-6.88 (m, 13H), 5.30 (t, J= 12.3 Hz, 1 H), 3.97 (m, 2H); 1 3C NMR 
(100 MHz, CDC13) 6 173.1,168.3,135.7,135.3,134.4,133.5,131.2,130.9,130.24, 
129.8,129.6,129.4,129.2,128.5,128.0,126.5,126.2,122.9,54.7,46.7; HRMS (ESI) 
m/z calcd for C22H18C1N202 [M+H]+: 377.1057, found: 377.1092; HPLC TR: 1.25 min. 
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5-(3-Chlorobenzoyl)-4,5-dihydro-3-phenyl-1 H-benzo[b)[1,4]diazepin-2(3H)-one 
(192) 
NO 
O 
CI 
Using 3-chlorobenzoylchloride (35 mg, 0.2 mmol) as per General Procedure G yielded 
32 mg (43 %) of 192 as a cream solid: mp: 204.6-206.5 °C; 'H NMR (400 MHz, CDC13) 
6 8.57 (brs, 1 H), 7.43-6.72 (m, 13H), 5.06 (t, J= 12.6 Hz, 1 H), 3.99 (m, 2H); 13 C NMR 
(100 MHz, CDCl3) S 173.3,169.7,136.8,135.1,134.7,134.4,134.2,130.4,130.2, 
129.8,129.2,129.1,128.6,128.5,128.1,126.5,126.1,122.8,55.9,46.8; HRMS (ESI) 
m/z calcd for C22H, 8C1N202 [M+H]+: 377.1057, found: 377.0894; HPLC TR: 1.49 min. 
5-(4-Chlorobenzoyl)-4,5-dihydro-3-phenyl-lH-benzo[b][1,4]diazepin-2(3H)-one 
(193) 
Using 4-chlorobenzoylchloride (35 mg, 0.2 mmol) as per General Procedure G yielded 
42 mg (56 %) of 193 as a cream solid: mp: 230.7-233 °C; 1H NMR (400 MHz, CDC13) 8 
8.53 (brs, IH), 7.43-6.72 (m, 13H), 5.05 (t, J= 12.5 Hz, IH), 3.99 (m, 2H), 1 3C NMR 
(100 MHz, CDCl3) 6 173.4,170.1,136.5,135.0,135.0,134.4,130.2,129.8,129.8, 
200 
129.0,128.5,128.3,128.1,126.6,122.8,56.0,46.8; HRMS (ESI) m/z calcd for 
CuHi8C1NZO2 fM+H]+: 377.1057, found: 377.0964; HPLC TR: 1.48 min. 
Synthesis of methyl 
-2-halophenylcarbamates 
A 50ml round bottomed flask equipped with magnetic stirrer was charged with 20m1 of 
chloroform (CHCI3), 5-chloro-2-iodoaniline (2.53g, 14.8mmol) 1.03g of pyridine 
(I 
. 
05m1,13mmol) and a catalytic amount of DMAP. The mixture was stirred in an ice 
bath while 1.13g of methyl chloroformate (0.93m1,12mmol) was added dropwise over I 
hour maintaining the temperature at 10 °C. The reaction was monitored by tlc (7: 3 40-60 
petroleum ether: EtOAc) developed in ninhydrin After that, the mixture was poured onto 
a large amount of crushed ice and H2O. The organic phase was washed three times with 
H2O (20 mL), saturated NaCI and dried over anhydrous MgSO4. The solvent was 
removed under reduced pressure. The crude was recrystallised from hexanes. 
Methyl 2-bromophenylcarbamate 
H 
aN, Cw 
Pale brown oil that crystallised from a small amount of hexane to give beige needles in 
the freezer which were filtered washed with light petroleum and dried under vacuum at 
room temperature 2.55g (74%): 'H NMR (400 MHz, CDCl3) 5 8.14 (d, J= 8.1 Hz, I H), 
7.51 (dd, J1= 8 Hz J2 
=1.4 Hz IH), 7.31 (td, J1= 8 Hz J2 =1.4 , 1H), 7.14 (brs IH), 3.81 
(s, 3H). 
201 
Methyl 4-chloro-2-iodopbenylcarbamate 
H 
N, CO2Me 
GII 
Beige needles 2.64g (85%): 'H NMR (400 MHz, CDCl3) 5 8.15 (s, IH), 7.65 (d, J=8.5 
Hz, I H), 6.97 (brs, 1 H), 5.41 (dd, J1 = 8.5 Hz, J2 = 2.48 Hz, 1 H), 3.82 (s, 3H). 
General Procedure H: Syntheses of aminoamides 246 
(tert-butoxycarbonyl)-protected L-leucine (2.0 g, 8.0 mmol), L-phenylalanine (2.12 g, 
8.0 mmol) or L-tryptophan (2.44 mg, 8.0 mmol) were dissolved in dimethylformamide 
(DMF) (5 mL) under a nitrogen atmosphere. HBTU (4.55 g, 12.0 mmol) and DIEA (2.7 
mL, 16 mmol) were successfully added. The reaction mixture was stirred for 1 hour. 
Pyrrolidine (0.74 mL, 9.0 mmol) or 2M dimethylamine in THE (4.5 mL, 9.0 mmol) was 
then added and the reaction was allowed to stir for 1 hour. The reaction was acidified 
with 2N HCI to pH 3, the mixture was diluted with water and extracted with EtOAc. The 
organic phase was washed with brine and dried (MgSO4). The solvent was evaporated 
under reduced pressure. The crude product was purified by flash chromatography on 
silica gel eluting with petroleum/EtOAc. 
General Procedure I: t-Boc Deprotection of amino amides. 
The amino amides were stirred in TFA for 1 hour at room temperature. The volatiles 
were removed under reduced pressure. 
202 
(S)-t-Buty{-4-methy{-1-oxo-1-(pyrrolidin-1-y1)pentan-2-ylcarbamate 
HN"Boc 
N 
"ýýo 
Using General Procedure H, 1.72 g (67 %) of the deisired compound was prepared as a 
colourless oil: 1H NMR (400 MHz, CDC13) S 5.23 (d, J=9.59 Hz, IH), 4.45 (td, J= 
9.59 Hz, 3.83 Hz, IH). 3.67 (m, IH), 3.51 (m, IH), 3.41 (m, 2H), 1.97 (m, 2H), 1.87 (m, 
2H), 1.72 (m, IR), 1.55-1.45 (m, IH) 1.42 (s, 9H), 1.40-1.31 (m, IH), 0.98 (d, J= 
6.6 Hz, 3H). 0.92 (d, J=6.6 Hz, 3H); HRMS (ESI) m/z calcd for C15H29N203 [M+H]+: 
285.2178, found: 285.3654. 
(S)-2-Amino-4-methyl-1-(pyrrolidin-1-yl)pentan-1-one 
NH2 
N 
On 
Using General Procedure I, 0.73g (65 %) of the title compound was obtained as a 
colourless oil: 'H NMR (400 MHz, CDC13) S 3.55-3.33 (m, 4H), 3.02 (s, 1H), 3.96 (s, 
IH), 2.03-1.76 (m, 4H), 1.41-1.30 (m, 2H) 0.93 (m, 6H); HRMS (ESI) m/z calcd for 
C, 0H21N20 [M+H]` required: 185.1654, found 185.1671. 
(S)-t-Butyl-l-oxo-3-phenyl-l-(pyrrolidin-1-yl)propan-2-ylcarbamate 
HN_ ' Boc 
N 
0 
203 
Using General Procedure H, 1.82 g (64 %) of the title compound was prepared as a 
colourless oil: 1H NMR (400 MHz, CDC13) S 7.31-7.15 (m, 5H), 5.40 (d, J=8.9 Hz, 
1 H), 4.57 (dd, J, 
= 
8.9 Hz, J2 = 6.0 Hz, 1 H), 3.38 (m, 3H), 2.96 (m, 2H), 2.54 (m, 1 H), 
1.88-1.47 (m, 4H), 1.43 (s, 9H); HRMS (ESI) m/z calcd for C18H27N203 [M+H]+ 
required 319.2022, found: 319.1843. 
(S)-2-Amino-3-phenyl-l-(pyrrolidin-1 
-yl)propan-1 -one 
NH2 
N 
0 
Using General Procedure I, 1.08g (87 %) of the title compound was obtained as a 
colourless oil: 'H NMR (400 MHz, CDC13) S 7.35-7.19 (m, 5H), 3.73 (t, J=6.9 Hz, 1 H), 
3.46 (m, 1 H), 3.33 (m, 4H), 2.94 (m, 2H), 2.70 (m, 1 H) 1.82-1.57 (m, 4H); HRMS (ES! ) 
m/z calcd for C, 3H, 9N20 (M+H)+ required: 219.1497, found 219.1329. 
(S)4-Butyl-3-(1H-indol-3-yi)-1-oxo-1-(pyrrolidin-l-yl)propan-2-ylcarbamate 
HN ýBoc 
O 
yN 
C1 NH 
Using General Procedure H, 1.06 g (85 %) of the title compound was prepared as a 
colourless oil: 'H NMR (400 MHz, CDC13) 6 8.15 (brs, IH), 7.62 (d, J=7.6 Hz, IH), 
7.33 (d, J=7.6 Hz, 1 H), 7.16 (t, J=7.6 Hz, 1 H), 7.13-7.05 (m, 2H), 5.51 (d, J=9 Hz, 
1 H), 4.66 (dd, J, =9 Hz, J2 = 6.0 Hz 1 H), 3.48-3.05 (m, 5H), 2.50 (m, 1 H), 1.61 (m, 
204 
2H), 1.44 (s, 9H), 1.38-1.19 (m, 3H); HRMS (ESI) m/z calcd for C20H28N3O3 [M+H]+ 
required: 358.2131, found: 358.2130. 
(S)-2-Amino-3-(1H. indol-3-yl)-1-(pyrroldin-1-yl)propan-l-one 
NH2 f: ) 
N 
O 
ý' NH 
Using General Procedure 1,0.72g (94 %) of the title compound was obtained as a pale 
brown oil: 1H NMR (400 MHz, CDCI3) 8 8.24 (s, 1H), 7.59 (d, J=8.5 Hz, IH), 7.36 (d, 
J=8.5 Hz, I H), 7.19 (t, J=7.5 Hz, I H) 7.14-7.06 (m, 2H), 3.83 (t, J=7.3 Hz, I H), 
3.49-3.42 (m, IH), 3.40-3.31 (m, 2H), 3.19-3.11 (m, 1H), 2.99-2.87 (m, 2H), 1.79-1.49 
(m, 6H); HRMS (ESI) m/z calcd for C15H20N30 [M+H]+ required: 258.1606, found: 
258.1574. 
(R)- t-Butyl4-methyl-l-oxo-l-(pyrrolidin-1-yl)pentan-2-ylcarbamate 
HNiý 
N, J 
0 
Using General Procedure H, 0.71 g (28 %) of the deisired compound was prepared as a 
colourless oil: 1H NMR (400 MHz, CDC13) S 5.23 (d, J=9.59 Hz, 1H), 4.45 (td, Jj = 
9.59 Hz, J2 
= 
3.83 Hz, 1 H), 3.67 (m, 1 H), 3.51 (m, 1 H), 3.41 (m, 2H) 1.97 (m, 2H), 1.87 
(m, 2H), 1.72 (m, IH), 1.55-1.45 (m, 1H), 1.42 (s, 9H), 1.40-1.31 (m, IH), 0.98 (d, J= 
6.6 Hz, 3H). 0.92 (d, J=6.6 Hz, 3H); HRMS (ESI) m/z calcd for C15H29N203 [M+H]+ 
required: 285.2178, found: 285.1938. 
205 
(R)-2-Amino4-methyl-l-(pyrrolidin-1-yl)pentan-l-one 
NH2 
00 
N 
Using General Procedure I, 430 g (94 %) Colourless oil, 1H NMR (400 MHz, CDC13) 6 
3.60 (brs, 1 H), 3.55-3.33 (m, 4H), 3.17 (', 2H), 1.96-1.76 (m, 4H), 1.45-1.30 (m, 2H), 
0.89 (s, 3H), 0.88 (s, 3H); HRMS (ESI) m/z calcd for C, oH21N20 [M+H]+ required: 
185.1654, found: 185.1342. 
(R)-t-Butyl-l-oxo-3-phenyl-l-(pyrroldin-1-yl)propan-2-ylcarbamate 
HN"Eloc^ 
00 
Using General Procedure H, 1.02 g (36 %) of the deisired compound was prepared as a 
colourless oil: 1H NMR (400 MHz, CDC13) 6 7.28-7.17 (m, 5H), 5.40 (d, J=8.8 Hz, 
IH), 4.57 (m, IH), 3.38 (m, 3H), 2.96 (m, 2H), 2.57 (m, IH), 1.88-1.47 (m, 4H), 1.43 (s, 
9H); HRMS (ES» m/z calcd for C, 8H27N203 [M+H]+ required 319.2022, found 
319.1941. 
(R)-2-Amino-3-phenyl-l-(pyrrolidin-l-yl)propan-1-one 
40 NHZ 
N 
0 
206 
Using General Procedure I, 0.62 g (89 %) Colourless oil, 1H NMR (400 MHz, CDC13) 8 
7.35-7.19 (m, 5H), 3.73 (t, J=6.9 Hz, 1H), 3.46 (m, IH), 3.33 (m, 4H), 2.94 (m, 2H), 
2.70 (m, IH), 1.82-1.57 (m, 4H); HRMS (ESI) m/z calcd for C13Hi9N20 [M+H]+ 
required: 219.1497, found 219.1212. 
(R)-t-Butyl-3-(1H-indol-3-yl)-I-oxo-1-(pyrrolidin-l. yl)propan-2-ylcarbamate 
HN"Boc ^ 
N40 
O 
ý' NH 
Using General Procedure H, 1.02 g (32 %) of the deisired compound was prepared as a 
white solid: 'H NMR (400 MHz, CDC13) 8 8.16 (brs, 1H), 7.62 (d, J=7.6 Hz, 1 H), 7.33 
(d, J=7.6 Hz, 1 H), 7.16 (t, J=7.6 Hz, 1 H), 7.13-7.05 (m, 2H), 5.50 (d, J=9 Hz, 1 H), 
4.67 (m, IH), 3.48-3.05 (m, 5H), 2.51 (m, 1H), 1.61 (m, 2H), 1.44 (s, 9H), 1.38-1.19 (m, 
3H); HRMS (ESI) m/z calcd for C2oH sN303 [M+HJ+ required: 358.2131, found: 
358.2057. 
(R)-2-Amino-3-(1H-indol-3-yi)-1-(pyrrolidin-1-yl)propan-1-one 
NH2 
N 
0 
NH 
Using General Procedure I, 715 mg (97 %) of the title compound was obtained as a 
cream solid, 1H NMR (400 MHz, CDCl3) 8 8.24 (s, IH), 7.59 (d, J=8.5 Hz, IH), 7.36 
(d, J=8.5 Hz, 1 H), 7.19 (t, J=7.5 Hz, 1 H), 7.14-7.06 (m, 2H), 3.83 (t, J=7.3 Hz, 1 H), 
207 
3.49-3.42 (m, IH), 3.40-3.31 (m, 2H), 3.19-3.11 (m, IH), 2.99-2.87 (m, 2H), 1.79-1.49 
(m, 6H); HRMS (ESI) m/z calcd for C15H2ON3O [M+H]+ required 258.1606, found: 
258.1580. 
(S)-2-Amino-N, N, 4trimethylpentanandde 
NH2 j 
N,, 
Using General Procedure I: 1H NMR (400 MHz, CDCl3) 6 3.68-3.76 (m, IH), 3.02 (s, 
3H), 2.96 (s, 3H), 1.75-1.93 (m, 1 H), 1.62 (s, 2H), 1.29-1.39 (m, 2H), 0.94 (d, J=6.6 
Hz, 3H), 0.93 (d, J=6.7 Hz, 3H); HRMS (ESI) m/z calcd for C8H, 9N20 [M+H]+: 
159.1497, found: 159.1597. 
(S)-2-Amino-N, N-dimethyl-3-phenylpropanamide 
NH2 1 
N, 
O 
Using General Procedure I: 1H NMR (400 MHz, CDC13) S 7.15-7.34 (m, 5H), 3.94 (t, J 
= 7.2 Hz, IH), 2.94 (dd, J1= 13.2, J2= 6.8 Hz, IH), 2.91 (s, 3H), 2.77 (dd, J1= 13.2, 
J2=7.4 Hz, IH), 2.73; (s, 3H), 1.80 (s, 2H), HRMS (ESI) m/z calcd for C11H17N20 
[M+H]+: 193.1341, found: 193.1347. 
208 
General Procedure J: syntheses of benzoimidazolones 
A Schlenk tube was charged with the appropriate methyl-2-halophenylcarbamate, 
(I. Ommol), Cu! (38mg, 0.2mmol), L-proline (46mg, 0.4mmol), and K3PO4 (424mg, 
2. Ommol), evacuated and backfilled with nitrogen (3 cycles). Aminoamide (1. Ommol) 
and DMSO (2ml) were added. The reaction mixture was stirred at 70 °C until the 
coupling was completed detected by TLC. The solution was then heated at 130 °C until 
the coupling product disappeared, monitored by TLC and mass spec. The cooled mixture 
was then partitioned between EtOAc and saturated NH4C1. The organic layer was 
washed with saturated NaCl, dried over anhydrous MgSO4 and concentrated under 
vacuum. The residue was then purified by normal phase flash column chromatography 
on silica gel with the appropriate ration of EtOAc and petroleum ether mobile phase to 
provide the desired product. 
(S)-1-(4-Methyl-l-oxo-l-(pyrrolidin-1-yl)pentan-2-yl)-1H-benzo[d]inhidazol-2(3H)- 
one (208) 
YO 
No 
N>=O 
H 
Using General Procedure J 81 mg, (27%) of 208 was obtained: mp 170.3-173 °C; 'H 
NMR (400 MHz, CDCI3) S 9.49 (s, I H), 7.46 (m, I H), 7.07 (m, 3H), 5.33 (dd, J, = 9.73 
Hz, J2 = 5.05 Hz, I H), 3.65 (m, I H), 3.53 (m, 1 H), 3.42 (m, I H), 3.29 (m, 1 H), 2.15 (m, 
1 H), 2.02-1.78 (m, 4H), 1.73 (m, I H), 1.01 (d, J=6.84 Hz, 3H), 0.09 (d, J=6.84 Hz, 
3H); 13C NMR (100 MHz, CDC13) 5 167.6,155.2,128.7,127.9,121.7,121.7,111.3, 
209 
109.4,52.1,46.4,46.4,37.9,26.3,24.6,23.9,23.2,22.0; HRMS (ESI) m/z calcd for 
C17H2N302 [M+H]+ required: 302.1869, found 302.1727; [a] 20 
_ 
-112° (c 0.75, DCM); 
HPLC TR: 8.73 min.. 
(S)-S-Chloro-l-(4-methyl-l-oxo-1-(pyrrolidin-1-yl)pentan-2-yl)-1H- 
benzo(d]imidazol-2(3H)-one (213) 
O 
No 
CI H 
Using General Procedure J, 141 mg, (42%) of 213 was obtained: mp 153-155 °C; 'H 
NMR (400 MHz, CDC13) 6 9.49 (s, 1 H), 7.56 (d, J=8.48 Hz, 1 H), 7.07 (d, J=2.01 Hz, 
1 H), 7.03 (dd, J, 
= 
8.48 Hz, J2 
= 
2.01 Hz, 1 H), 5.33 (dd, J/ = 9.9 Hz, J2 = 5.80 1 H), 3.64 
(m, 1 H), 3.35 (m, 1 H), 3.39 (m, 2H), 2.12 (m, 1 H), 2.02-1.71 (m, 5H), 1.42 (m, 1 H), 
1.01 (d, J=6.62 Hz, 3H), 0.9 (d, J=6.62 Hz, 3H); 13C NMR (100 MHz, CDCl3) 6 
167.6,155.4,129.0,127.4,127.3,121.6,112.2,109.9,52.2,46.6,46.4,37.8,26.22, 
24.6,24.0,23.1,21.9; HRMS (ES» m/z caled for C17H23C1N302 [M+H]+: 336.1479, 
found 336.1434; [a] ö 20 = -67.4° (c 1.84, DCM); HPLC TR: 10.02 min. 
210 
(S)-1-(1-Oxo-3-phenyl-l-(pyrroldin-1-yl)propan-2-yl)-1H-benzo[d]imidazol-2(3H)- 
one (210) 
\O 
No 
X=O 
N 
H 
Using General Procedure J, 231 mg, (69%) of 210 was obtained: mp 162-165 °C; 'H 
NMR (400 MHz, CDCl3) S 8.73 (s, I H), 7.56 (m, I H), 7.21-6.97 (m, 4H), 5.41 (m, I H), 
3.58-3.28 (m, 5H), 3.15 (m, IH), 1.80 (m, 3H), 1.70 (m, IH); 13 C NMR (100 MHz, 
CDC13) S 166.8,155.0,137.1,129.3,128.6,128.3,127.7,126.7,121.8,121.8,121.8, 
11 1.0,109.7,55.3,46.4,46.4,35.3,26.2,23.9; HRMS (ESI) m/z calcd for C20H22N302 
[M+H]+336.1712, found 336.1597; [a] 20 
= 
-97.2 0 (c 0.91, DCM) HPLC TR: 8.83 min. 
(S)-5-Chloro-l-(1-oxo-3-phenyl-14pyrrolidin-1-yl)propan-2-yl)-1 H- 
benzo[djimidazol-2(3H)-one (215) 
\0 
N: ) 
N ý\ ýO 
CI aH 
Using General Procedure J, 152 mg, (41 %) of 215 was obtained: mp 91-93 °C; 'H NMR 
(400 MHz, CDCl3) 8 9.24 (s, 1 H), 7.32 (d, J=8.75 Hz, 1 H), 7.21-6.98 (m, 4H), 5.41 (m, 
1H), 3.51 (m, 2H), 3.42 (m, 2H), 3.31 (m, 1H), 3.20 (m, IH), 1.89-1.68 (m, 4H); 13C 
NMR (100 MHz, CDC13) 6 166.6,155.0,136.7,129.2,128.6,128.4,127.5,127.3, 
211 
126.9,121.8,112.1,110.1,55.4,46.5,46.4,35.3,26.1,23.9; HRMS (ESI) m/z calcd for 
C20H21C1N302 [M+H]+: 370.1322, found 370.1314; [a] ;°= 
-41.7° (c 1.49, DCM). HPLC 
TR: 9.93 min 
(S)-1-(3-(Indol-3-yl)-1-7oxo-1-(pyrnolidin-1-yl)propan-2-yl)-1H-benzo[d]imidazol- 
2(3H)-one (211) 
NH 
O 
No 
cr»o 
H 
U sing General Procedure J, 45 mg, (12 %) of 211 was obtained: 1H NMR (400 MHz, 
CDCl3) 6 9.76 (s, 1 H), 8.08 (s, I H), 7.61 (d, 7.1 Hz, 1 H), 7.53 (d, 7.1 Hz, I H), 7.20-7.21 
(m, 5H), 7.21 (d, i=8.41 Hz, 1 H), 6.93 (m, I H), 6.81 (d, J=2.28 Hz, I H), 5.53 (m, 
IH), 3.74 (m, IH), 3.55-3.36 (m, 4H), 3.14 (m, IH), 1.79-1.61 (m, 4H); 13 C NMR (100 
MHz, CDCl3) 6 167.3,155.2,136.0,128.7,128.0,127.5,123.2,121.8,121.8,121.7, 
1 19.3,118.4,111.2,111.1,110.8,109.7,54.5,46.4,46.4,26.1,25.1,23.8; HRMS (ESI) 
m/z calcd for C22H23N402 [M+H]`: 375.1821, found 375.1798; [a]ö = 
-68.2° (c 2.2, 
DCM); HPLC TR: 8.83 min. 
212 
(S)-5-Chloro-1-(3-(indol-3-yl)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-1H- 
benzo[djimidazol-2(3H)-one (216) 
NH 
O 
No 
\ ýO 
CI H 
Using General Procedure J, 86 mg, (21 %) of 216 was obtained: 'H NMR (400 MHz, 
CDCI3) S 9.10 (s, I H), 7.88 (b,,, I H), 7.57 (d, J=8.4 Hz, I H), 7.53 (d, J=7.3 Hz, I H), 
7.21 (d, J=8.41 Hz, 1 H), 7.14 (dt, J, = 7.5 Hz, Jz = 1.2 Hz, 1 H), 7.11-7.06 (m, 2H), 
6.93 (d, J=2.03 Hz, 1 H), 6.84 (d, J=2.35 Hz, 1 H), 5.51 (m, 1 H), 3.70 (m, 1 H), 3.56- 
3.33 (m, 4H), 3.20 (m, IH), 1.88-1.67 (m, 4H); 13C NMR (100 MHz, CDC13) 6 167.0, 
155.1,136.0,128.7,127.4,127.4,127.3,123.0,122.0,121.8,119.5,118.4,112.1,111.2, 
110.7,110.0,54.5,46.5,46.3,26.1,25.1,23.9; HRMS (ESI) m/z calcd for 
C22H22CIN4O2 (M+Hj+ required: 409.1431, found 409.1603; [a] 20 = 
-40° (c 0.5, DCM); 
HPLC TR: 8.83 min. 
(S)-2-(1,2-Dihydro-2-oxobenzo[d]imidazol-3-yl)"N, N, 4-trimethylpentanamide (207) 
0 
N 
o IN N 
H 
Using General Procedure J, 151 mg, (55 %) of 207 was obtained: mp 198-200 °C; 1H 
NMR (400 MHz, CDC13) 5 8.86 (s, IH), 7.41 (m, IH), 7.05 (m, 3H), 5.45 (dd, Jj = 9.3 
213 
Hz, Jz 
= 5.4 Hz, 1 H), 3.06 (s, 3H), 2.94 (s, 3H), 2.10 (m, 1 H), 1.94 (m, 1 H), 1.44 (m, 
1 H), 1.01 (d, J=6.5 Hz, 3H), 0.89 (d, J=6.5 Hz, 3H); 13C NMR (100 MHz, CDC13) S 
169.1,155.2,128.6,128.1,121.7,121.6,111.1,109.6,50.3,38.2,37.0,36.2,24.5,23.1, 
22.0; HRMS (ESI) mfz calcd for C15H22N302 [M+H]+ required 276.1712, found 
276.1649; [a] '= 
-193.4° (c 1.82, DCM); HPLC TR: 8.52 min. 
(S)-2-(6-Chloro-1,2-dihydr)-2-oxobenizo[dlimidazol-3-yl)-N, N, 4- 
trimethylpentanamide (212) 
O 
N 
II 
CI' vN H 
Using General Procedure J, 152 mg, (49 %) of 212 was obtained: mp 149-152 °C; 'H 
NMR (400 MHz, CDC13) 5 9.22 (s, IH), 7.37 (d, J=8.9 Hz, IH), 7.07-7.01 (m, 2H), 
5.45 (dd, J, = 9.9 Hz, J2 5.8 Hz, IH), 3.08 (s, 3H), 2.95 (s, 3H), 2.08 (m, 1H), 
1.94 (m, 1 H), 1.41 (m, 1 H), 1.00 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H); 13 C NMR 
(100 MHz, CDC13) 6 168.0,155.2,128.9,127.4,127.3,121.7,112.2,110.0,50.3,38.1, 
37.1,36.1,24.6,23.0,22.0; HRMS (ESI) m/z calcd for C15H21C1N302 [M+H]' required 
310.1322, found 310.1245; [a], 20, 
= 
-110.4° (c 1.19, DCM); HPLC TR: 9.69 min. 
214 
(S)-2-(1,2-Dihydro-2-oxobenzo[d]imidazol-3-yl)-N, N-dimethyl-3- 
phenylpropannmide (209) 
IO 
N 
Cr? 
=o 
Using General Procedure J, 189 mg, (61 %) of 209 was obtained: mp 166-168 °C; 'H 
NMR (400 MHz, CDC13) S 8.33 (s, 1 H), 7.52 (m, I H), 7.20-6.99 (m, 8H), 5.54 (dd, J1 
= 
9 Hz, J2 = 6.4 Hz, IH), 3.49 (m, IH), 3.35 (m, 1H), 2.95 (s, 3H), 2.94 (s, 3H); 13 C NMR 
(100 MHz, CDC13) 6 168.3,154.8,137.1,129.3,128.5,128.3,127.8,126.7,121.8, 
121.9,110.9,109.8,53.7,36.9,36.2,35.6; HRMS (ESI) m/z calcd for C18H20N302 
[M+H)` 310.1556, found 310.1440; [a] 20 
_ 
-182.9° (c 1.05, DCM); HPLC TR: 8.29 min 
(S)-2-(6-Chloro-l, 2-dihydro-2-oxobenzo[d]imidazol-3-yl)-N, N-dimethyl-3- 
phenylpropanamide (214) 
CI 
Using General Procedure J, 308 mg, (58 %) of 214 was obtained: mp 141-143 °C; 'H 
NMR (400 MHz, CDC13) 8 9.62 (m, I H), 7.46 (d, J=8.6 Hz, 1 H), 7.19-7.01 (m, 7H), 
5.53 (m, I H), 3.45 (m, I H), 3.33 (m, I H), 2.95 (m, 6H); 13C NMR (100 MHz, CDC13) 8 
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168.2,154.9,136.7,129.2,128.9,128.4,127.5,127.1,126.9,121.8,111.9,110.3,53.7, 
37.0,36.2,35.6; HRMS (ESI) m/z calcd for C18H19C1N302 [M+H]+ 344.1166, found 
344.1173; [a) 
m= -64.9° (c 2.25, DCM); HPLC TR: 9.93 min. 
5.2 Computational Methods 
5.2.1 General methods 
2D structures were prepared using Chemdraw Ultra Version 8.0 (Cambridge Soft) and 
saved in skc format. The remaining programs used are by Openeye212 and the following 
versions were used throughout. Babel 3 Version 2.1 was used to convert file formats. 
Vida Version 2.1.1 was used for preparing the query molecules, visualisation of results 
from ROCS and FRED and creating images. The Zinc database was filtered with Filter 
Version 2.0.1. Multi-conformer dataset generation was performed using Omega Version 
2.1.0. ROCS Version 2.2 was used to perform the shape based screen and all docking 
was performed with FRED Version 2.2 and scored with the default scoring function, 
Chemgauss 3. 
5.2.2 Command lines, parameter flies and prefixes. 
The above versions of all of the Openeye programs, with the exception of Vida, are 
run from the command line. Unless specifically flagged on the command line all 
parameters run at their default settings. Examples of command lines used to perform the 
tasks as outlined are given. Each time the programmes are run a param file is created 
which lists all of the parameters and their settings used. Examples of parameter files 
from Omega and ROCS showing all of the settings used during conformer generation 
and screening in this project are given Sections 5.2.6-5.2.9. It is possible to use the 
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. 
param file generated during a run to perform subsequent runs with the same parameters 
by flaging 
-param <filename>. param on the command line. Any parameter flagged on 
the command line will take precedence over the corresponding setting in the param file. 
The 
-prefix flag on the command line is used to prefix all output files produced by a run 
with the same name. 
5.2.3 Spiro-oxindole query preparation 
The 2D structure of MI-43 was prepared using Chemdraw Ultra Version 8.0 saved in 
. 
skc format and converted to. ism (isomeric SMILES) using Babel 3. 
prompt> babel3 
-in M143. skc -out M143. ism 
All stereoisomers were enumerated using Flipper (a component of Omega) the output 
was saved in sdf format. 
prompt> flipper 
-in M143. ism -out M143. sdf 
The desired stereoisomer was visually selected using Vida2 saved as oeb. gz format and 
a multi conformer database of it was generated using Omega2 and also saved in oeb. gz 
format. Conformers were enumerated up to a maximum energy of 8 kcal mol"' above 
that global minimum sampled at a density such that conformers had a minimum RMSD 
of 0.5 as defined by the 
-ewindow and -rms flags respectively. 
prompt> omega 
-in M143. oeb. gz -out MI43_multi. oeb. gz -ewindow 8 -rms 
0.5 
-prefix M1219-multi 
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The multi conformer database was docked into MDM2 1 YCR 1 using FRED and the top 
20 poses as ranked by the default scoring function, Chemgauss 3, were output. 
prompt> fred 
-dbase M143_multi. oeb. gz -rec 1YCR_rec. oeb. gz -prefix M143 
-num alt poses 20 
The docked poses were visualised in Vidal. The top ranked pose bound in the predicted 
manner132 and was selected and saved in oeb. gz format to be used as the ROCS query. 
5.2.4 Nudin and Benzodiazepiene query preparation 
Using Vida 2 Nutlin-2 and the benzodiazepiene were extracted from their respective 
X-ray co-crystal structures, 1 RV 1 and ME downloaded from the PDB database. The 
atoms of the solubilising groups of Nutlin-2 were deleted and both structures were saved 
as oeb. gz format to be used as ROCS queries. 
5.2.5 Database preparation 
The the "all purchasable subset" of the Zinc database with protanation states enumerated 
between pH 5.75 to 8.25 was downloaded in mol2 format. The filter file, 
blockbuster drug. txt, was prepared by taking the most linient combination of allowed 
physical properties and chemistry/functional groups from the supplied 
filter blockbuster. txt and filter drug. txt files. Blockbuster_drug. txt Section 5.2.8 was 
used as the basis for filtering the database with Filter Version 2.0.1. The filtered dataset 
was saved in oeb. gz format. 
prompt> filter 
-in zinc purchaseable. moi2 -out 
zinc-purchaseable_blockbusterdrug. oeb. gz 
-filter blockbuster_drug. txt 
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The multi conformer database was generated using Omega Version 2.1.0 and written in 
. 
oeb. gz format with offset rotor compression. Conformers were enumerated up to a 
maximum energy of 8 kcal mol-' above the global minimum sampled at a density such 
that conformers had a minimum RMSD of 0.5 as defined by the 
-ewindow and -rms 
flags respectively. The task was distributed to X processors in Y work stations as defined 
in the file pvm. conf. An example of a pvm. conf file is shown in Section 5.2.9 
prompt> omega 
-in zinc purchaseable_blockbusterdrug. oeb. gz -out 
zinc-purchasable-blockbusterdrug_multi. oeb. gz. oeb. gz -ewindow 8 
-rms 0.5 
-prefix zinc purchasable_blockbusterdrug_multi -rotorOffsetCompress true 
- 
pvmconf pvm. conf 
ROCS, Version 2.2, was used to screen the multiconformer database. Chemistry overlap 
was optimised using the Implicit Mills Dean forcefield supplied with ROCS. The top 
500 hits as ranked by combo score were output in 
. 
sdf format. The task was distributed 
to X processors in Y work stations as defined in the file pvm. conf (Section 5.2.9 
prompt> ROCS 
-query benzodiazepiene_pdb. oeb. gz -dbase 
zinc purchasable_blockbusterdrug_multi. oeb. gz 
-besthits 500 -rankby combo - 
optchem true 
-chemff ImplicitMillsDean -prefix 
zinc purchasable_blockbusterdrug_benzodiazepiene -pvmconf pvm. conf 
The hits were visually inspected and manually clustered in Vida 2. 
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5.2.6 Omega. param fite examples 
The Omega param file used in this project to generate the multi conformer dataset of the 
Zinc all purchasable database. 
#Interface settings 
#File Options : 
-commentEnergy false (default) 
-in zinc purchaseable_blockbusterdrug. oeb. gz 
-includeInput false (default) 
#-log (Not set, no default) 
-out zinc purchasable_blockbusterdrug_multi. oeb. gz 
#-param (Not set, no default) 
-prefix zinc. purchasable_blockbusterdrug_multi 
-rotorOffsetCompress true 
-sdEnergy false (default) 
#-status (Not set, no default) 
-verbose false (default) 
-warts false (default) 
#3D Construction Parameters : 
#-addfraglib (Not set, no default) 
-buildff mmff94s_NoEstat (default) 
-canonOrder true (default) 
-deleteFixHydrogens true (default) 
-dielectric 1.000000 (default) 
-exponent 1.000000 (default) 
#-fixfile (Not set, no default) 
-fixrms 0.150000 (default) 
-fromCT true (default) 
-maxmatch 10 (default) 
#-setfraglib (Not set, no default) 
-umatch true (default) 
#Structure Enumeration : 
-enumNitrogen true (default) 
-enumRing true (default) 
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#Torsion Driving Parameters : 
#-erange (Not set, no default) 
-ewindow 8.000000 
t-maxConfRange (Not set, no default) 
-maxconfgen 50000 (default) 
-maxconfs 400 (default) 
-maxrot -1 (default) 
-maxtime 120.000000 (default) 
-rangeIncrement 5 (default) 
-rms 0.500000 
#-rmsrange (Not set, no default) 
-searchff mmff94s_NoEstat (default) 
-tordrive true (default) 
#-torlib (Not set, no default) 
#PVM : 
l-pvmconf pvm. conf 
-pvmdebug false (default) 
#-pvmlog (Not set, no default) 
-pvmpass 10 (default) 
5.2.7 Example of the ROCS Parameter file used in this screen 
#Interface settings 
AInputOptions : 
-query benzodiazepiene_pdb. oeb. gz 
-mcquery false (default) 
-dbase zinc purchasable_blockbusterdrug_multi. oeb. gz 
-scdbase false (default) 
#-param (Not set, no default) 
MOutputOptions : 
-prefix zinc, purchasable_blockbusterdrug_benzodiazepiene 
-besthits 500 (default) 
-cutoff 0.000000 (default) 
-rankby combo 
-maxconfs 1 (default) 
-maxhits 0 (default) 
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#HitsOutputOptions : 
-conflabel title (default) 
-outputquery true (default) 
-nostructs false (default) 
#-hitsfile (Not set, no default) 
-oformat sdf (default) 
#ReportOutputOptions : 
-report each (default) 
o-reportfile (Not set, no default) 
-stats hits (default) 
ALogOutputOptions : 
A-logfile (Not set, no default) 
-verbose false (default) 
#ShapeOptions : 
-tanimoto_cutoff 0.000000 (default) 
-subtan false (default) 
#-randomstarts (Not set, no default) 
-opt true (default) 
-scoreonly false (default) 
4ColorOptions : 
-allcolor false (default) 
-chemff ImplicitMillsDean 
-optchem true 
MPVM 
-pvmconf pvm. conf 
-pvmdebug false (default) 
-pvmpass 5 (default) 
5.2.8 The Filter Me used in this project, blockbuster_drug. txt. 
4/*****a+***a************aaaa***a*. a*a*******a****a**a**aa**+*********** 
#Copyright (C) 2000-2005 by OpenEye Scientific Software, Inc. 
4***********f*******************************+*********************a+****/ 
#This file defines the rules for filtering multi-structure files based on 
#properties and substructure patterns. 
MIN_MOLWT 130 "Minimum molecular weight" 
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MAX_MOLWT 781 "Maximum molecular weight" 
MIN_NUM_HVY 9 "Minimum number of heavy atoms" 
MAX_NUM_HVY 55 "Maximum number of heavy atoms" 
MIN_RING_SYS 0 "Minumum number of ring systems" 
MAX_RING_SYS 5 "Maximum number of ring systems" 
MIN_RING_SIZE 0 "Minimum atoms in any ring system" 
MAX_RING_SIZE 20 "Maximum atoms in any ring system" 
MIN_CON_NON_RING 0 "Minimum number of connected non-ring atoms" 
MAX_CON_NON_RING 19 "Maximum number of connected non-ring atoms" 
MIN_FCNGRP 0 "Minimum number of functional groups" 
MAX_FCNGRP 7 "Maximum number of functional groups" 
MIN_UNBRANCHED 1 "Minimum number of connected unbranched non-ring atoms" 
MAX_UNBRANCHED 13 "Maximum number of connected unbranched non-ring atoms" 
MIN_CARBONS 3 "Minimum number of carbons" 
MAX_CARBONS 41 "Maximum number of carbons" 
MIN_HETEROATOMS 1 "Minimum number of heteroatoms" 
MAX_HETEROATOMS 14 "Maximum number of heteroatoms" 
MIN_Het_C_Ratio 0.04 "Minimum heteroatom to carbon ratio" 
MAX_Het_C_Ratio 4.0 "Maximum heteroatom to carbon ratio" 
MIN_HALIDE_FRACTION 0.0 "Minimum Halide Fraction" 
MAX_HALIDE_FRACTION 0.66 "Maximum Halide Fraction" 
#count ring degrees of freedom = (#BondsInRing) -4- (RigidBondsInRing) - 
(BondsSharedWithOtherRings) 
#must be >= 0, from JCAMD 14: 251-265,2000. 
ADJUST_ROT_FOR_RING true "BOOLEAN for whether to estimate degrees of 
freedom in rings" 
MIN-ROT-BONDS 0 
MAX-ROT-BONDS 16 
MIN_RIGID_BONDS 4 
"Minimum number of rotatable bonds" 
"Maximum number of rotatable bonds" 
"Minimum number of rigid bonds" 
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MAX_RIGID_BONDS 55 "Maximum number of rigid bonds" 
MIN_HBOND_DONORS 0 "Minimum number of hydrogen-bond donors" 
MAX_HBOND_DONORS 9 "Maximum number of hydrogen-bond donors" 
MIN_HBOND_ACCEPTORS 0 "Minimum number of hydrogen-bond acceptors" 
MAX_HBOND_ACCEPTORS 13 "Maximum number of hydrogen-bond acceptors" 
MIN_LIPINSKI_DONORS 0 "Minimum number of hydrogens on 0&N atoms" 
MAX_LIPINSKI_DONORS 6 "Maximum number of hydrogens on 0&N atoms" 
MIN_LIPINSKI_ACCEPTORS 1 "Minimum number of oxygen & nitrogen atoms" 
MAX_LIPINSKI_ACCEPTORS 14 "Maximum number of oxygen & nitrogen atoms" 
MIN_COUNT_FORMAL_CRG 0 "Minimum number formal charges" 
MAX_COUNT_FORMAL_CRG 4 "Maximum number of formal charges" 
MIN_SUM_FORMAL_CRG 
-2 "Minimum sum of formal charges" 
MAX_SUM_FORMAL_CRG 2 "Maximum sum of formal charges" 
MIN_CHIRAL_CENTERS 0 "Minimum chiral centers" 
MAX_CHIRAL_CENTERS 21 "Maximum chiral centers" 
MIN_XLOGP 
-3.0 "Minimum XLogP" 
MAX_XLOGP 6.85 "Maximum XLogP" 
#choices are insoluble<poorly<moderately<soluble<very<highly 
MIN_SOLUBILITY insoluble "Minimum solubility" 
PSA_USE_SandP false "Count S and P as polar atoms" 
MIN_2D_PSA 0.0 "Minimum 2-Dimensional (SMILES) Polar Surface Area" 
MAX_2D_PSA 205.0 "Maximum 2-Dimensional (SMILES) Polar Surface Area" 
AGGREGATORS true "Eliminate known aggregators" 
PRED_AGG false "Eliminate predicted aggregators" 
#secondary filters (based on multiple primary filters) 
GSK_VEBER false "PSA>140 or >10 rot bonds" 
MAX_LIPINSKI 3 "Maximum number of Lipinski violations" 
MIN_ABS 0.11 "Minimum probability F>10% in rats" 
PHARMACOPIA false "Loge > 5.88 or PSA > 131.6" 
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ALLOWED-ELEMENTS H, C, N, O, F, P, S, C1, Br, I 
ELIMINATE_METALS Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd 
#acceptable molecules must have <= instances of each of the patterns below 
#specific, undesirable functional groups 
RULE 0 quinone 
RULE 0 pentafluorophenyl_esters 
RULE 0 paranitrophenyl_esters 
RULE 0 HOBT esters 
RULE 0 triflates 
RULE 0 lawesson_s_reagent 
RULE 0 phosphoramides 
RULE 1 beta_carbonyl_quat_nitrogen 
RULE 0 acylhydrazide 
RULE 0 cation C C1 IP or S 
RULE 0 phosphoryl 
RULE 0 alkyl_phosphate 
RULE 1 phosphinic_acid 
RULE 0 phosphanes 
RULE 0 phosphoranes 
RULE 0 imidoyl_chlorides 
RULE 0 nitroso 
RULE 0 N_P_S_Halides 
RULE 0 carbodiimide 
RULE 0 isonitrile 
RULE 0 triacyloxime 
RULE 0 cyanohydrins 
RULE 0 acyl_cyanides 
RULE 0 sulfonylnitrile 
RULE 0 phosphonylnitrile 
RULE 0 azocyanamides 
RULE 0 beta_azo_carbonyl 
RULE 2 polyenes 
RULE 0 saponin_derivatives 
RULE 1 cytochalasin_derivatives 
RULE 4 cycloheximide_derivatives 
RULE 1 monensin_derivatives 
RULE 1 squalestatin_derivatives 
#functional groups which often eliminate compounds from consideration 
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RULE 0 acid-halide 
RULE 0 aldehyde 
RULE 3 alkyl-halide 
RULE 0 anhydride 
RULE 0 azide 
RULE 0 azo 
RULE 2 di-peptide 
RULE 1 michael_acceptor 
RULE 0 beta_halo_carbonyl 
RULE 3 nitro 
RULE 0 oxygen-cation 
RULE 0 peroxide 
RULE 0 phosphonic_acid 
RULE 0 phosphonic_ester 
RULE 0 phosphoric-acid 
RULE 0 phosphoric-ester 
RULE 1 sulfonic acid 
RULE 0 sulfonic ester 
RULE 0 tricarbo_phosphene 
RULE 0 epoxide 
RULE 0 sulfonyl_halide 
RULE 0 halopyrimidine 
RULE 0 perhalo_ketone 
RULE 0 aziridine 
RULE 1 oxalyl 
RULE 0 alphahalo_amine 
RULE 0 halo-amine 
RULE 1 halo_alkene 
RULE 0 acyclic_NCN 
RULE 0 acyclic-NS 
RULE 0 SCN2 
RULE 0 terminal-vinyl 
RULE 0 hetero_hetero 
RULE 0 hydrazine 
RULE 0 N_methoyl 
RULE 2 NS_beta_halothyl 
RULE 0 propiolactones 
RULE 0 nitroso 
RULE 0 iodoso 
RULE 0 iodoxy 
RULE 0 noxide 
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#groups of molecules 
RULE 2 dye 
#functional groups which are allowed, but may not be wanted in high quantities 
#common functional groups 
RULE 6 alcohol 
RULE 5 alkene 
RULE 4 amide 
RULE 4 amino acid 
RULE 3 amine 
RULE 4 primary_amine 
RULE 4 secondary-amine 
RULE 4 tertiary-amine 
RULE 2 carboxylic-acid 
RULE 6 halide 
RULE 4 iodine 
RULE 3 ketone 
RULE 4 phenol 
RULE 2 imine 
RULE 1 methyl-ketone 
RULE 1 alkylaniline 
RULE 4 sulfonamide 
RULE 1 sulfonylurea 
RULE 0 phosphonamide 
RULE 1 alphahalo_ketone 
RULE 0 oxaziridine 
RULE 1 cyclopropyl 
RULE 2 guanidine 
RULE 0 sulfonimine 
RULE 0 sulfinimine 
RULE 1 hydroxamic_acid 
RULE 0 phosphoryl 
RULE 0 sulfinylthio 
RULE 0 disulfide 
RULE 0 enol_ether 
RULE 2 enamine 
RULE 0 organometallic 
RULE 0 dithioacetal 
RULE 1 oxime 
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RULE 0 isothiocyanate 
RULE 0 isocyanate 
RULE 3 lactone 
RULE 3 lactam 
RULE 1 thioester 
RULE 1 carbonate 
RULE 0 carbamic_acid 
RULE 1 thiocarbamate 
RULE 0 triazine 
RULE 1 malonic 
#other functional groups 
RULE 2 alkyne 
RULE 4 aniline 
RULE 4 aryl-halide 
RULE 2 carbainate 
RULE 3 ester 
RULE 6 ether 
RULE 1 hydrazone 
RULE 0 nonacylhydrazone 
RULE 1 hydroxylamine 
RULE 2 nitrile 
RULE 2 sulfide 
RULE 2 sulfone 
RULE 2 sulfoxide 
RULE 0 thiourea 
RULE 1 thioamide 
RULE 1 thiol 
RULE 2 urea 
RULE 0 hemiketal 
RULE 0 hemiacetal 
RULE 0 ketal 
RULE 3 acetal 
RULE 0 aminal 
RULE 0 hemiaminal 
#protecting groups 
RULE 0 benzyloxycarbonyl_CBZ 
RULE 0 t_butoxycarbonyl_tBOC 
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RULE 0 fluorenylmethoxycarbonyl_Fmoc 
RULE 1 dioxolane 5MR 
RULE 1 dioxane 6MR 
RULE 1 tetrahydropyran_THP 
RULE 1 methoxyethoxymethyl_MEM 
RULE 2 benzyl_ether 
RULE 2 t_butyl_ether 
RULE 0 trimethylsilyl_TMS 
RULE 0 t_butyldimethylsilyl_TBDMS 
RULE 0 triisopropylsilyl_TIPS 
RULE 0 t_butyldiphenylsilyl_TBDPS 
RULE 1 phthalimides_PHT 
RULE 2 arenesulfonyl 
5.2.9 Example PVM. conf. 
This is an example of the format of a PVM. conf file used to distribute Omega and 
ROCS jobs to 14 processors across 10 workstations The number I or 2 denotes the 
number of CPUs to be used in that host. 
host <host name> 2 
host <host name> 2 
host <host name> 2 
host <host name> 1 
host <host name> 1 
host <host name> 1 
host <host name> 1 
host <host name> 1 
host <host name> 1 
host <host name> 2 
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